

TABLE B-8 Interpretation of Lab Values (continued)

Value	Normal Range	Purpose or Comment	Increased In	Decreased In
Acetone, ketones	0	Elevation indicates ketosis.	Diabetic ketoacidosis; starvation; fever; prolonged vomiting; high-protein, high-fat, or low-CHO diet; diarrhea; anorexia	
Aldosterone	6–16 mg/24 h			
Ammonia	20–70 mEq/L		Hepatic disease or coma, renal failure, severe heart failure, high-protein diet	Essential hypertension
Amylase	260–950 Somogyi units/24 h		Perforated peptic ulcer, acute pancreatitis, mumps, cholecystitis, renal insufficiency, alcohol poisoning	Hepatitis, pancreatic insufficiency, severe burns
Calcium, normal diet	<250 mg/24 h		Hyperparathyroidism, high calcium or vitamin D in diet, immobilization, metastatic bone disease, multiple myeloma, renal tubular acidosis	Decreased levels may reflect poor intake. Hypoparathyroidism, rickets, renal failure, steatorrhea, osteomalacia
Cortisol, urinary free	10–100 µg/dL		Elevated in stress	Adrenal insufficiency
Creatinine clearance	Males (20 years old): 90 mL/min/SA; females (20 years old): 84 mL/min/SA; decreases by 6 mL/min/SA per decade		Pregnancy, childhood, exercise.	Ascites, dehydration, renal failure, heart failure, shock, cirrhosis
Epinephrine, norepinephrine	Epinephrine: <10 µg/24 h; Norepinephrine <100 µg/24 h		Stress	
Estrogens	4–25 mg/24 h in males; 4–60 mg/24 h in females, higher in pregnancy			
Hemoglobin, myoglobin	0	Any amount	Blood loss, urinary tract injury	
5-Hydroxyindoleacetic acid (5-HIAA)	0	Serotonin excretion		
Oxalate pH	20–60 mg/24 h		Calcium oxalate stones	
	4.6–8; average of 6 (dependent on diet)	Depends on time of sampling and food ingested	Alkaline: metabolic alkalemia, proteus infection, aged specimen, large amount of fruits and vegetables eaten	Acidic: high-protein intake
Protein (albumin)	<30 mg/24 h (0 qualitative)	Amino acids in urine should be 0.4–1 g/L.	Nephrotic syndrome	
Specific gravity	1.003–1.030	Ability to concentrate urine	High in antidiuretic hormone deficiency	Low in renal tubular dysfunction
Sugar	0		Hyperglycemia, ketosis, DKA	
3-Methyl histidine, urine		Indicator of lean body mass turnover	Increased levels may reflect loss of lean body mass.	
Urea	20–35 g/L			
Uric acid	0.2–2.0 g/L			
Vanillylmandelic acid (VMA)	<6.8 mg/24 h	Metabolite of both epinephrine and norepinephrine		
Volume	1000–1500 mL	Varies slightly between individuals	Diabetes insipidus	Dehydration

The table provides estimated and sample normal values; normal ranges will vary by the techniques used by the laboratory completing the tests. Developed from: Pagana KD, Pagana TJ. *Mosby's manual of diagnostic and laboratory tests*. 4th ed. Philadelphia: Mosby, 2009.

TABLE B-9 Quick Reference: Food–Drug Interactions

Drugs	Effects and Precautions	Drugs	Effects and Precautions
<i>Antibiotics</i>		<i>Cholesterol-Lowering Drugs</i>	
Cephalosporins, penicillin	Take on an empty stomach to speed absorption of the drugs.	Cholestyramine	Increases the excretion of folate and vitamins A, D, E, and K.
Erythromycin	Do not take with fruit juice or wine, which decrease the drug's effectiveness.	Gemfibrozil	Avoid fatty foods, which decrease the drug's efficacy in lowering cholesterol.
Sulfa drugs	Increase the risk of vitamin B ₁₂ deficiency.	<i>Heartburn and Ulcer Medications</i>	
Tetracycline	Dairy products reduce the drug's effectiveness. Lowers vitamin C absorption.	Antacids	Interfere with the absorption of many minerals; for maximum benefit, take medication 1 hour after eating.
<i>Anticonvulsants</i>		Cimetidine, famotidine, sucralfate	Avoid high-protein foods, caffeine, and other items that increase stomach acidity.
Dilantin, phenobarbital	Increases the risk of anemia and nerve problems due to a deficiency in folate and other B vitamins.	<i>Hormone Preparations</i>	
<i>Antidepressants</i>		Oral contraceptives	Salty foods increase fluid retention. Drugs reduce the absorption of folate, vitamin B ₆ , and other nutrients; increase intake of foods high in these nutrients to avoid deficiencies.
Fluoxetine	Reduces appetite and can lead to excessive weight loss.	Steroids	Salty foods increase fluid retention. Increase intake of foods high in calcium, vitamin K, potassium, and protein to avoid deficiencies.
Lithium	A low-salt diet increases the risk of lithium toxicity; excessive salt reduces the drug's efficacy.	Thyroid drugs	Iodine-rich foods may lower the drug's efficacy.
Monoamine oxidase (MAO) inhibitors	Foods high in tyramine (e.g., aged cheeses, processed meats, legumes, wine, and beer) can bring on a hypertensive crisis.	<i>Laxatives</i>	
Tricyclics	Many foods, particularly legumes, meat, fish, and foods high in vitamin C, reduce absorption of the drugs.	Mineral oils	Overuse can cause a deficiency of vitamins A, D, E, and K.
<i>Antihypertensives, Heart Medications</i>		<i>Painkillers</i>	
Angiotensin-converting enzyme (ACE) inhibitors	Take on an empty stomach to improve the absorption of the drugs.	Aspirin and stronger nonsteroidal anti-inflammatory drugs	Always take with food to lower the risk of gastrointestinal irritation; avoid taking with alcohol, which increases the risk of bleeding. Frequent use of these drugs lowers the absorption of folate and vitamin C.
Alpha-blockers	Take with liquid or food to avoid excessive drop in blood pressure.	Codeine	Increase fiber and water intake to avoid constipation.
Antiarrhythmic drugs	Avoid caffeine, which increases the risk of an irregular heartbeat.	<i>Sleeping Pills, Tranquilizers</i>	
Beta-blockers	Take on an empty stomach; food, especially meat, increases the drug's effects and can cause dizziness and low blood pressure.	Benzodiazepines	Never take with alcohol. Caffeine increases anxiety and reduce drug's effectiveness.
Digitalis	Avoid taking with milk and high-fiber foods, which reduce absorption; increases potassium loss.	<i>Weight Loss–Inducing Drugs</i>	
Diuretics	Increases the risk of potassium deficiency.	Many drugs cause weight loss because of changes in appetite or other side effects.	
Potassium-sparing diuretics	Unless a doctor advises otherwise, do not take diuretics with potassium supplements or salt substitutes, which can cause potassium overload.		
Thiazide diuretics	Increases the reaction to MSG.		
<i>Asthma Drugs</i>			
Pseudoephedrine	Avoid caffeine, which increases feelings of anxiety and nervousness.		
Theophylline	Charbroiled foods and a high-protein diet reduce absorption. Caffeine increases the risk of drug toxicity.		

TABLE B-10 Sample Worksheet for Using Standardized Nutrition Terminology

Nutrition Care Process—Critical thinking worksheet to help determine the appropriate standardized language to document and support the NCP

STEP ONE: NUTRITION ASSESSMENT

Complete a comprehensive assessment of a patient using the established assessment standards/guidelines set by your facility or practice setting. Be sure to include “comparative standards:” anthropometrics, estimated needs, and nutrient intake as well as identify the reference standards used to analyze the calculated/numerical data such as the DRIs, BMI, and NCHS charts.

STEP TWO: NUTRITION DIAGNOSIS

- (1) List all of the patient’s problems/issues:
- (2) Cross off medical problems/medical diagnoses.
- (3) Cross off issues that do not have supporting evidence (of signs/symptoms).
- (4) Cross off issues where the root etiology (cause of) cannot be determined.
- (5) Place a “✓” by the issues you will be able to re-evaluate upon follow-up; be sure to have updated signs/symptoms data on the reassessment date.
- (6) Of the checked issues, circle those that are the most urgent nutrition problem(s) to resolve and the priority issue to start addressing.
- (7) Based on the problem(s) circled, choose the diagnosis that best suits the nutrition issue in its most detailed form.
- (8) Write P.E.S statement(s) with the appropriate “root” etiology and signs/symptoms:

P: _____ related to **E:** _____ as evidenced by
S/S: _____ ***See examples

STEP THREE: NUTRITION INTERVENTION (Direct interventions at the **etiology**. If a dietitian cannot change the etiology, then direct the interventions at reducing the signs/symptoms of the nutrition diagnosis).

Nutrition Prescription: (Proper diet and regimen to meet the nutrient needs of what?) _____

Based upon scope of practice and clinical privilege established by your facility or practice setting, choose:

- | | |
|--|---|
| 1) <u>Recommended Interventions</u> (other practitioner must do) | 2) <u>Interventions you can/will do on your own</u> (actions) |
| • intervention term: _____ | • intervention term: _____ |
| goal of intervention: _____ | goal of intervention: _____ |
| • intervention term: _____ | • intervention term: _____ |
| goal of intervention: _____ | goal of intervention: _____ |
| • intervention term: _____ | • intervention term: _____ |
| goal of intervention: _____ | goal of intervention: _____ |

Goal of intervention = why you chose that intervention/strategy – what the intervention is intended to do/accomplish

STEP FOUR: MONITORING & EVALUATION (Directed at the **signs/symptoms** to monitor the success of intervention(s) and progress toward goal(s))

- 1) Indicate when/timeframe during which you plan to reassess: within _____ days/weeks/months
 - 2) List signs/symptoms from PES above and match to M&E Terms (unshaded) from Assess/M&E list (indicators)
 - 3) Establish criteria for each M&E indicator (pt goals)
 - Signs/Symptoms: _____
M&E term: _____
Criteria-Pt will: _____
 - Signs/Symptoms: _____
M&E term: _____
Criteria-Pt will: _____
 - Signs/Symptoms: _____
M&E term: _____
Criteria-Pt will: _____
- Reassessment or follow-up encounter
- 1) Do you have the info/data needed to compare previous signs/symptoms to the current time? If no, you need to address this as an intervention recommendation, and check it at the next encounter. If yes, evaluate progress toward the M&E criteria on the left (pt goals).
☐ Pt met goal/criteria ☐ Pt did not meet goal/criteria
 - 2) Based upon progress toward pt goals, evaluate progress toward the resolution of the nutrition problem from the PES:
☐ Resolved (nutrition problem no longer exists)
☐ Improvement shown (nutrition problem still exists)
☐ Unresolved no improvement shown
☐ No longer appropriate (change in condition)
 - 3) If no improvement is shown, you may need to change intervention(s).

Criteria = measurable patient-centered goals

(continued)

TABLE B-10 Sample Worksheet for Using Standardized Nutrition Terminology (*continued*)

***SAMPLE COMMON PES STATEMENTS			
Diagnostic Label	Domain Code	- Common Etiology "as related to . . ."	Common Signs/Symptoms "as evidenced by . . ." [with M/E codes]
Inadequate oral food/ beverage intake	NI-2.1	- Decreased appetite - Nausea - Emesis - Altered mental status - Increased needs with advanced Ca - Increased needs due to wound healing, infection, multiple frax - Increased needs secondary to catabolic state - Comfort measures only (Hospice)	- Poor po intake of $\leq 25\%$ of meals [M&E – FH-1.3.2] - Wt loss of $>5\%$ in 1–2 months [M&E – AD-1.1.4] - Poor po intake of $\leq 25\%$ of meals [M&E – FH-1.3.2] - Consumption of minimal comfort foods $<10\%$ needs [M&E – FH-1.2.1]
Inadequate intake from enteral/ parenteral nutrition	NI-2.3	- Current TF formula/rate - Increased needs sec to surgery - Infusion goal not reached due to intolerance of feeding	- Current nutrition regimen only meeting ___% of est. needs [M&E – FH-1.2.1] - TF/TPN only meeting ___% of est. needs [M&E – FH-1.4.1] - Wt loss of ___% in ___ weeks/months [M&E – AD-1.1.4] - Delayed wound healing [M&E – PD-1.1.8]
Excessive intake from enteral/parenteral nutrition	NI-2.4	Decreased needs due to ventilator	- Current nutrition regimen meeting $\geq 100\%$ of est. needs [M&E – FH-1.2.1] - TF/TPN meeting $\geq 100\%$ of est. needs [M&E – FH-1.4.1]
Increased nutrient needs (protein)	NI-5.1	- Increased nutrient demands (PRO) for: - Wound healing - Surgical wounds	- Prealb or alb of ___g/L (decreased) [M&E – BD-1.11.1] - Loss of skin integrity (surgical wounds) [M&E – PD-1.1.8] - Loss of muscle mass [M&E – PD-1.1.4] - Stage ___ pressure ulcer [M&E – PD-1.1.8] - Inadequate protein intake– consuming only ___% pro needs [M&E – FH-1.6.2]
Malnutrition	NI-5.2	- End-stage liver disease - Short gut - Small bowel transplant - Mental illness - Ascites - ETOH dependency	- Decreased albumin of ___g/L [M&E – BD-1.11.1] - Decreased food intake, consuming only ___% meals [M&E – FH-1.3.2] - Pt refusing to eat [M&E – FH-1.3.2] - Wt loss of ___% in ___ weeks/months [M&E – AD-1.1.4] - Evident temporal wasting [M/E – PD-1.1.6] - Evident minimal body fat / fat stores [M/E – PD-1.1.4] - Evident cachexia [M/E – PD-1.1.4] - Delayed wound healing [M/E – PD-1.1.8]

Provided courtesy of Sherri Jones, MS, MBA, RD, LDN. UPMC Presbyterian Shadyside, Pittsburgh PA.

TABLE B-11 Clinical Case Review and Audit

Assessment	3 Exceeds Very detailed	2-Met Goals Competent	1-Unsat. Large amt missing	Comments
Pathophysiology of disease/disorder				
Stage/phase (if applicable)				
Relevance of nutrition status in this disorder/disease				
Prognosis for this disease				
Up-to-date interpretation of evidence-based research				
General information noted- Ht, Wt				
Social background reviewed				
Past medical status/socioeconomic status				
Family history; genetics, if relevant				
Pertinent medical/surgical status reviewed/documented				
Medications and potential drug/nutrient interactions assessed/noted				
Laboratory values: skewed values and relevance noted				
Typical diet recall or diet Hx analyzed				
Correct calculations/anthropometrics used to estimate nutrition needs				
Nutrition Diagnoses	3 Exceeds Very detailed	2-Met Goals Competent	1-Unsat. Large amt missing	Comments
1-2 Nutrition diagnosis(es) identified & appropriate				
P.E.S statements: logical, able to be managed by an RD in this setting				
Nutrition Interventions	3 Exceeds Very detailed	2-Met Goals Competent	1-Unsat. Large amt missing	Comments
Short- and long-term goals set with pt/significant other				
Recommendations based on etiologies of problems				
Food-nutrient delivery:				
Education:				
Counseling:				
Coordination of care:				
Monitoring and Evaluation	3 Exceeds Very detailed	2-Met Goals Competent	1-Unsat. Large amt missing	Comments
Progress: day to day analysis – Intake				
Progress: day to day analysis – Clinical				
Progress: day to day analysis – Behavioral/Environmental				
Documented need for f/up; timeframe noted				
If education provided, pt/family understanding is documented				
Nutrition support – kilocalories, protein, fluid, recommendations proper				
Nutrition care plans updated in a timely manner				
Meal plan established if warranted				
Age-appropriate standards and assessment tools used if needed				
Discharge plan or needs discussed				
Communication and Documentation	3 Exceeds Very detailed	2-Met Goals Competent	1-Unsat. Large amt missing	Comments
Organized; follows a comprehensible sequence				
Educational flow sheets documented accurately				
Uses correct grammar and terms				
Follow-up notes re-evaluate nutrition diagnoses, status, plans				
Evaluator: _____	Date: _____	Medical Record # _____		
TOTAL POINTS: _____				

TABLE B-12 Tips for Adult Education and Counseling

The adult as a learner	During the process of maturation, a person moves from dependency toward increasing self-directedness but at different rates for different people and in different dimensions of life. Teachers have a responsibility to encourage and nurture this movement. Adults have a deep psychological need to be generally self-directing, but they may be dependent in certain temporary situations.
The learner's experience	As people grow and develop, they accumulate an increasing reservoir of experience that becomes an increasingly rich resource for learning—for themselves and for others. Furthermore, people attach more meaning to lessons they gain from experience than those they acquire passively. Accordingly, the primary techniques in education are experiential ones—laboratory experiments, discussion, problem-solving cases, field experiences, case reports.
Readiness to learn	People become ready to learn something when they experience a need to learn it in order to cope more satisfyingly with real-life tasks and problems. The educator has a responsibility to create conditions and provide tools and procedures for helping learners discover their “need to know.” Learning programs should be organized around life-application categories and sequenced according to the learners’ readiness to learn. Key: Attend to learners’ developmental readiness.
Orientation to learning	Adult learners see education as a process of developing increased competence to achieve their full potential in life. They want to be able to apply whatever knowledge and skill they gain today to living more effectively tomorrow. Accordingly, learning experiences should be organized around competency-development categories. People are performance-centered in their orientation to learning.
Assumptions	1. All learners can think; critical and creative thinking are goals. 2. There needs to be a safe, risk-taking environment and sufficient time to learn. 3. The environment for learning should be rich and responsive. 4. Offer challenging problem-solving opportunities.
Chief assessment factors for learning	1. Socioeconomic factors 2. Cultural/religious beliefs and background 3. Age and sex of patient and significant others (SOs) 4. Birth order of patient and family involvement 5. Occupation 6. Medical status and medical history 7. Marital status; number and ages of children 8. Cognitive status; educational level 9. Readiness to learn and staging: precontemplation, contemplation, preparation, action, or maintenance 10. Emotional status (stress, acceptance of illness, chronic disease, or condition)
Health literacy and teaching tools	Low health literacy (the ability to read, understand, and act on health information) is a public health issue. One out of five American adults reads at the fifth-grade level or below, and the average American reads at the eighth to ninth grade level. Most consumers need help understanding healthcare information. Patients prefer medical information that is easy to read and understand. Easy-to-read healthcare materials are <i>essential</i> . Provide important information first.
Written materials	Print very clearly and avoid handwritten messages. Use large print; font size should be a minimum of 12 points. Double space text to avoid crowding. Avoid using all capital letters. Use headings to introduce the upcoming topic. Avoid abbreviations, and use black ink on light-colored paper. Information must be current and accurate. Provide important information first. Highlight the “need to know” versus the “nice to know.” Present information in a “how to” manner. Use a conversational style. Spell out numbers below 10. Limit syllables to —one or two per word. Keep sentences short, and use bullets when possible.
Educational tools	Newsletters and bulletin boards Demonstrations or role-playing Laboratory reports, flip charts Food recall or intake records with feedback Educational games and fun quizzes Group classes or supermarket tours Educational video and audio tapes

(continued)

TABLE B-12 Tips for Adult Education and Counseling (*continued*)

Visual aids	Visuals should be able to stand alone, without words. Use photographs and realistic images. Use culturally appropriate food models, empty packages of real foods, and measuring cups and spoons. Work with restaurant menus where needed. Share simple recipes.
Principles of learning	The recipient must value the information. Pace should be adequate for learner; take small steps. Environment should be conducive to learning (free of distractions and stress), and patient should be ready to learn (free from pain). Information must be meaningful, relevant, and organized. Material should be logical in sequence. Counselor must be truly interested in sharing the information. Adequate follow-up should be available for the reinforcement of facts and principles. For adult learners, information that is useful in the present is more meaningful than facts learned for the “future.” Adults tend to prefer problem-solving information (survival skills) over learning facts.
Principles of teaching	The counselor must first listen to the patient. Involve the patient in setting mutual objectives. Small segments of information should be presented in understandable language in small, manageable “sound bytes.” An organized plan should be used to teach. Clear objectives should be established, with timelines and short- and long-term outcomes. Feedback should be used with each step. Be prepared to receive evaluation (peer review) from the patient; improve as needed. Good eye contact should be maintained with the patient. Be aware, however, that direct or prolonged eye contact can be seen as rude or threatening by some cultures; know your client. Appropriate teaching tools or audiovisual aids should be used as appropriate. Using a sixth- to eighth-grade reading level is suggested, preferably with an easy layout, visual appeal, and illustrations. Questions must be allowed for clarification. Praise and positive reinforcement should be offered to the learner. Carl Rogers emphasizes the use of “unconditional positive regard” for all persons.
Counseling tips	Knowledge does not automatically ensure compliance. Behavioral change takes time and encouragement. Trial and error will be common for the patient in learning new behaviors. An increase in self-esteem comes with an improvement in behavior. The counselor should appropriately foster independence. Empathy is an important part of humanistic care. The counselor serves as an intervention specialist. The “patient-centered” approach to counseling is effective. Assess the stage of change and motivation level of client. Evaluate past experiences with dietary changes and anticipated challenges. Goal-setting requires the patient to recognize the need for change, establish a goal, monitor goal-related activity, and use self-reward for goal attainment. Identify challenges, obstacles, coping strategies, and skills. Help the client to anticipate lapses and relapses.
Patient assessment of chronic illness care (PACIC tool)	Patient-centered model of behavioral counseling using the 5 As: Assess: Beliefs, behavior, and knowledge. Advise: Provide specific information about health risks and benefits of change. Agree: Collaboratively set goals based on the patient’s interest and confidence in their ability to change behavior. Assist: Identify personal barriers, strategies, problem-solving techniques, and social/environmental support. Arrange: Specify a plan for follow-up (e.g., visits, phone calls, mailed reminders).
Counseling in hospice care	Attempt to reduce fears related to eating. Recognize stages of terminal illness: fear of abandonment, finding a natural and realistic approach, building bridges, and ownership of the experience. Pain management is most important for quality of life. Respect the individual’s cultural beliefs and needs. Identify a patient advocate who will address concerns as care progresses. Help maintain self-esteem and dignity. Comfort foods can be important to patient satisfaction; address these needs on a meal-to-meal basis. Listen for hidden messages from the patient; communicate with other healthcare team members.

TABLE B-13 Health-Promotion Intervention Models

Because increasing evidence suggests that health-promotion interventions that are based on social and behavioral science theories are more effective than those lacking a theoretical base, five models are described here (Glanz and Bishop, 2010.)

Behavioral Ecological Model (BEM)





Figure B-4 Behavioral Ecological Model (BEM). (Image courtesy of Hovell et al [2002].)

Behavioral Ecological Model (BEM) Principle	Processes	Application
Environment influences behavior	Consequences are produced by the behavior	Control or change risky environment
Hierarchy of interacting reinforcement contingencies	Interaction is key	Interaction among both physical and social contingencies explain and ultimately control health behavior.

Hovell MF, Wahlgren DR, Gehrman C. The Behavioral Ecological Model: Integrating public health and behavioral science. In DiClemente RJ, Crosby R, Kegler M, (eds.). *New and Emerging Theories in Health Promotion Practice & Research*. Jossey-Bass Inc., San Francisco, California, 2002.


(continued)

TABLE B-13 Health-Promotion Intervention Models (continued)**Health Belief Model****Figure B-5** Health Belief Model (HBM). (Image courtesy of Glanz et al (2002).)

Health Belief Model Concept	Definition	Application
Perceived susceptibility	One's opinion of chances of getting a condition.	Define population(s) at risk, risk levels. Personalize risk based on a person's features or behavior. Heighten perceived susceptibility if too low.
Perceived severity	One's opinion of how serious a condition and its sequelae are.	Specify consequences of the risk and the condition.
Perceived benefits	One's opinion of the efficacy of the advised action to reduce risk or the seriousness of impact.	Define action to take: how, where, when; clarify the positive effects to be expected.
Perceived barriers	One's opinion of the tangible and psychological costs of the advised action.	Identify and reduce barriers through reassurance, incentives, and assistance.
Cues to action	Strategies to activate readiness.	Provide how-to information; promote awareness, reminders.
Self-efficacy	Confidence in one's ability to take action.	Provide training, guidance in performing action.


Glanz K, Bishop DB. The role of behavioral science theory in development and implementation of public health interventions. *Annu Rev Public Health*. 31:399, 2010.
 Glanz, K., Rimer, BK, Lewis, FM. *Health Behavior and Health Education. Theory, Research and Practice*. San Francisco: Wiley & Sons., 2002.

(continued)

TABLE B-13 Health-Promotion Intervention Models (*continued*)**Motivational Interviewing****Figure B-6** Key Words for Motivational Interviewing.

Motivational Interviewing (MI) Concept	Definition	Application
Motivation to change comes from the client, not the counselor	Direct persuasion is not an effective method for achieving change. Client must articulate and resolve his or her own ambivalence.	Counseling style is a quiet, eliciting one. Partnership is the goal, not an expert—recipient relationship.
Resolution of ambivalence	Directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence.	Compared with nondirective counseling, it is more focused and goal-directed. Readiness to change is a fluctuating product of personal interaction.


Rollnick S., & Miller, W.R. What is motivational interviewing? *Behavioural and Cognitive Psychotherapy*, 23: 325, 1995.

Social Cognitive Theory**Figure B-7** Self-Efficacy as part of Social Cognitive Theory.

Social Cognitive Theory Principle	Processes	Application
Human functioning is self-regulated	Cognitive, vicarious, and self-reflective processes	Human adaptation to change
Dynamic interplay of personal, behavioral, and environmental influences	Self as organizing, proactive, self-reflective	People are not reactive organisms shepherded by environmental forces or concealed inner impulses
People watch and learn from others	Interactive learning	Confidence comes from practice
Self-efficacy is the belief in the ability to succeed in specific situations	Positive approaches to goals, tasks, and challenges.	Those who believe they can perform well are more likely to view difficult tasks as something to be mastered rather than something to be avoided.

Bandura, A. *Social foundations of thought and action: A social cognitive theory*. Englewood Cliffs, NJ: Prentice Hall, 1986.

(continued)

TABLE B-13 Health-Promotion Intervention Models (continued)**Transtheoretical Model (TTM)****Figure B-8** Transtheoretical Model (TTM). (Image courtesy of Prochaska and DiClemente (1982).)

TTM Stage	Definition	Helping Processes
Precontemplation	Individual has the problem (whether he/she recognizes it or not) and has no intention of changing.	Consciousness raising (information and knowledge) Dramatic relief (role-playing) Environmental reevaluation (how problem affects physical environment)
Contemplation	Individual recognizes the problem and is seriously thinking about changing.	Self-reevaluation (assessing one's feelings regarding behavior)
Preparation for action	Individual recognizes the problem and intends to change the behavior within the next month. Some behavior change efforts may be reported but the defined behavior change criterion has not been reached consistently.	Self-liberation (commitment or belief in the ability to change)
Action	Individual has enacted consistent behavior change for less than six months.	Reinforcement management (overt and covert rewards) Helping relationships (social support, self-help groups) Counterconditioning (alternatives for behavior) Stimulus control (avoid high-risk cues)
Maintenance	Individual maintains new behavior for six months or more.	Support and encouragement

Prochaska JO, DiClemente CC. Trans-theoretical therapy – toward a more integrative model of change. *Psychotherapy: Theory, Research & Practice*. 19(3):276, 1982.

TABLE B-14 Sample Monitoring and Evaluation Audits for Patient Education

This patient education audit identifies the ability of the patient to demonstrate or verbalize how he or she will or has changed behaviors after nutritional instructions.

Any Patient

1. Patient is able to personalize the MyPyramid food guidance system.
2. Patient is able to explain the importance of his or her diet for his or her health.
3. Patient is able to plan ____ day's menus and snacks from his/her dietary pattern.
4. Patient is able to incorporate desirable economic/ethnic food choices into his/her prescribed diet.
5. Patient has been following ____ diet at home for a period of time and is able to describe the elements of this diet with accuracy.
6. Patient expresses recognition of a need to lose/gain weight.
7. Patient is able to describe specific food allergies and food ingredients to avoid.
8. Patient is able to describe the reasons for following ____ diet (e.g., improve appearance, increase energy, reduce chances for complications, improve quality of life).
9. Patient is able to describe the impact of appropriate activity or exercise on health and nutritional well-being.

Cardiac Diet

1. Patient is able to name three beverages that are high in caffeine.
2. Patient is able to describe modifications in his or her diet that will be needed to prevent further coronary complications: saturated versus poly- and monounsaturated fats, sodium and potassium, fiber, and use of the DASH diet.
3. Patient is able to categorize correctly into the proper food pyramid lists.
4. Patient is able to plan menus for home use that include appropriate modifications.
5. Patient is able to name snack foods that can be included in dietary plan.

Diabetes Diet

1. Patient is able to explain the relationship of diet with complications of diabetes.
2. Patient is able to name foods that contain CHO.
3. Patient is able to preplan meals for ____ weeks.
4. Patient is able to verbalize a simple definition of diabetes.
5. Patient is able to describe the role of medications related to food intake.
6. Patient is able to explain the rationale for following a prudent diet to prevent complications such as heart disease.
7. Patient is able to explain how proper spacing of meals affects his/her disorder.
8. Patient is able to describe symptoms of ketoacidosis and insulin shock and can name foods to take or avoid for each condition.
9. After looking at several food labels, patient is able to point out ingredients that mean carbohydrate.
10. Patient is able to describe techniques for managing special events (travel, parties, restaurants, holiday meals, weekends).
11. Patient is able to describe his or her personal exercise prescription as ____ minutes of activity ____ times per week.

12. Patient is able to describe 1–2 items to carry in case of episodes of low blood glucose.
13. Patient is able to define when to call his or her health provider (e.g., when glucose is above/below normal ____ times).
14. Patient is able to discuss proper foot care, the need for eye exams, and the need for foot exams.

Dumping Syndrome Diet

1. Patient is able to verbalize the effects of diet on dumping syndrome.
2. Patient is able to explain the guidelines to be followed to prevent dumping syndrome (e.g., beverages are served 30 minutes before or after meals; concentrated sweets are omitted or severely limited).

Gliadin-Free/Gluten-Restricted Diet

1. Patient is able to examine food labels and to name ingredients that must be avoided.
2. Patient is able to list products that must be avoided in diet.
3. Patient is able to plan menus that can be used at home.
4. Patient is able to adapt recipes for use at home.

High-Fiber Diet

1. Patient is able to verbalize foods that can be used to increase fiber in his or her diet, to desired level of ____ grams daily.
2. Patient is able to explain the role of fiber in his or her particular disorder.
3. Patient is able to describe the purpose of adequate fluids in the dietary regimen and is able to consume ____ milliliters daily.

Lactose Intolerance Diet

1. Patient is able to name foods or beverages that must be avoided.
2. Patient is able to plan menus that are nutritionally complete for calcium but are lactose restricted.
3. Patient demonstrates awareness that he or she can tolerate up to ____ milliliters of lactose per day at this time.
4. Patient is able to discuss the difference between lactose intolerance and milk allergy.

Low-Cholesterol and Dyslipidemia Diets

1. Patient is able to describe simple definitions for cholesterol and saturated, polyunsaturated, and monounsaturated fats.
2. Patient is able to identify foods that have high cholesterol content.
3. Patient is able to name vegetable oils that may be used in the diet.
4. Patient is able to describe three cooking methods that are acceptable for the dietary regimen.
5. Patient is able to name foods that are good sources of monounsaturated fats.

(continued)

TABLE B-14 Sample Monitoring and Evaluation Audits for Patient Education (*continued*)*Low-Fat Diet*

1. Patient is able to name foods that he or she must omit for the low-fat diet.
2. Patient is able to explain the role of fat in his or her condition.
3. Patient is able to note grams of fat from a given food label.

Mineral-Altered Diets (Iron, Potassium, Calcium, Sodium)

1. Patient is able to name foods that are high/low in minerals.
2. Patient is able to accurately select menu choices for days that include/exclude foods that are high in mineral.
3. Patient is able to plan menus for home that are high/low in minerals.

Pregnancy Diet

1. Patient is able to describe nutritional changes to her diet in order to have a healthy baby.
2. Patient is able to describe why breastfeeding is an important consideration.

Protein-Altered Diets

1. Patient can identify foods that contain protein of high biological value.
2. Patient can name foods to include/omit in diet to increase/decrease the protein content of meals and snacks.

Renal Diets

1. Patient is able to describe restrictions that are needed in regard to protein, sodium, potassium, fluid, calories, and phosphorus.
2. Patient is able to plan menus that are balanced for the restricted nutrients.
3. Patient is able to name “free” foods that he or she can eat as desired.
4. Patient is able to discuss how foods, nutrients, and prescribed medications may interact.

Sodium Restrictions

1. Patient is able to name foods that are naturally high in sodium.
2. Patient is able to name foods that have been processed or prepared with an excess of sodium.
3. Patient is able to explain the difference between “salt” and “sodium” in foods.
4. Patient is able to list seasonings that can be used at home in place of salt and salt-containing seasonings.
5. Patient is able to plan menus for home that will be low in sodium.
6. Patient is able to identify salt substitutes that he or she can use for his or her condition.
7. Patient is able to discuss how other minerals (potassium, calcium, magnesium) play a role in the specific condition.

Vegetarian Diet

1. Patient is able to identify correctly two or more complementary protein foods.
2. Patient is able to plan menus that provide adequate protein and vitamin B₁₂, zinc, and so on for age and gender.

Weight Management Diet

1. Patient is able to verbalize his or her primary motivation for losing weight and current readiness for a change in behaviors.
2. Patient is able to describe his or her realistic goal for weight loss—either short term or long term, including a timetable.
3. Patient is able to list foods that are low in energy and may be eaten as snacks.
4. Patient is able to categorize foods into the proper pyramid food categories.
5. Patient is able to demonstrate a proper technique for recording food intake at home.
6. Patient has demonstrated weight loss over a certain timeframe.

Acuity Ranking for Dietitian Services and Concept Map

Over 100 dietitians, clinical nutrition managers, and specialists were surveyed for this acuity ranking for dietitian services, and a summary is given below. Levels of consensus on acuity are indicated for the medical diagnoses and conditions in this text. Where strong consensus was available, this table provides the acuity ranking for the nutritional involvement needed from a registered dietitian (RD). The survey asked the ques-

tions listed in Table C-1. Table C-2 summarizes the rankings given by participants to the nutrition acuity by condition or disease. Concept maps are useful for organizing data to prepare assessments or case reviews. Figure C-1 can be used or adapted as a teaching tool for skill development. Figure C-2 provides an example of a process chart for considering all aspects of data for a comprehensive functional nutrition plan.

TABLE C-1 Nutrition Acuity and Medical Diagnosis–Related Survey Questions

Rate your opinion about the level of dietitian involvement (over time, not just per visit) for the following diagnoses on a 1 to 5 rating scale where

1 = Little involvement; minimal, can be delegated to others	4 = Extensive involvement needed over time
2 = Some roles in oversight of nutrition care	5 = Unable to determine; no opinion or experience
3 = Moderate involvement needed over time	

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
NORMAL LIFE-CYCLE CONDITIONS			
Pregnancy, normal	Child, normal (1–2)	Pregnancy, high risk	
Lactation	Teenager, normal		
Infant, normal (birth up to 6 months)	Adult male, normal		
Infant, normal (6–12 months) (1–2)	Adult female, normal		
	Elderly male, normal		
	Elderly female, normal		
DIETARY PRACTICES AND MISCELLANEOUS CONDITIONS			
Periodontal disease (1–2)	Complementary medicine and herbal/botanical counseling	Pressure ulcer, stages 1 or 2 (2–3)	Pressure ulcer, stages 3 or 4 or multiple
Temporomandibular joint (TMJ) dysfunction	Cultural food pattern, advisement and planning	Vitamin deficiency prevention or counseling	
Skin disorders (acne, rosacea, eczema, psoriasis)	Vegetarian diet advisement or planning	Food allergy, multiple or complex (3–4)	
Ménière's syndrome	Religious dietary patterns, advisement/planning		
	Dental difficulties (caries, wired jaw, mouth pain, xerostomia) (2–3)		
	Vision and self-feeding problems (low vision or chewing problems) (1–2)		
	blindness, coordination		
	Food allergy, simple (2–3)		
	Foodborne illness, prevention or counseling		

(continued)

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses (continued)

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
PEDIATRICS: BIRTH DEFECTS, GENETIC, ACQUIRED DISORDERS			
Attention deficit disorders	Abetalipoproteinemia (variable)	Bronchopulmonary dysplasia (3–4)	Failure to thrive, pediatric
Autism spectrum disorders (1–2)	Biliary atresia (2–3)	Cerebral palsy	Inborn errors of carbohydrate metabolism
Adrenoleukodystrophy (variable)	Congenital heart disease	Cleft palate	Hirschsprung's disease (congenital megacolon)
Leukodystrophies (variable)	Cystinosis and Fanconi's syndrome (variable)	Homocystinuria (3–4)	HIV infection and AIDS, pediatric
Otitis media	Down syndrome	Maple syrup urine disease (MSUD) (3–4)	Low birth weight or premature infant (3–4)
	Fetal alcohol syndrome (1–2)	Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	Necrotizing enterocolitis
	Large for gestational age infant (variable)	Myelomeningocele (variable)	Phenylketonuria (PKU)
		Obesity, childhood (prevention, treatment) (3–4)	Tyrosinemia (variable)
		Prader-Willi syndrome (3–4)	Urea cycle disorders (variable)
		Rickets, nutritional	
		Spina bifida and neural tube defects	
		Wilson's disease (hepatolenticular degeneration)	
NEUROLOGICAL AND PSYCHIATRIC CONDITIONS			
Neurological Disorders			
Migraine headache, prevention or counseling	Epilepsy or seizure disorders	Amyotrophic lateral sclerosis	Brain trauma
Trigeminal neuralgia (1–2)	Multiple sclerosis	Cerebral aneurysm	Coma
	Myasthenia gravis and neuromuscular junction disorders	Guillain-Barré syndrome	
	Parkinson's disease	Huntington's chorea (variable)	
	Tardive dyskinesia	Spinal cord injury	
Eating Disorders			
		Stroke (cerebrovascular accident)	
		Anorexia nervosa	
		Binge eating disorder (3–4)	
		Bulimia (3–4)	
		Other disordered eating patterns (3–4)	
Psychiatric Disorders			
Bipolar disorder (1–2)		Alzheimer's disease or other dementias	
Depression with numerous medications (1–2)			
Schizophrenia and psychoses (1–2)			
Substance use disorders			

(continued)

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses (*continued*)

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
PULMONARY DISORDERS			
Asthma	Cor pulmonale (variable)	Chronic obstructive pulmonary diseases (emphysema or chronic bronchitis)	Chylothorax
Bronchiectasis	Interstitial lung disease (1–2)	Cystic fibrosis	Respiratory failure and ventilator dependency
Bronchitis, acute	Sarcoidosis	Respiratory distress syndrome (3–4)	
Pneumonia (1–2)	Sleep apnea	Transplantation, lung (3–4)	
Pulmonary embolism (1–2)	Thoracic empyema		
	Tuberculosis		
CARDIOVASCULAR DISORDERS			
Angina pectoris	Peripheral artery disease	Atherosclerosis, coronary heart disease, and dyslipidemias	Cardiac cachexia
Arteritis		Cardiomyopathies	Heart transplantation or heart–lung transplantation
Pericarditis and cardiac tamponade		Heart failure	
Thrombophlebitis		Hypertension	
		Myocardial infarction	
GASTROINTESTINAL DISORDERS			
Upper GI			
Dyspepsia or indigestion (1–2)	Esophageal varices (2–3)	Dysphagia (3–4)	
	Hiatal hernia, esophagitis, and gastroesophageal reflux (GERD) (2–3)	Esophageal stricture or spasm, achalasia, or Zenker’s diverticulum	
	Gastric retention or gastroparesis (2–3)	Esophageal trauma (3–4)	
	Peptic ulcer	Gastritis and gastroenteritis	
		Giant hypertrophic gastritis (Ménétrier’s disease)	
		Gastrectomy and/or vagotomy (3–4)	
		Vomiting, pernicious	
Lower GI			
Lactose malabsorption (lactase deficiency) (variable)	Diarrhea, dysentery, and traveler’s diarrhea	Fat malabsorption syndrome	Tropical sprue
Constipation (1–2)	Diverticular diseases (2–3)	Megacolon, acquired	Celiac disease
Fecal incontinence	Peritonitis	Irritable bowel disease	Crohn’s disease (3–4)
Hemorrhoids, hemorrhoidectomy	Colostomy (2–3)	Carcinoid syndrome	Ulcerative colitis
Proctitis		Ileostomy	Short bowel syndrome
		Intestinal lymphangiectasia (variable)	Intestinal fistula
		Whipple’s disease (intestinal lipodystrophy) (3–4)	Intestinal transplantation

(continued)

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses (continued)

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
HEPATIC, PANCREATIC, AND BILIARY DISORDERS			
Jaundice	Ascites and chylous ascites Hepatitis Pancreatic insufficiency (2–3) Gallbladder disease, surgical or nonsurgical Biliary cirrhosis Cholestatic liver disease (2–3)	Alcoholic liver disease Hepatic cirrhosis Hepatic encephalopathy, failure or coma (3–4) Pancreatitis, acute (3–4) Pancreatitis, chronic Zollinger–Ellison syndrome (variable)	Liver transplantation
ENDOCRINE DISORDERS			
Adrenocortical insufficiency, chronic	Pregnancy-induced Hypertension and preeclampsia	Metabolic syndrome (3–4) Prediabetes (3–4)	Type 1 diabetes Pancreatic transplantation
Addison's disease (variable)	Syndrome of inappropriate antidiuretic hormone (SIADH)	Diabetic gastroparesis (3–4)	Type 2 diabetes mellitus, adults
Cushing's syndrome (variable)		Diabetic ketoacidosis (3–4)	Type 2 diabetes mellitus, children and teens
Acromegaly (variable)	Parathyroid disorders	Hyperosmolar hyperglycemic state (3–4)	Gestational diabetes
Hyperaldosteronism (variable)	(altered calcium)	Hypoglycemia, iatrogenic	
Hypopituitarism (variable)		Hyperinsulinism and spontaneous hypoglycemia (3–4)	
Pheochromocytoma (variable)		Diabetes insipidus	
Hyperthyroidism			
Hypothyroidism			
WEIGHT MANAGEMENT, UNDERNUTRITION, AND MALNUTRITION		Underweight or unintentional weight loss (3–4) Protein–calorie malnutrition, mild (3–4)	Overweight or uncomplicated obesity Obesity, medical (with comorbidities) Protein–calorie malnutrition, moderate or severe Energy malnutrition Refeeding syndrome
MUSCULOSKELETAL AND COLLAGEN DISORDERS			
Ankylosing spondylitis (variable)	Immobilization, extended	Rhabdomyolysis (variable)	
Myofascial pain syndromes: fibromyalgia or polymyalgia rheumatica	Muscular dystrophy		
Osteomyelitis, acute (1–2)	Osteoarthritis and degenerative joint disease		
Paget's disease (osteitis deformans) (variable)	Osteopenia and osteomalacia		
Polyarteritis nodosa (variable)	Osteoporosis		
Rheumatoid arthritis	Systemic lupus erythematosus		
Ruptured intervertebral disc			
Scleroderma (systemic sclerosis) (1–2)			

(continued)

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses (*continued*)

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
HEMATOLOGY: ANEMIAS AND BLOOD DISORDERS			
Aplastic anemia	Anemia, hemolytic from vitamin E deficiency (2–3)		
Anemia from parasitic infestation	Anemia, iron deficiency		
Anemia, sickle cell	Anemia, nutritional (folic acid, copper, etc.)		
Anemia, sideroblastic	Anemia, pernicious or vitamin B ₁₂ deficiency		
Polycythemia vera (Osler's disease)	Hemochromatosis (iron overloading)		
Thalassemia (Cooley's anemia)	Hemorrhage, acute or chronic		
Thrombocytic purpura			
CANCER			
	Breast cancer	Brain tumor	Bone marrow transplantation
	Choriocarcinoma	Esophageal cancer (3–4)	
	Leukemia, chronic	Gastric carcinoma (3–4)	
	Lung cancer	Hepatic carcinoma	
	Myeloma (simple or multiple) (2–3)	Intestinal carcinoma (3–4)	
	Prostate cancer	Leukemia, acute	
		Lymphoma, Hodgkin's disease	
		Lymphoma, non-Hodgkin's	
		Oral cancer (3–4)	
		Osteosarcoma (2–3)	
		Pancreatic carcinoma	
		Radiation colitis or enteritis (3–4)	
		Wilms' tumor (embryoma of kidney)	
SURGICAL DISORDERS			
Appendectomy	Surgery, general	Bowel surgery	Gastric bypass surgery
Cesarean delivery	Sodium imbalances: hyponatremia or hypernatremia	Open heart surgery	
Hysterectomy, abdominal	Potassium imbalances: hypokalemia or hyperkalemia	Pancreatic surgery (3–4)	
Pelvic exenteration	Calcium imbalances: hypocalcemia or hypercalcemia		
Spinal surgery (1–2)	Magnesium imbalances: hypomagnesemia or hypermagnesemia		
Total hip arthroplasty	Phosphate imbalances: hypophosphatemia or hyperphosphatemia		
Tonsillectomy and adenoidectomy	Amputation, one or more limbs		
	Parathyroidectomy		

(continued)

TABLE C-2 Acuity for Dietitian Roles in Medical Diagnoses (continued)

Minimal Role of Dietitian–1	Some Roles of Dietitian–2	Moderate Role of Dietitian–3	Extended Role of Dietitian–4
AIDS, INFECTIONS, BURNS, IMMUNOLOGY, AND TRAUMA			
Candidiasis	Bacterial endocarditis	AIDS and HIV infection, adult (3–4)	Burns, major thermal injury
Chronic fatigue syndrome (1–2)	Burns, minor thermal injury	Sepsis or septicemia	Multiple organ dysfunction
Fever >102°F	Encephalitis or Reye’s syndrome	Trauma, major	
Herpes simplex 1 or 2	Fracture, hip or long bone		
Herpes zoster (shingles)	Trauma, minor		
Infection, general			
Influenza (flu, respiratory)			
Intestinal parasites			
Meningitis			
Mononucleosis			
Pelvic inflammatory disease			
Poliomyelitis			
Rheumatic fever			
Toxic shock syndrome			
Trichinosis			
Typhoid fever			
RENAL DISORDERS			
Pyelonephritis	Inborn errors: polycystic kidney disease	Inborn errors: vitamin D-resistant rickets (3–4)	Chronic kidney disease
Urolithiasis (renal stones) (1–2)	Glomerulonephritis, acute	Inborn errors: Hartnup disease (variable)	Hemodialysis
	Glomerulonephritis, chronic	Nephrosclerosis (2–3)	Peritoneal renal dialysis
	Nephritis (Bright’s disease) (2–3)	Renal failure, acute	Renal transplantation
	Nephrotic syndrome (2–3)		
ENTERAL–PARENTERAL NUTRITION			Tube feeding, initiation, monitoring, or home
			Parenteral nutrition, initiation, monitoring, or home

Thanks to Matthew Dallas, MS, RD, for summarizing this table.




Figure C-1 Concept Map. Used with permission from Molaison, E.F., Taylor, K., Erickson, D., and Connell, C.L. (2009). Perception of concept mapping as a learning tool by dietetic internship students and preceptors. *Journal of Allied Health*, 38, e-97–e-103.




Figure C-2 Integrative & Functional Medical Nutrition Therapy (IFMNT) Process Guide. (© 2010 Copyright. Used with permission from M. Swift, D. Noland & E. Redmond.)



Dietary Reference Intakes

Dietary Reference Intakes (DRIs): Recommended Intakes for Individuals, Vitamins

Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	Vit A (µg/d) ^a	Vit C (mg/d)	Vit D (µg/d) ^{b,c}	Vit E (mg/d) ^d	Vit K (µg/d)	Thia- min (mg/d)	Ribo- flavin (mg/d)	Niacin (mg/d) ^e	Vit B ₆ (mg/d)	Folate (µg/d) ^f	Vit B ₁₂ (µg/d)	Panto- themic Acid (mg/d)	Biotin (µg/d)	Choline ^g (mg/d)
<i>Infants</i>														
0–6 mo	400*	40*	5*	4*	2.0*	0.2*	0.3*	2*	0.1*	65*	0.4*	1.7*	5*	125*
7–12 mo	500*	50*	5*	5*	2.5*	0.3*	0.4*	4*	0.3*	80*	0.5*	1.8*	6*	150*
<i>Children</i>														
1–3 y	300	15	5*	6	30*	0.5	0.5	6	0.5	150	0.9	2*	8*	200*
4–8 y	400	25	5*	7	55*	0.6	0.6	8	0.6	200	1.2	3*	12*	250*
<i>Males</i>														
9–13 y	600	45	5*	11	60*	0.9	0.9	12	1.0	300	1.8	4*	20*	375*
14–18 y	900	75	5*	15	75*	1.2	1.3	16	1.3	400	2.4	5*	25*	550*
19–30 y	900	90	5*	15	120*	1.2	1.3	16	1.3	400	2.4	5*	30*	550*
31–50 y	900	90	5*	15	120*	1.2	1.3	16	1.3	400	2.4	5*	30*	550*
51–70 y	900	90	10*	15	120*	1.2	1.3	16	1.7	400	2.4 ⁱ	5*	30*	550*
> 70 y	900	90	15*	15	120*	1.2	1.3	16	1.7	400	2.4 ⁱ	5*	30*	550*
<i>Females</i>														
9–13 y	600	45	5*	11	60*	0.9	0.9	12	1.0	300	1.8	4*	20*	375*
14–18 y	700	65	5*	15	75*	1.0	1.0	14	1.2	400 ^j	2.4	5*	25*	400*
19–30 y	700	75	5*	15	90*	1.1	1.1	14	1.3	400 ^j	2.4	5*	30*	425*
31–50 y	700	75	5*	15	90*	1.1	1.1	14	1.3	400 ^j	2.4	5*	30*	425*
51–70 y	700	75	10*	15	90*	1.1	1.1	14	1.5	400	2.4 ^h	5*	30*	425*
> 70 y	700	75	15*	15	90*	1.1	1.1	14	1.5	400	2.4 ^h	5*	30*	425*
<i>Pregnancy</i>														
14–18 y	750	80	5*	15	75*	1.4	1.4	18	1.9	600 ^j	2.6	6*	30*	450*
19–30 y	770	85	5*	15	90*	1.4	1.4	18	1.9	600 ^j	2.6	6*	30*	450*
31–50 y	770	85	5*	15	90*	1.4	1.4	18	1.9	600 ^j	2.6	6*	30*	450*
<i>Lactation</i>														
14–18 y	1,200	115	5*	19	75*	1.4	1.6	17	2.0	500	2.8	7*	35*	550*
19–30 y	1,300	120	5*	19	90*	1.4	1.6	17	2.0	500	2.8	7*	35*	550*
31–50 y	1,300	120	5*	19	90*	1.4	1.6	17	2.0	500	2.8	7*	35*	550*

NOTE: This table (taken from the DRI reports, see www.nap.edu) presents Recommended Dietary Allowances (RDAs) in **bold type** and Adequate Intakes (AIs) in ordinary type followed by an asterisk (*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97 to 98 percent) individuals in a group. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevent being able to specify with confidence the percentage of individuals covered by this intake.

^a As retinol activity equivalents (RAEs). 1 RAE = 1 µg retinol, 12 µg β-carotene, 24 µg α-carotene, or 24 µg β-cryptoxanthin. The RAE for dietary provitamin A carotenoids is twofold greater than retinol equivalents (RE), whereas the RAE for preformed vitamin A is the same as RE.

^b As cholecalciferol. 1 µg cholecalciferol = 40 IU vitamin D.

^c In the absence of adequate exposure to sunlight.

^d As α-tocopherol. α-Tocopherol includes *RRR*-α-tocopherol, the only form of α-tocopherol that occurs naturally in foods, and the *2R*-stereoisomeric forms of α-tocopherol (*RRR*-, *RSR*-, *RRS*-, and *RSS*-α-tocopherol) that occur in fortified foods and supplements. It does not include the *2S*-stereoisomeric forms of α-tocopherol (*SRR*-, *SSR*-, *SSR*-, and *SSS*-α-tocopherol), also found in fortified foods and supplements.

^e As niacin equivalents (NE). 1 mg of niacin = 60 mg of tryptophan; 0–6 months = preformed niacin (not NE).

^f As dietary folate equivalents (DFE). 1 DFE = 1 µg food folate = 0.6 µg of folic acid from fortified food or as a supplement consumed with food = 0.5 µg of a supplement taken on an empty stomach.

^g Although AIs have been set for choline, there are few data to assess whether a dietary supply of choline is needed at all stages of the life cycle, and it may be that the choline requirement can be met by endogenous synthesis at some of these stages.

^h Because 10 to 30 percent of older people may malabsorb food-bound B₁₂, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with B₁₂ or a supplement containing B₁₂.

ⁱ In view of evidence linking folate intake with neural tube defects in the fetus, it is recommended that all women capable of becoming pregnant consume 400 µg from supplements or fortified foods in addition to intake of food folate from a varied diet.

^j It is assumed that women will continue consuming 400 µg from supplements or fortified food until their pregnancy is confirmed and they enter prenatal care, which ordinarily occurs after the end of the preconceptional period—the critical time for formation of the neural tube.

Copyright 2004 by the National Academy of Sciences. All rights reserved.

Dietary Reference Intakes (DRIs): Recommended Intakes for Individuals, Elements
Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	Calcium (mg/d)	Chromium (µg/d)	Copper (µg/d)	Fluoride (mg/d)	Iodine (µg/d)	Iron (mg/d)	Magnesium (mg/d)	Manganese (mg/d)	Molybdenum (µg/d)	Phosphorus (mg/d)	Selenium (µg/d)	Zinc (mg/d)	Potassium (g/d)	Sodium (g/d)	Chloride (g/d)
<i>Infants</i>															
0–6 mo	210*	0.2*	200*	0.01*	110*	0.27*	30*	0.003*	2*	100*	15*	2*	0.4*	0.12*	0.18*
7–12 mo	270*	5.5*	220*	0.5*	130*	11	75*	0.6*	3*	275*	20*	3	0.7*	0.37*	0.57*
<i>Children</i>															
1–3 y	500*	11*	340	0.7*	90	7	80	1.2*	17	460	20	3	3.0*	1.0*	1.5*
4–8 y	800*	15*	440	1*	90	10	130	1.5*	22	500	30	5	3.8*	1.2*	1.9*
<i>Males</i>															
9–13 y	1,300*	25*	700	2*	120	8	240	1.9*	34	1,250	40	8	4.5*	1.5*	2.3*
14–18 y	1,300*	35*	890	3*	150	11	410	2.2*	43	1,250	55	11	4.7*	1.5*	2.3*
19–30 y	1,000*	35*	900	4*	150	8	400	2.3*	45	700	55	11	4.7*	1.5*	2.3*
31–50 y	1,000*	35*	900	4*	150	8	420	2.3*	45	700	55	11	4.7*	1.5*	2.3*
51–70 y	1,200*	30*	900	4*	150	8	420	2.3*	45	700	55	11	4.7*	1.3*	2.0*
> 70 y	1,200*	30*	900	4*	150	8	420	2.3*	45	700	55	11	4.7*	1.2*	1.8*
<i>Females</i>															
9–13 y	1,300*	21*	700	2*	120	8	240	1.6*	34	1,250	40	8	4.5*	1.5*	2.3*
14–18 y	1,300*	24*	890	3*	150	15	360	1.6*	43	1,250	55	9	4.7*	1.5*	2.3*
19–30 y	1,000*	25*	900	3*	150	18	310	1.8*	45	700	55	8	4.7*	1.5*	2.3*
31–50 y	1,000*	25*	900	3*	150	18	320	1.8*	45	700	55	8	4.7*	1.5*	2.3*
51–70 y	1,200*	20*	900	3*	150	8	320	1.8*	45	700	55	8	4.7*	1.3*	2.0*
> 70 y	1,200*	20*	900	3*	150	8	320	1.8*	45	700	55	8	4.7*	1.2*	1.8*
<i>Pregnancy</i>															
14–18 y	1,300*	29*	1,000	3*	220	27	400	2.0*	50	1,250	60	13	4.7*	1.5*	2.3*
19–30 y	1,000*	30*	1,000	3*	220	27	350	2.0*	50	700	60	11	4.7*	1.5*	2.3*
31–50 y	1,000*	30*	1,000	3*	220	27	360	2.0*	50	700	60	11	4.7*	1.5*	2.3*
<i>Lactation</i>															
14–18 y	1,300*	44*	1,300	3*	290	10	360	2.6*	50	1,250	70	14	5.1*	1.5*	2.3*
19–30 y	1,000*	45*	1,300	3*	290	9	310	2.6*	50	700	70	12	5.1*	1.5*	2.3*
31–50 y	1,000*	45*	1,300	3*	290	9	320	2.6*	50	700	70	12	5.1*	1.5*	2.3*

NOTE: This table presents Recommended Dietary Allowances (RDAs) in **bold type** and Adequate Intakes (AIs) in ordinary type followed by an asterisk (*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97 to 98 percent) individuals in a group. For healthy breastfed infants, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover needs of all individuals in the group, but lack of data or uncertainty in the data prevent being able to specify with confidence the percentage of individuals covered by this intake.

SOURCES: *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride* (1997); *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B₆, Folate, Vitamin B₁₂, Pantothenic Acid, Biotin, and Choline* (1998); *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids* (2000); *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc* (2001); and *Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate* (2004). These reports may be accessed via <http://www.nap.edu>.

Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels (UL^a), Vitamins
Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	Vitamin A (μg/d) ^b	Vitamin C (mg/d)	Vitamin D (μg/d)	Vitamin E (mg/d) ^{c,d}	Vitamin K	Thiamin	Ribo-flavin	Niacin (mg/d) ^d	Vitamin B ₆ (mg/d)	Folate (μg/d) ^d	Vitamin B ₁₂	Pantothenic Acid	Biotin	Choline (g/d)	Carotenoids ^e
<i>Infants</i>															
0–6 mo	600	ND ^f	25	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
7–12 mo	600	ND	25	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
<i>Children</i>															
1–3 y	600	400	50	200	ND	ND	ND	10	30	300	ND	ND	ND	1.0	ND
4–8 y	900	650	50	300	ND	ND	ND	15	40	400	ND	ND	ND	1.0	ND
<i>Males, Females</i>															
9–13 y	1,700	1,200	50	600	ND	ND	ND	20	60	600	ND	ND	ND	2.0	ND
14–18 y	2,800	1,800	50	800	ND	ND	ND	30	80	800	ND	ND	ND	3.0	ND
19–70 y	3,000	2,000	50	1,000	ND	ND	ND	35	100	1,000	ND	ND	ND	3.5	ND
> 70 y	3,000	2,000	50	1,000	ND	ND	ND	35	100	1,000	ND	ND	ND	3.5	ND
<i>Pregnancy</i>															
14–18 y	2,800	1,800	50	800	ND	ND	ND	30	80	800	ND	ND	ND	3.0	ND
19–50 y	3,000	2,000	50	1,000	ND	ND	ND	35	100	1,000	ND	ND	ND	3.5	ND
<i>Lactation</i>															
14–18 y	2,800	1,800	50	800	ND	ND	ND	30	80	800	ND	ND	ND	3.0	ND
19–50 y	3,000	2,000	50	1,000	ND	ND	ND	35	100	1,000	ND	ND	ND	3.5	ND

^aUL = The maximum level of daily nutrient intake that is likely to pose no risk of adverse effects. Unless otherwise specified, the UL represents total intake from food, water, and supplements. Due to lack of suitable data, ULs could not be established for vitamin K, thiamin, riboflavin, vitamin B₁₂, pantothenic acid, biotin, carotenoids. In the absence of ULs, extra caution may be warranted in consuming levels above recommended intakes.

^b As preformed vitamin A only.

^c As α-tocopherol; applies to any form of supplemental α-tocopherol.

^dThe ULs for vitamin E, niacin, and folate apply to synthetic forms obtained from supplements, fortified foods, or a combination of the two.

^e β-Carotene supplements are advised only to serve as a provitamin A source for individuals at risk of vitamin A deficiency.

^fND = Not determinable due to lack of data of adverse effects in this age group and concern with regard to lack of ability to handle excess amounts. Source of intake should be from food only to prevent high levels of intake.

SOURCES: *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride* (1997); *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B₆, Folate, Vitamin B₁₂, Pantothenic Acid, Biotin, and Choline* (1998); *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids* (2000); and *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc* (2001). These reports may be accessed via <http://www.nap.edu>.

Copyright 2004 by the National Academy of Sciences. All rights reserved.

Dietary Reference Intakes (DRIs): Tolerable Upper Intake Levels (UL^a), Elements
Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	Arsenic ^b	Boron (mg/d)	Calcium (g/d)	Chromium	Copper (μg/d)	Fluoride (mg/d)	Iodine (μg/d)	Iron (mg/d)	Magnesium (mg/d) ^c	Manganese (mg/d)	Molybdenum (μg/d)	Nickel (mg/d)	Phosphorus (g/d)	Potassium	Selenium (μg/d)	Silicon ^d	Sulfate	Vanadium (mg/d) ^e	Zinc (mg/d)	Sodium (g/d)	Chloride (g/d)
<i>Infants</i>																					
0–6 mo	ND ^f	ND	ND	ND	ND	0.7	ND	40	ND	ND	ND	ND	ND	ND	45	ND	ND	ND	4	ND	ND
7–12 mo	ND	ND	ND	ND	ND	0.9	ND	40	ND	ND	ND	ND	ND	ND	60	ND	ND	ND	5	ND	ND
<i>Children</i>																					
1–3 y	ND	3	2.5	ND	ND	1.3	200	40	65	2	300	0.2	3	ND	90	ND	ND	ND	7	1.5	2.3
4–8 y	ND	6	2.5	ND	ND	2.2	300	40	110	3	600	0.3	3	ND	150	ND	ND	ND	12	1.9	2.9
<i>Males</i>																					
<i>Females</i>																					
9–13 y	ND	11	2.5	ND	ND	10	600	40	350	6	1,100	0.6	4	ND	280	ND	ND	ND	23	2.2	3.4
14–18 y	ND	17	2.5	ND	ND	10	900	45	350	9	1,700	1.0	4	ND	400	ND	ND	ND	34	2.3	3.6
19–70 y	ND	20	2.5	ND	ND	10	1,100	45	350	11	2,000	1.0	4	ND	400	ND	ND	1.8	40	2.3	3.6
>70 y	ND	20	2.5	ND	ND	10	1,100	45	350	11	2,000	1.0	3	ND	400	ND	ND	1.8	40	2.3	3.6
<i>Pregnancy</i>																					
14–18 y	ND	17	2.5	ND	ND	10	900	45	350	9	1,700	1.0	3.5	ND	400	ND	ND	ND	34	2.3	3.6
19–50 y	ND	20	2.5	ND	ND	10	1,100	45	350	11	2,000	1.0	3.5	ND	400	ND	ND	ND	40	2.3	3.6
<i>Lactation</i>																					
14–18 y	ND	17	2.5	ND	ND	10	900	45	350	9	1,700	1.0	4	ND	400	ND	ND	ND	34	2.3	3.6
19–50 y	ND	20	2.5	ND	ND	10	1,100	45	350	11	2,000	1.0	4	ND	400	ND	ND	ND	40	2.3	3.6

^a UL = The maximum level of daily nutrient intake that is likely to pose no risk of adverse effects. Unless otherwise specified, the UL represents total intake from food, water, and supplements. Due to lack of suitable data, ULs could not be established for arsenic, chromium, silicon, potassium, and sulfate. In the absence of ULs, extra caution may be warranted in consuming levels above recommended intakes.

^b Although the UL was not determined for arsenic, there is no justification for adding arsenic to food or supplements.

^c The ULs for magnesium represent intake from a pharmacological agent only and do not include intake from food and water.

^d Although silicon has not been shown to cause adverse effects in humans, there is no justification for adding silicon to supplements.

^e Although vanadium in food has not been shown to cause adverse effects in humans, there is no justification for adding vanadium to food and vanadium supplements should be used with caution. The UL is based on adverse effects in laboratory animals and this data could be used to set a UL for adults but not children and adolescents.

^f ND = Not determinable due to lack of data of adverse effects in this age group and concern with regard to lack of ability to handle excess amounts. Source of intake should be from food only to prevent high levels of intake.

SOURCES: *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride* (1997); *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B₆, Folate, Vitamin B₁₂, Pantothenic Acid, Biotin, and Choline* (1998); *Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids* (2000); *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc* (2001); and *Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate* (2004). These reports may be accessed via <http://www.nap.edu>.

**Dietary Reference Intakes (DRIs): Estimated Energy Requirements (EER) for Men and Women
30 Years of Age^a**

Food and Nutrition Board, Institute of Medicine, National Academies							
Height (m [in])	PAL ^b	Weight for BMI ^c of 18.5 kg/m ² (kg [lb])	Weight for BMI of 24.99 kg/m ² (kg [lb])	EER, Men ^d (kcal/day)		EER, Women ^d (kcal/day)	
				BMI of 18.5 kg/m ²	BMI of 24.99 kg/m ²	BMI of 18.5 kg/m ²	BMI of 24.99 kg/m ²
1.50 (59)	Sedentary	41.6 (92)	56.2 (124)	1,848	2,080	1,625	1,762
	Low active			2,009	2,267	1,803	1,956
	Active			2,215	2,506	2,025	2,198
	Very active			2,554	2,898	2,291	2,489
1.65 (65)	Sedentary	50.4 (111)	68.0 (150)	2,068	2,349	1,816	1,982
	Low active			2,254	2,566	2,016	2,202
	Active			2,490	2,842	2,267	2,477
	Very active			2,880	3,296	2,567	2,807
1.80 (71)	Sedentary	59.9 (132)	81.0 (178)	2,301	2,635	2,015	2,211
	Low active			2,513	2,884	2,239	2,459
	Active			2,782	3,200	2,519	2,769
	Very active			3,225	3,720	2,855	3,141

^a For each year below 30, add 7 kcal/day for women and 10 kcal/day for men. For each year above 30, subtract 7 kcal/day for women and 10 kcal/day for men.

^b PAL = physical activity level.

^c BMI = body mass index.

^d Derived from the following regression equations based on doubly labeled water data:

Adult man: $EER = 662 - 9.53 \times \text{age (y)} + PA \times (15.91 \times \text{wt [kg]} + 539.6 \times \text{ht [m]})$

Adult woman: $EER = 354 - 6.91 \times \text{age (y)} + PA \times (9.36 \times \text{wt [kg]} + 726 \times \text{ht [m]})$

Where PA refers to coefficient for PAL

PAL = total energy expenditure ÷ basal energy expenditure

PA = 1.0 if PAL ≥ 1.0 < 1.4 (sedentary)

PA = 1.12 if PAL ≥ 1.4 < 1.6 (low active)

PA = 1.27 if PAL ≥ 1.6 < 1.9 (active)

PA = 1.45 if PAL ≥ 1.9 < 2.5 (very active)

Dietary Reference Intakes (DRIs): Acceptable Macronutrient Distribution Ranges

Food and Nutrition Board, Institute of Medicine, National Academies			
Macronutrient	Range (percent of energy)		
	Children, 1–3 y	Children, 4–18 y	Adults
Fat	30–40	25–35	20–35
<i>n</i> -6 polyunsaturated fatty acids ^a (linoleic acid)	5–10	5–10	5–10
<i>n</i> -3 polyunsaturated fatty acids ^a (α-linolenic acid)	0.6–1.2	0.6–1.2	0.6–1.2
Carbohydrate	45–65	45–65	45–65
Protein	5–20	10–30	10–35

^a Approximately 10% of the total can come from longer-chain *n*-3 or *n*-6 fatty acids.

SOURCE: *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids* (2002).

Dietary Reference Intakes (DRIs): Recommended Intakes for Individuals, Macronutrients
Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	Total Water ^a (L/d)	Carbohydrate (g/d)	Total Fiber (g/d)	Fat (g/d)	Linoleic Acid (g/d)	α-Linolenic Acid (g/d)	Protein ^b (g/d)
<i>Infants</i>							
0–6 mo	0.7*	60*	ND	31*	4.4*	0.5*	9.1*
7–12 mo	0.8*	95*	ND	30*	4.6*	0.5*	13.5
<i>Children</i>							
1–3 y	1.3*	130	19*	ND	7*	0.7*	13
4–8 y	1.7*	130	25*	ND	10*	0.9*	19
<i>Males</i>							
9–13 y	2.4*	130	31*	ND	12*	1.2*	34
14–18 y	3.3*	130	38*	ND	16*	1.6*	52
19–30 y	3.7*	130	38*	ND	17*	1.6*	56
31–50 y	3.7*	130	38*	ND	17*	1.6*	56
51–70 y	3.7*	130	30*	ND	14*	1.6*	56
> 70 y	3.7*	130	30*	ND	14*	1.6*	56
<i>Females</i>							
9–13 y	2.1*	130	26*	ND	10*	1.0*	34
14–18 y	2.3*	130	26*	ND	11*	1.1*	46
19–30 y	2.7*	130	25*	ND	12*	1.1*	46
31–50 y	2.7*	130	25*	ND	12*	1.1*	46
51–70 y	2.7*	130	21*	ND	11*	1.1*	46
> 70 y	2.7*	130	21*	ND	11*	1.1*	46
<i>Pregnancy</i>							
14–18 y	3.0*	175	28*	ND	13*	1.4*	71
19–30 y	3.0*	175	28*	ND	13*	1.4*	71
31–50 y	3.0*	175	28*	ND	13*	1.4*	71
<i>Lactation</i>							
14–18 y	3.8*	210	29*	ND	13*	1.3*	71
19–30 y	3.8*	210	29*	ND	13*	1.3*	71
31–50 y	3.8*	210	29*	ND	13*	1.3*	71

NOTE: This table presents Recommended Dietary Allowances (RDAs) in **bold** type and Adequate Intakes (AIs) in ordinary type followed by an asterisk (*). RDAs and AIs may both be used as goals for individual intake. RDAs are set to meet the needs of almost all (97 to 98 percent) individuals in a group. For healthy infants fed human milk, the AI is the mean intake. The AI for other life stage and gender groups is believed to cover the needs of all individuals in the group, but lack of data or uncertainty in the data prevent being able to specify with confidence the percentage of individuals covered by this intake.

^a Total water includes all water contained in food, beverages, and drinking water.

^b Based on 0.8 g/kg body weight for the reference body weight.

Dietary Reference Intakes (DRIs): Additional Macronutrient Recommendations
Food and Nutrition Board, Institute of Medicine, National Academies

Macronutrient	Recommendation
Dietary cholesterol	As low as possible while consuming a nutritionally adequate diet
Trans fatty acids	As low as possible while consuming a nutritionally adequate diet
Saturated fatty acids	As low as possible while consuming a nutritionally adequate diet
Added sugars	Limit to no more than 25% of total energy

SOURCE: *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids* (2002).

Dietary Reference Intakes (DRIs): Estimated Average Requirements for Groups
Food and Nutrition Board, Institute of Medicine, National Academies

Life Stage Group	CHO (g/d)	Protein (g/d)	Vit A (µg/d) ^a	Vit C (mg/d)	Vit E (mg/d) ^b	Thiamin (mg/d)	Ribo-flavin (mg/d)	Niacin (mg/d) ^c	Vit B ₆ (mg/d)	Folate (µg/d) ^a	Vit B ₁₂ (µg/d)	Copper (µg/d)	Iodine (µg/d)	Iron (mg/d)	Magnesium (mg/d)	Molybdenum (µg/d)	Phosphorus (mg/d)	Selenium (µg/d)	Zinc (mg/d)
Infants																			
7–12 mo	10													6.9					2.5
Children																			
1–3 y	100	11	210	13	5	0.4	0.4	5	0.4	120	0.7	260	65	3.0	65	13	380	17	2.5
4–8 y	100	15	275	22	6	0.5	0.5	6	0.5	160	1.0	340	65	4.1	110	17	405	23	4.0
Males																			
9–13 y	100	27	445	39	9	0.7	0.8	9	0.8	250	1.5	540	73	5.9	200	26	1,055	35	7.0
14–18 y	100	44	630	63	12	1.0	1.1	12	1.1	330	2.0	685	95	7.7	340	33	1,055	45	8.5
19–30 y	100	46	625	75	12	1.0	1.1	12	1.1	320	2.0	700	95	6	330	34	580	45	9.4
31–50 y	100	46	625	75	12	1.0	1.1	12	1.1	320	2.0	700	95	6	350	34	580	45	9.4
51–70 y	100	46	625	75	12	1.0	1.1	12	1.4	320	2.0	700	95	6	350	34	580	45	9.4
> 70 y	100	46	625	75	12	1.0	1.1	12	1.4	320	2.0	700	95	6	350	34	580	45	9.4
Females																			
9–13 y	100	28	420	39	9	0.7	0.8	9	0.8	250	1.5	540	73	5.7	200	26	1,055	35	7.0
14–18 y	100	38	485	56	12	0.9	0.9	11	1.0	330	2.0	685	95	7.9	300	33	1,055	45	7.3
19–30 y	100	38	500	60	12	0.9	0.9	11	1.1	320	2.0	700	95	8.1	255	34	580	45	6.8
31–50 y	100	38	500	60	12	0.9	0.9	11	1.1	320	2.0	700	95	8.1	265	34	580	45	6.8
51–70 y	100	38	500	60	12	0.9	0.9	11	1.3	320	2.0	700	95	5	265	34	580	45	6.8
> 70 y	100	38	500	60	12	0.9	0.9	11	1.3	320	2.0	700	95	5	265	34	580	45	6.8
Pregnancy																			
14–18 y	135	50	530	66	12	1.2	1.2	14	1.6	520	2.2	785	160	23	335	40	1,055	49	10.5
19–30 y	135	50	550	70	12	1.2	1.2	14	1.6	520	2.2	800	160	22	290	40	580	49	9.5
31–50 y	135	50	550	70	12	1.2	1.2	14	1.6	520	2.2	800	160	22	300	40	580	49	9.5
Lactation																			
14–18 y	160	60	880	96	16	1.2	1.3	13	1.7	450	2.4	985	209	7	300	35	1,055	59	10.9
19–30 y	160	60	900	100	16	1.2	1.3	13	1.7	450	2.4	1,000	209	6.5	255	36	580	59	10.4
31–50 y	160	60	900	100	16	1.2	1.3	13	1.7	450	2.4	1,000	209	6.5	265	36	580	59	10.4

NOTE: This table presents Estimated Average Requirements (EARs), which serve two purposes: for assessing a adequacy of population intakes, and as the basis for calculating Recommended Dietary Allowances (RDAs) for individuals for those nutrients. EARs have not been established for vitamin D, vitamin K, pantothenic acid, biotin, choline, calcium, chromium, fluoride, manganese, or other nutrients not yet evaluated via the DRI process.

^a As retinol activity equivalents (RAEs). 1 RAE = 1 µg retinol, 12 µg β-carotene, 24 µg α-carotene, or 24 µg β-cryptoxanthin. The RAE for dietary provitamin A carotenoids is two-fold greater than retinol equivalents (RE), whereas the RAE for preformed vitamin A is the same as RE.

^b As α-tocopherol. α-Tocopherol includes *RRR*-α-tocopherol, the only form of α-tocopherol that occurs naturally in foods, and the *2R*-stereoisomeric forms of α-tocopherol (*RRR*-, *RSR*-, *RSS*-, and *RSS*-α-tocopherol) that occur in fortified foods and supplements. It does not include the *2S*-stereoisomeric forms of α-tocopherol (*SRR*-, *SSR*-, *SRS*-, and *SSS*-α-tocopherol), also found in fortified foods and supplements.

^c As niacin equivalents (NE). 1 mg of niacin = 60 mg of tryptophan.

^d As dietary folate equivalents (DFE). 1 DFE = 1 µg food folate = 0.6 µg of folic acid from fortified food or as a supplement consumed with food = 0.5 µg of a supplement taken on an empty stomach.

SOURCES: *Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride* (1997); *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B₆, Folate, Vitamin B₁₂, Pantothenic Acid, Biotin, and Choline* (1998); *Dietary Reference Intakes for Vitamin E, Selenium, and Carotenoids* (2000); *Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc* (2001), and *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids* (2002). These reports may be accessed via www.nap.edu.

Note: Italicized *f*'s and *t*'s refer to figures and tables

- A1c levels, 523*t*
 Abacavir, 834*t*
 Abatacept, 681*t*
 Abducens nerve, 221*t*
 Abetalipoproteinemia, 144–145
 Absorption, 384
 Acanthocytosis, 144–145
 Acarbose, 401, 543
 Accidents, 44*t*
 Accolate, 296*t*
 Accutane (isotretinoin), 112
 Acesulfame potassium (Sunette), 533*t*
 Acetaldehyde, 174
 Acetaminophen, 381, 679*t*
 Acetylcholine, 224*t*, 227
 Acetylcholine receptors (AChRs), 251
 Achalasia, 390–391
 Achondroplasia, 45*t*
 Achromycin V (tetracycline), 486*t*
 Acid-base balance, 860*t*
 Aciphex (rabeprazole), 409*t*, 512
 Acne, 110, 112
 Acquired autoimmune hemolytic anemia, 705*t*
 Acquired immunity, 820*t*
 Acquired immunodeficiency syndrome (AIDS), 829–837
 clinical indicators, 831–832*t*
 clinical staging, 830*t*
 drugs and side effects, 833, 834–836
 nutritional guidelines for, 831*t*, 833
 nutritional objectives for, 832–833
 patient education, 833–837
 supplements, 833
 ACRI6, 245
 Acrobose (Precose), 547*t*
 Acrodermatitis enteropathica, 112
 Acromegaly, 573–574
 Actigall (ursodiol), 152, 517
 Actinomycin D, 787
 Actonel (risedronate), 670*t*, 673
 Actos (pioglitazone), 547*t*
 Acute anemia, 689*t*
 Acute gastritis, 402
 Acute glomerulonephritis, 879
 Acute leukemia, 793*t*
 Acute lymphocytic leukemia, 793*t*
 Acute myelogenous leukemia, 793*t*
 Acute necrotizing ulcerative gingivitis, 103
 Acute pyelonephritis, 894
 Acute renal failure (ARF), 864
 Acute respiratory distress syndrome (ARDS), 317
 Acute stress disorder, 222*t*
 Acyclovir, 283, 755*t*, 835*t*
 Adalimumab (Humira), 332*t*, 681*t*
 Adderall (amphetamine), 147*t*
 Adderol, 356
 Addiction, 287–289
 Addison's disease, 582–584
 Adefovir, 834*t*
 Adenocarcinoma, 732*t*
 Adenoidectomy, 811*t*
 Adenoma, 732*t*
 Adipex (phentermine), 617*t*
 Adjustment disorder, 222*t*
 Admixture, 899*t*
 Adolescents, 33–37
 body mass index for, 605*t*
 drug effects, 36
 eating behavior, 34
 food safety tips, 36
 growth and development of, 33–34
 HIV infection in, 177–179
 nutritional guidelines for, 36–38
 nutritional objectives for, 35
 pregnancy in, 36*t*
 recommended intakes, 35*t*
 sports nutrition, 38
 supplements, 36
 type 1 diabetes in, 521*t*
 type 2 diabetes in, 521*t*, 549–551
 Adrenal cortex, 570*t*, 585–586
 Adrenal gland disorders. *See also* Endocrine disorders
 Addison's disease, 582–584
 adrenocortical insufficiency, 582–584
 hyperaldosteronism, 585–586
 pheochromocytoma, 586–588
 Adrenalin, 570*t*
 Adrenergic system blockers, 361*t*
 Adrenocortical insufficiency, 582–584
 Adrenocorticotrophic hormone, 569*t*, 571
 Adriamycin (doxorubicin), 774, 835*t*
 Adrucil (5-fluorouracil), 512
 Adults, 44–56
 disorders and related genes, 45–46*t*
 drugs and side effects, 49, 52*t*
 food and nutrition, 48–49
 functional foods, 50–51*t*
 leading causes of death, 44*t*
 nutritional guidelines for, 49–53
 nutritional objectives for, 47
 nutrition-related concerns for women, 48*t*
 single gene disorders in, 141*t*
 supplements, 49
 ADV (adefovir), 834*t*
 Advair, 296*t*
 Advil (ibuprofen), 408, 657, 660*t*
 AeroBid (flunisolide), 296*t*
 African American diet, 85
 African diet, 85
 Age-related macular degeneration (AMD), 106–108
 Aging. *See* Elderly
 Agoraphobia, 223*t*
 Agrylin (anagrelide), 727, 729
 Albuterol, 296*t*
 Alcohol consumption
 addiction, 288*t*
 bone health and, 665*t*
 breast cancer and, 784
 calories, 51
 dietary guideline for, 4*t*
 headaches and, 247*t*
 heart disease and, 338*t*
 pregnancy and, 8
 Alcoholic liver disease, 474–477
 Alcoholism, 287
 Aldosterone, 583, 860*t*
 Aldosterone blockers, 361*t*
 Aldosteronism, 45*t*
 Alendronate (Fosamax), 52*t*, 670*t*, 844
 Alendronic acid, 669
 Aleve (naproxen), 657
 Alfalfa, 71*t*
 Alfence (rabeprazole), 409*t*
 Alferon N, 486*t*
 Alimentum, 20
 Alitame, 533*t*
 Alkeran (melphalan), 798
 Alkylating agents, 744*t*
 allergens, 125*t*
 Allergic pneumonia, 314*t*
 Allergies, 122–127
 allergens, 125*t*
 clinical indicators, 124
 education, 131
 food processing concerns, 126*t*
 gastrointestinal, 122–123
 in infants, 21*t*
 nutritional guidelines for, 124–125
 nutritional objectives for, 124
 patient education, 126–127
 prevalence of, 122
 supplements, 126
 symptoms, 122
 Allicin, 736*t*
 Allium, 736*t*, 768
 Allopregnanolone, 229
 Allopurinol (Aloprim), 646
 Allyl sulfides, 735*t*, 736*t*, 790*t*
 Aloe vera, 71*t*, 534*t*
 Aloprim (allopurinol), 646
 Alpha carotene, 790*t*
 Alpha linolenic acid, 338*t*, 433
 Alpha lipoic acid, 71*t*, 534*t*
 5-Alpha reductase, 52*t*
 Alpha thalassemia, 720
 Alpha-1-antitrypsin deficiency, 45*t*
 Alpha-adrenergic blockers, 616*t*
 Alpha-carotene, 499*t*
 Alpha-glucosidase deficiency, 176*t*
 Alpha-glucosidase inhibitors, 547*t*

- Alphanate, 723
 Alport syndrome, 862–863
 Alprazolam (Xanax), 284*t*, 616*t*
 Aluminum hydroxide, 396–397, 409*t*
 Aluminum-containing binders, 872*t*
 Alupent (metaproterenol), 296*t*
 Alzheimer's disease, 45*t*, 227–231
 AM80, 250
 Amantadine (Symmetrel), 255*t*
 Amaryl (glimepiride), 547*t*
 Amica, 71*t*
 Amiloride (Midamor), 486*t*
 Amino acids, 520
 in breast milk, 13*t*
 for healthy vision, 108*t*
 nutritional relevance, 224*t*
 in pregnancy, 7
 Aminosalicylates, 436
 Aminosalicylic acid, 332*t*
 5-Aminosalicylic acid, 436, 467
 Amitiza (lubiprostone), 420*t*
 Amitriptyline (Elavil), 284*t*, 616*t*, 657
 Amnesic disorder, 222*t*
 Amoxapine (Asendin), 284*t*
 Amoxicillin, 895
 Amoxil, 895
 Amphetamines, 147*t*, 288*t*
 Amphogel, 409*t*
 Amphotericin, 755*t*
 Amphotericin-B, 835*t*
 Ampicillins, 486*t*
 Amputations, 524*t*, 808*t*, 809*t*
 Amylin (Symlin), 547*t*
 Amyotrophic lateral sclerosis (ALS), 45*t*, 232–234
 Anabolic steroids, 258, 288*t*, 836*t*, 841*t*
 Anadrol-50, 616*t*
 Anafranil, 283*t*, 284*t*
 Anagrelide, 727, 729
 Anakinra (Kineret), 681*t*
 Analgesics, 235, 258, 364*t*, 376, 496*t*, 510*t*, 679*t*, 683, 755*t*, 804, 841*t*
 Anastrozole (Arimidex), 784
Ancylostoma duodenale, 845*t*
 Andersen disease, 176*t*
 Androderm, 616*t*
 Androgens, 570*t*, 616*t*
 Androstenedione, 40, 42*t*, 79*t*
 Anemia, 687–690. *See also* Hematologic disorders
 aplastic, 696–698
 assessment factors, 687
 in cancer patients, 739*t*
 of chronic disease, 690–692
 Cooley's, 720
 copper deficiency, 698–700
 Diamond-Blackfan, 692–693
 Fanconi's, 696–698
 folic acid deficiency, 701–704
 glucose-6-phosphate dehydrogenase deficiency, 705*t*
 hemolytic, 705–706
 iron deficiency, 89*t*
 iron tests, 689*t*
 iron-deficiency, 706–709
 Mediterranean, 720
 megaloblastic, 713–714
 in neonates, 692–694
 parasitic, 710–712
 pernicious, 713–714
 of prematurity, 692–694
 of renal diseases, 694–696
 sickle cell, 719
 sideroblastic, 715–716
 signs and symptoms, 689*t*
 spherocytic, 705*t*
 Vitamin B₁₂ deficiency, 713–714
 Anencephaly, 194
 Anesthesia, 804
 Anethol, 433, 644
 Angina pectoris, 343–345
 Angioplasty, 378
 Angiotensin, 860*t*
 Angiotensin II receptor antagonists, 371*t*
 Angiotensin II receptor blockers (ARBs), 886
 Angiotensin receptor blockers, 361*t*
 Angiotensin-converting enzyme inhibitors (ACEI), 361*t*, 371*t*, 872*t*, 886
 Ankylosing spondylitis, 643–644
 Anorexia, 739*t*
 Anorexia athletica (compulsive exercising), 274*t*
 Anorexia nervosa, 266–268, 581
 Antabuse (disulfiram), 476
 Antacids, 391, 394, 396, 398, 402, 409*t*, 841*t*
 Anthocyanidins, 500*t*
 Anthocyanins, 734*t*, 790*t*
 Antiangiogenesis, 732*t*
 Antiangiogenic agent, 744*t*
 Antianxiety agents, 616*t*
 Antibiotic lock technique, 804
 Antibiotic ointments, 841*t*
 Antibiotics, 152, 154, 160, 193, 296*t*, 310*t*, 402, 423, 429, 432, 442*t*, 459*t*, 486*t*, 491*t*, 498*t*
 oral, 841*t*
 Antibodies, 732*t*
 Anticholinergics, 255*t*, 296*t*
 Anticoagulant therapy, 356
 Anticoagulants, 366, 374, 379
 Anticonvulsants, 30, 174, 235, 239, 265, 276, 616*t*
 Antidepressants, 230*t*, 255*t*, 268, 616*t*, 755*t*, 835*t*, 872*t*
 Antidiarrheals, 401, 423–424, 429, 432, 459*t*
 Antidiuretic hormone, 571
 Antiemetic agents, 9, 411, 559, 744*t*
 Antiepileptic drugs, 268
 Antiestrogen therapy, 784
 Antifungals, 835*t*
 Antihemophilic factor, 723
 Antihistamines, 126, 616*t*, 727, 755*t*
 Anti-hyperglycemics, 547*t*
 Antihypertensive agents, 486*t*, 586, 685
 Anti-inflammatory drugs, 230*t*, 486*t*, 660*t*, 683, 685
 Anti-inflammatory factors, 13*t*
 Antimalarials, 651
 Antimetabolites, 744*t*
 Antimicrobial factors, 13*t*
 Antineoplastic agents, 745*t*, 835*t*
 Antioxidants, 185, 225*t*, 337*t*, 339*t*, 476, 499–500*t*, 534*t*, 733, 790*t*, 835*t*
 Antiplatelet drugs, 379
 Antiproliferative agents, 893*t*
 Antipsychotics, 149, 230*t*, 276, 283*t*, 616*t*
 Antithymocyte globulin, 755*t*
 Anti-tumor necrosis factor alpha, 431, 432–433
 Antiviral agents, 255*t*, 442*t*, 486*t*, 755*t*
 Anturane (sulfipyrazone), 646
 Anusol, 466
 Anxiety disorders, 222*t*
 APalpha, 229
 Apigenin, 499*t*, 734*t*
 Aplastic anemia, 696–698
 Apokyn (apomorphine hydrochloride), 255*t*
 Apolipoprotein B deficiency, 144–145
 Apolipoprotein E, 227, 338*t*
 Appendectomy, 809*t*
 Appetite stimulants, 836*t*
 Apresoline (hydralazine), 376
 Aptivus, 834*t*, 835*t*
 AquaMEPHYTON (phytonadione), 486*t*
 Arachidonic acid, 186
 Aralen (chloroquine), 651
 Arctic root, 77*t*
 Aredia (pamidronate), 673
 Arginase, 214*t*
 Arginine, 214*t*, 824*t*
 Arginine vasopressin, 571
 Argininosuccinate lyase, 214*t*
 Argininosuccinate synthetase, 214*t*
 Argininosuccinic aciduria, 214*t*
 Aricept, 168
 Aricept (donepezil), 230*t*
 Arimidex (anastrozole), 784
 Aripiprazole (Abilify), 283*t*
 Aristolochic acid, 79*t*
 Arnica, 113
 Aromatic amino acid, 483
 Arrhythmias, 373
 Arsenic trioxide (Trisenox), 798
 Artane (trihexyphenidyl), 255*t*
 Artemisinin, 712*t*
 Arterial vascular disease, 525*t*
 Arteritis, 345–347
 Arthritis, 638
 Ascariasis, 845*t*
 Ascites, 477–479
 Asendin (amoxapine), 284*t*
 Ashwagandha, 746*t*
 Asian diet, 85
 Aspart (Novolog), 533*t*
 Aspartame, 533*t*
 Aspartate, 224*t*
 Asperger's disorder, 148
 Aspiration pneumonia, 314*t*
 Aspirin, 338*t*, 366, 374, 381, 679*t*, 697, 727
 Astaxanthin, 499*t*
 Asthma, 293–296
 Astragalus, 80*t*, 746*t*
 Astragalus, 736*t*
 Atamet, 255*t*
 Atazanavir, 834*t*
 Atenolol (Tenormin), 486*t*, 616*t*
 Atherogenic dyslipidemia, 540
 Atherosclerosis, 347–351
 Athletes, 38–43
 children and adolescent athletes, 38
 drugs and side effects, 40–42
 female, 38
 food safety tips, 43
 meal planning, 41*t*

- nutritional guidelines, 40, 42*t*
 nutritional objectives for, 39–40
 proteins for, 40*t*
 supplements, 42, 42*t*
 Ativan (lorazepam), 284*t*
 Atomoxetine (Strattera), 31, 147*t*
 Atonic constipation, 418–419
 Atopic dermatitis, 110–111, 112
 Atorvastatin, 350*t*, 886
 Atripia, 834*t*
 Atrophic gastritis, 401
 Atrovent, 296*t*, 302
 Attention-deficit disorders, 145–147, 222*t*
 Attention-deficit hyperactivity disorder (ADHD) disorders, 145–147
 Autism, 148
 Autism spectrum disorder (ASD), 148–150
 Autistic disorder, 222*t*
 Autoimmune inner-ear disease, 128–129
 Autoimmune kidney diseases, 879–881
 Autoimmune thyroiditis, 589
 Autonomic neuropathy, 524*t*
 Avandia (rosiglitazone), 547*t*
 Avastin (bevacizumab), 744*t*, 762
 Avenanthramides, 735*t*
 Aventyl, 284*t*, 616*t*
 Avlimil, 71*t*
 Avonex, 250
 Axid (nizatidine), 409*t*
 Ayuverda, 71*t*
 Azathioprine (Imuran), 250, 312, 329*t*, 364*t*, 436, 486*t*, 496*t*, 510*t*, 644, 651, 680*t*, 755*t*
 Azilect (rasagiline), 255*t*
 Azithromycin, 310*t*
 Azmacort (triamcinolone), 296*t*

 B cells, 821*t*
 Baclofen, 160, 250, 265
 Bacterial diarrheas, 421
 Bacterial pneumonia, 314*t*
 Bactrim, 486*t*, 836*t*, 895
 Bad breath, 98*t*
 Baking ingredients, 491*t*
 Baldness, 52*t*
 Ban lan gen, 747*t*
 Baraclude (Entecavir), 486*t*
 Barberrry, 71*t*
 Bariatric surgery, 812–815
 Barrett's esophagus, 395
 Basal cell carcinoma, 732*t*
 Basiliximab, 893*t*
 Bassen-Kornzweig syndrome, 144–145
 Beans, 491*t*, 535*t*
 Becker muscular dystrophy, 653*t*
 Beclomethasone, 755*t*
 Bee pollen, 126
 Belatacept, 893*t*
 Belimumab (Benlysta), 650
 Belladonna, 79*t*
 Benacol (sterol), 615
 Benadryl (diphenhydramine), 616*t*
 Benazepril (Lotensin), 886
 Benefiber, 235, 420*t*, 424
 Benemid (probenecid), 646
 Benlysta (belimumab), 650
 Benzo-alpha-pyrones, 735*t*
 Benzodiazepines, 284*t*, 616*t*
 Benzoyl peroxide, 110
 Benzotropine (Cogentin), 255*t*
 Beta thalassemia, 720
 Beta-adrenergic blockers, 616*t*
 Beta-agonists, 296*t*
 Beta-blockers, 356, 361*t*, 371*t*, 394, 476, 486*t*
 Beta-carotene, 499*t*, 734*t*, 736*t*, 760, 790*t*
 Beta-cryptoxanthin, 790*t*
 Beta-galactosidofructose, 486*t*
 Betaine, 149, 181, 194, 784
 Betaine-tHcy methyltransferase (BHMT), 194
 Betaseron, 250
 Beta-sitosterol, 736*t*
 Bevacizumab (Avastin), 744*t*, 762
 Beverages, 492*t*
 Bexxar, 744*t*
 Bezafibrate, 513
 Bezoar formation, 397–399
 Biaxin (clarithromycin), 315
 Bicytopenia, 698
Bifidobacterium infantis, 444
Bifidus infantis, 193
 Bigorexia, 274*t*
 Biguanides, 547*t*
 Bilberry, 72*t*, 534*t*
 Bile acid sequestrant, 350*t*
 Bile salt replacements, 459*t*
 Bile salts, 498*t*
 Biliary atresia, 150–152
 Biliary cirrhosis, 512–514
 Biliary disorders, 471–473
 Bilirubin, 500*t*
 Binge eating disorder, 222*t*, 269–270
 Biochanin A, 736*t*
 Bioflavonoids, 736*t*
 Biogenic amine, 224*t*
 Biogenic monoamines, 224*t*
 Biological response modifiers, 681*t*
 Biotherapy, 732*t*
 Biotin, 119*t*, 534*t*
 Bipolar disorders, 222*t*, 273–276, 279*t*
 Bisacodyl, 417, 420*t*
 Bismuth subsalicylate, 409*t*
 Bisoprolol, 616*t*
 Bisphosphonates, 310*t*, 670*t*, 752, 755*t*, 798, 844
 Bitter melon, 72*t*, 534*t*
 Bitter orange, 80*t*
 Black cohosh, 72*t*, 746*t*
 Bladder cancer, 772–773
 Bleeding disorders, 722–724
 Bleomycin, 764*t*, 835*t*
 Blindness, 106–108
 Blocadren (timolol), 486*t*
 Blood clotting factors, 722*t*
 Blood formation, nutritional factors in, 689*t*
 Blood glucose, 526*t*
 Blood lipids, 526*t*
 Blood pressure, 367–369, 526*t*, 540, 860*t*, 880
 Blood urea nitrogen (BUN), 694
 Body dysmorphic disorder, 222*t*, 274*t*
 Body mass index (BMI), 604–605*t*
 for adolescents, 605*t*
 for children, 198, 605*t*
 mortality and, 605*t*
 for older adults, 605*t*
 for pregnant women, 604*t*
 underweight and, 622
 Body weight
 in amputees, 808*t*
 calculation of, 604*t*, 606*t*
 Bone cancer, 751–752
 Bone disorders, 641–642
 Bone marrow transplantation, 753–756
 Boniva (ibandronate), 670*t*
 Borage, 80*t*
 Borage oil, 72*t*
 Boron, 665*t*
 Bortezomib (Velcade), 798, 893*t*
 Bosentan, 306
 Boswellia, 72*t*
 Botanicals. *See* Complementary nutrition
 Botulinum toxin, 195, 246
 Bowel surgery, 816–818
 Bradycardia, 373
 Brain. *See also* Neurological disorders
 cranial nerves, 221*t*
 nutrients for brain health, 225–226*t*
 parts and functions, 220*t*
 trauma, 234–236
 tumor, 756–758
 Brainstem, 220
 Branched-chain amino acids (BCAAs), 483
 Brancher enzyme deficiency, 176*t*
 Breads, 359*t*
 Breast cancer, 46*t*, 782–785. *See also* Cancer
 Breast milk, 12
 food antigens in, 17
 for infants with cerebral palsy, 159
 nutrient content of, 13*t*
 premature, 186
 storage of, 18
 Breastfeeding, 12–18. *See also* Pregnancy
 from 0–6 months, 19–20
 from 6–12 months, 22
 benefits of, 14
 common problems in, 15*t*
 drugs and, 17
 food and nutritional recommendations
 for, 16–17
 food safety and, 18
 HIV-infected mothers, 178
 nutritional objectives for, 14–16
 promotion of, 14
 recommended intakes in, 16*t*
 supplements, 17
 Brewer's yeast, 72*t*
 Broken jaw, 99–100
 Broken tooth, 98*t*
 Bromelain, 72*t*, 661*t*, 746*t*
 Bromocriptine (Parlodel), 255*t*, 289, 574
 Bronchiectasis, 297–298
 Bronchitis, 298–299, 300
 Bronchodilators, 154, 296*t*, 298, 299, 302, 310*t*, 413
 Bronchopulmonary dysplasia, 152–154
 Bruxism, 105
 B-type natriuretic peptide (BNP), 305, 357
 Buckthorn bark, 72*t*
 Buddhism, dietary practices of, 91
 Budesonide, 296*t*, 432, 436, 513
 Buerger's disease, 346, 378
 Bulimia nervosa, 6, 270–273
 Bulking agents, 420*t*, 444, 451
 Bumetanide, 486*t*
 Bumex, 486*t*

- Buphenyl (sodium phenylbutyrate), 215
 Bupleurum, 72*t*
 Buprenorphine, 289
 Bupropion, 284*t*
 Burdock, 72*t*
 Burns, 838–841
 Busulfan, 727, 755*t*, 794*t*
 Butcher's broom, 72*t*
 Butyrophenone (Haldol), 283*t*
 Byetta (exenatide), 547*t*
- C93, 787
 Cachexia, 630, 739*t*
 Caffeic acid, 734*t*
 Caffeine, 42*t*, 247*t*, 280, 288*t*, 665*t*
 Calan (verapamil), 345
 Calcet, 669*t*
 Calciferol, 595–596
 Calcijex (calcitriol), 872*t*
 Calcineurin inhibitors, 893*t*
 Calcitonin, 570*t*
 Calcitonin-salmon (Miacalcin), 670*t*
 Calcitriol, 111, 208–209, 670*t*, 872*t*
 Calcium
 anti-cancer roles, 735*t*
 bone health and, 665*t*
 depression and, 278
 in foods, 53*t*, 735*t*
 health claims, 55*t*
 imbalance, 806*t*
 for infants, 19
 for oral tissue and dental care, 97*t*
 in post-transplant nutrition, 495*t*
 recommended intakes for children, 29*t*
 sources of, 341–342*t*
 supplements, 669*t*
 Calcium carbonate, 779
 Calcium channel blockers, 345, 356, 371*t*, 391
 Calcium glucarate, 747*t*
 Calcium glycerophosphate (Preliel), 397
 Calcium oxalate stone, 882–883, 884*t*
 Calcium polycarbophil (FiberCon), 420*t*
 Calcium supplements, 459*t*
 Calcium-containing binders, 872*t*
 Calendula, 72*t*, 113
 Calories
 adding to diet, 302*t*
 in post-transplant nutrition, 495*t*
 Caltrate 600, 669*t*
 Campath-1 H, 744*t*
 Campesterol, 736*t*
 Camptosar (irinotecan), 744*t*
 Cancer
 assessment factors, 731
 bladder, 772–773
 bone, 751–752
 brain tumor, 756–758
 breast, 782–785
 as cause of death, 44*t*
 choriocarcinoma, 786–787
 clinical indicators, 742*t*
 colorectal, 759–762
 complementary nutrition, 745
 definitions, 732*t*
 dietary fats and, 55*t*
 drugs and chemotherapy agents, 744–745*t*
 enteral nutrition for, 738*t*
 esophageal, 763–766
 food safety tips, 745
 gastric, 767–769
 head and neck, 763–766
 kidney, 772–773
 leukemia, 791–794
 liver, 769–771
 lymphomas, 795–796
 myeloma, 797–798
 nutrition support therapy for, 738*t*
 nutritional guidelines for, 742–743
 nutritional objectives for, 742*t*
 pancreatic, 777–779
 patient education, 745, 750*t*
 prevention, 733
 prostate, 788–790
 risk factors, 737*t*
 risk reduction, 733
 selenium and, 56*t*
 side effects of treatment, 739–741
 skin, 780–782
 thyroid, 763–766
 treatment guidelines, 738–750
 urinary tract, 772–773
 Canker sores, 98*t*
 Cannabidiol, 500*t*
 Cannabinoids, 250, 500*t*
 Canthaxanthin, 499*t*
 Capoten (captopril), 886
 Capsaicin, 72*t*, 247, 433, 644, 736*t*, 746*t*
 Capsicum, 72*t*
 Captopril (Capoten), 886
 Carafate (sucralfate), 409*t*
 Carbamazepine, 241*t*, 265, 268, 616*t*
 Carbamoylphosphate synthetase, 214*t*
 Carbatrol (carbamazepine), 241*t*
 Carbazochrome, 466
 Carbidopa, 255*t*
 Carbohydrates
 dietary guideline for, 3*t*
 heart disease and, 338*t*
 malabsorption, 155–157
 metabolic disorders, 155–157
 in post-transplant nutrition, 495*t*
 recommended intakes, 48–49
 recommended intakes for children, 29*t*
 Carcinogens, 733
 Carcinoid syndrome, 412–413
 Carcinoma, 732*t*
 Cardiac cachexia, 352–354
 Cardiac glycosides, 361*t*
 Cardiac neuropathy, 524*t*
 Cardiac tamponade, 375–377
 Cardiomyopathies, 354–356
 Cardioresenal syndrome, 866
 Cardiovascular agents, 616*t*
 Cardiovascular disorders, 336–343
 angina pectoris, 343–345
 arteritis, 345–347
 assessment factors, 335
 atherosclerosis, 347–351
 cardiac cachexia, 352–354
 cardiac tamponade, 375–377
 cardiomyopathies, 354–356
 coronary artery disease, 347–351
 diabetes and, 525*t*
 dietary recommendations for, 337*t*
 dyslipidemia, 347–351
 factors in, 338–339*t*
 heart failure, 357–362
 heart valve diseases, 365–367
 herbs and botanical products for, 340*t*
 hypertension, 367–371
 lipids and, 336
 myocardial infarction, 372–375
 pericarditis, 375–377
 peripheral artery disease, 377–379
 thrombophlebitis, 379–381
 Cardizem (diltiazem), 345
 Cardura (doxazosin), 616*t*
 Carmustine, 755*t*, 798
 Carnitine, 860*t*, 872*t*
 Carotenoids, 110, 499*t*
 Carvedilol, 616*t*
 Cascara, 72*t*
 Catabolic illness, 525*t*
 Cataract, 106–108
 Catatonic disorder, 222*t*
 Catechin, 499*t*, 734*t*, 735*t*
 Catecholamines, 587*t*
 Catechol-O-methyltransferase (COMT)
 inhibitors, 255*t*
 Cat's claw, 746*t*
 Cayenne, 73*t*
 CD20 antibody, 681*t*
 Ceftriaxone, 233, 895
 Celebrex (celecoxib), 660*t*
 Celecoxib, 660*t*, 679*t*
 Celexa, 616*t*
 Celiac disease, 414–415
 Central nervous system (CNS), 220
 Cephalosporins, 315
 Cephulac, 420*t*, 486*t*
 Cerebellum, 220
 Cerebral aneurysm, 236–238
 Cerebral palsy, 155*t*, 158–160
 Cerebrovascular accident (CVA), 259–263
 Cerebrum, 220
 Cerebyx (fosphenytoin), 241*t*
 Cerefolin, 229
 Cerivastatin, 350*t*, 676
 Ceruloplasmin, 698
 Cervical radiculopathy, 683
 Cesarean delivery, 809*t*
 Cetuximab, 744*t*
 Cevimeline (Evoxac), 681*t*
 Chamomile, 73*t*, 113, 746*t*
 Chaparral, 79*t*, 538
 Chasteberry, 73*t*
 Cheese, 247*t*
 Chemical pneumonia, 314*t*
 Chemotherapy, 332*t*, 616*t*, 732*t*, 739*t*, 755*t*
 Chemotherapy agents, 744*t*
 Chewing problems, 107, 108–109
 Chicoric acid, 500*t*
 Childhood disintegrative disorder, 222*t*
 Children
 body mass index for, 605*t*
 clinical indicators, 28
 constipation in, 418–419
 daily estimated calories, 30*t*
 dietary recommendations for, 32*t*
 drugs and side effects, 30–31
 eating behavior, 27
 energy requirements/expenditures, 142*t*
 failure to thrive, 169–171
 food and nutrition, 29–30

- food safety tips, 32
 HIV infection in, 177–179
 immunocompetence of, 822*t*
 infectious diseases, 28
 lead poisoning, 32*t*
 malnutrition in, 27–28
 measles, 32*t*
 normal growth rates, 164*t*
 nutritional guidelines for, 29–30, 31
 nutritional objectives for, 28–29
 obesity in, 27, 197–201
 clinical indicators, 198*t*
 complications, 198*t*
 drugs and side effects, 200
 food safety tips, 201*t*
 genetic markers, 198*t*
 nutritional guidelines for, 200–201
 nutritional objectives for, 199–200
 patient education, 200–201
 weight loss diets for, 199*t*
 weight loss program for, 201*t*
 pediatric disorders, 137–143
 anthropometric, 138*t*
 behavioral, 138–139*t*
 clinical, 139–140*t*
 developmental disabilities, 140*t*
 eating/feeding skills, 140*t*
 genetic/metabolic, 140*t*
 nutritional risks, 143*t*
 physical activity, 32*t*, 142*t*
 recommended intakes, 29*t*
 refeeding, 635
 sports nutrition, 38
 supplements, 31
 type 1 diabetes in, 521*t*, 523*t*
 type 2 diabetes in, 521*t*, 523*t*, 549–551
 Chili powder, 746*t*
 Chinese asparagus, 73*t*
 Chinese diet, 85
 Chinese herbal medicine, 746*t*
 Chinese PC-SPES, 746*t*
 Chitosan, 73*t*
 Chlorambucil, 727, 794*t*
 Chloramphenicol, 716
 Chlordiazepoxide (Librium), 284*t*, 616*t*
 Chloride, 63*t*, 340
 Chloride channel activators, 420*t*
 Chlorogenic acid, 500*t*, 734*t*
 Chloroquine (Aralen), 651
 Chlorothiazide, 486*t*
 Chlorpromazine (Thorazine), 283*t*
 Chocolate, 247*t*, 288*t*
 Cholec syrup, 491*t*
 Cholangiolitic hepatitis, 512–514
 Cholecalciferol, 208–209
 Cholecystitis, 516–517
 Cholecystokinin, 569*t*
 Cholelithiasis, 516–517
 Cholestasis, 514–516
 Cholesterol, 55*t*
 Cholesterol spinach, 73*t*
 Cholestyramine, 152, 350*t*, 424, 459*t*, 491*t*, 515
 Choline, 121, 181, 226*t*, 784
 deficiency of, 119*t*
 toxicity of, 121
 Cholinesterase inhibitors, 230*t*
 Chollysarcosine, 429
 Chondroitin, 73*t*, 660*t*
 Choriocarcinoma, 786–787
 Christianity, dietary practices of, 94
 Chromium, 97*t*, 340*t*, 534*t*
 Chromium picolinate, 73*t*, 581, 615
 Chronic anemia, 689*t*
 Chronic gastritis, 401, 402
 Chronic glomerulonephritis, 879
 Chronic heart failure (CHF), 353
 Chronic kidney disease (CKD), 864–873.
 See also Renal disorders
 acute renal failure, 864
 chronic renal failure, 865
 clinical indicators, 866*t*
 drugs and side effects, 872*t*
 fluid restriction, 873*t*
 hypertension and, 368
 nutritional guidelines for, 869
 nutritional objectives for, 868–869
 patient education, 869–873
 protein-energy malnutrition in, 866–868*t*
 stages and symptoms of, 865*t*
 supplements, 869
 Chronic leukemias, 793*t*
 Chronic lymphocytic leukemia, 793*t*
 Chronic myelogenous leukemia, 793*t*
 Chronic obstructive pulmonary disease (COPD), 300–303
 Chronic pancreatitis, 501–506
 Chronic pyelonephritis, 894
 Chronulac (lactulose), 420*t*, 486*t*, 491*t*
 Chrysanthemum, 73*t*
 Church of Jesus of Latter Day Saints, 94
 Chylothorax, 304–305
 Chylous ascites, 477–479
 Cialis (tadalafil), 52*t*
 Cidofovir, 835*t*
 Cimetidine (Tagamet), 283, 409*t*, 459*t*
 Cinacalcet (Sensipar), 598, 872*t*
 Cinnamic acid, 500*t*
 Cinnamon, 73*t*, 534*t*
 Ciprofloxacin, 424, 436, 455, 895
 Circadian rhythm disorder, 222*t*, 285–286
 Cirrhosis, 44*t*, 512–514
 Cisplatin, 764*t*
 Citracal, 669*t*
 Citrate stones, 884*t*
 Citric acid, 500*t*
 Citrucel (methylcellulose), 420*t*
 Citrulline, 215
 Citrullinemia, 214*t*
 Clarithromycin (Biaxin), 315
 Cleft lip and cleft palate, 161–162
 Clofibrate, 350*t*
 Clomipramine, 149, 284*t*
 Clonazepam (Klonopin), 160, 241*t*, 284*t*
 Clonidine, 149, 459*t*
 Clorazepate (Tranxene), 284*t*
 Closed enteral system, 899*t*
 Closed fractures, 842
Clostridium difficile infection, 422
 Clotrimazole (Mycellex), 755*t*, 835*t*
 Cloves, 644, 746*t*
 Clozapine, 264, 283*t*
 Clozaril, 264, 283*t*, 616*t*
 Club drugs, 288*t*
 CNS lymphoma, 757*t*
 Cobalamin, 181
 Cocaine, 288*t*
 Coenzyme Q10, 73*t*, 229, 230*t*, 262, 340*t*, 350, 357, 362, 676, 736*t*, 886
 Cogentin (benztropine), 255*t*
 Cognex (tacrine), 230*t*
 Colchicine (Colcrys), 646
 Colcrys (colchicine), 646
 Colectomy, 816
 Colesevelam, 350, 350*t*
 Colestipol, 350*t*, 515
 Coleus, 73*t*
 Colic, 21*t*
 Colitis, 741*t*
 Collagen-IV nephropathies, 862–863
 Colon, loss of, 456*t*
 Colorectal cancer, 759–762
 Colostomy, 450–452
 Coma, 238–239, 900–901*t*
 Combivent, 296*t*
 Combivir, 834*t*
 Comfrey, 79*t*
 Comminuted fractures, 842
 Common cold, 826*t*
 Complementary nutrition, 70–83
 for allergies, 126
 for cancer patients, 746–749*t*
 clinical indicators, 82*t*
 drugs and side effects, 83–84
 food safety tips, 83
 for foodborne illnesses, 135
 guidelines for, 82*t*
 hazardous products in, 79–81*t*
 for heart disease, 340*t*
 herbs, botanicals, and supplements in, 71–81*t*
 for infants, 22
 nutritional objectives for, 82
 patient education, 83
 for rheumatic disorders, 639
 supplements, 83
 Compound fracture, 842
 Compression fractures, 842–843
 Compulsive exercising, 274*t*
 Comtan (entacapone), 255*t*
 Concerta (methylphenidate), 147*t*
 Condiments, 492*t*
 Conduct disorder, 222*t*
 Cone flower, 73*t*
 Congenital hyperinsulinism, 567–569
 Congenital glucose-galactose malabsorption, 155, 157
 Congenital heart disease (CHD), 163–164.
 See also Cardiovascular disorders
 drugs and side effects, 164
 genetic markers, 163
 incidence of, 163
 medications for, 159*t*
 nutritional guidelines for, 164
 nutritional objectives for, 163–164
 supplements, 164
 Congenital hypothyroidism, 592
 Congenital megacolon, 175–177
 Congenital muscular dystrophy, 653*t*
 Congenital renal glycosuria, 155
 Conivaptan, 580
 Conn's syndrome, 585
 Constipation, 418–420. *See also* Gastrointestinal disorders
 cancer and, 739*t*

- Constipation (*continued*)
 fecal incontinence and, 463*t*
 in infants, 21*t*
- Constulose (lactulose), 491*t*
- Continent ileostomy, 453
- Continuous positive airway pressure (CPAP), 324
- Conversion disorder, 222*t*
- Cooley's anemia, 720
- Coordination problems, 106–107, 108
- Copegus (ribavirin), 481
- Copper, 19, 97*t*, 294*t*, 338*t*, 665*t*
 deficiency of, 698–700, 712*t*
 food sources, 700*t*
- Copper deficiency anemia, 698–700
- Copper sulfate, 700*t*
- Cor pulmonale, 305–306
- Corgard (nadolol), 345, 486*t*
- Cori disease, 176*t*
- Corn syrup, 532*t*
- Coronary artery bypass graft (CABG), 809*t*
- Coronary artery disease (CAD), 347–351, 525*t*
- Coronary heart disease (CHD), 55*t*, 56*t*
- Coronary occlusion, 372–375
- Cortef, 572
- Corticosteroids, 30, 152, 217, 258, 296*t*, 329*t*, 364*t*, 417, 432, 436, 442*t*, 454, 476, 486*t*, 496*t*, 510*t*, 572, 616*t*, 674, 680*t*, 697, 729, 744*t*, 755*t*, 796, 835*t*, 893*t*
- Corticotropin-releasing hormone, 225*t*
- Cortisol, 572, 583
- Cortisone, 572
- Cotazym (pancreatic enzyme), 508
- Cotrim, 895
- Coumadin, 317, 318, 356, 374, 381
- Coumarins, 735*t*
- Coumestans, 734*t*
- Coviracil, 834*t*
- Cozaar (losartan), 886
- Cranberry, 73*t*
- Cranial arteritis, 346
- Cranial nerves, 221*t*
- Craniopharyngiomas, 757*t*
- Craniotomy, 810*t*
- C-reactive protein, 338*t*, 688
- Creatinine index, 867
- Creon (pancreatic enzyme), 508
- CREST syndrome, 684
- Crestor (rosuvastatin), 886
- Cretinism, 592
- Crixivan, 835*t*
- Crohn's disease, 430–433, 760
- Cromolyn (Intal), 296*t*
- Cultural food patterns, 84–87
 African/African American, 85
 Asian, 85
 drugs and side effects, 86–87
 Hispanic/Latino, 85
 Hmong, 85
 Indian/Pakistani, 86
 Mediterranean diet, 86
 Middle Eastern, 86
 Native American, 86
 nutritional objectives, 85
 patient education, 87
 religious food practices, 86
 supplements, 87
- Cuprimine (D-penicillamine), 217, 486*t*
- Curative therapy, 732*t*
- Curcumin, 73*t*, 433, 500*t*, 644
- Curry, 73*t*
- Cushing's syndrome, 575–576
- Cyanidin, 500*t*
- Cyclic vomiting syndrome, 274*t*
- Cyclizine, 411
- Cyclobenzaprine (Flexeril), 657
- Cyclooxygenase-2 (COX-2) inhibitors, 660*t*, 679*t*, 719
- Cyclophosphamide, 312, 651, 697, 727, 744*t*, 755*t*, 774, 784, 787, 798, 886
- Cyclosporine, 126, 329*t*, 364*t*, 436, 442*t*, 496*t*, 510*t*, 538*t*, 644, 646, 680*t*, 755*t*, 893*t*
- Cymbalta (duloxetine), 284*t*, 657
- Cyproheptadine HCl (Periactin), 631
- Cystagon (cysteamine), 166
- Cystathionine-beta-synthase (CBS), 180
- Cysteamine (Cystagon), 166
- Cystic fibrosis, 46*t*, 307–310
- Cystine stones, 882, 884*t*
- Cystinosis, 165–166
- Cystitis, 894
- Cytochrome P450, 110
- Cytokines, 13*t*, 225*t*, 821*t*, 838
- Cytotec (misoprostol), 660*t*
- Cytotoxic T cells, 821*t*
- Cytovene, 835*t*
- Cytosan (cyclophosphamide), 312, 651, 755*t*, 774, 784
- Da qing ye, 73*t*
- Daclizumab, 893*t*
- Da-huang, 77*t*
- Daidzein, 499*t*, 736*t*
- Dairy products, 303*t*, 338*t*, 359*t*, 491*t*
- Dalmane (flurazepam), 284*t*
- Dandelion, 73*t*
- Danshen, 340*t*
- Dantrium (Dantrolene), 160
- Dantrolene (dantrium), 160
- Darunavir, 834*t*
- Darvon (propoxyphene), 283
- Dasatinib (Sprycel), 794*t*
- DASH diet, 342*t*, 354, 357, 366, 369, 374
- Dawn phenomenon, 522*t*
- Daytrana (methylphenidate), 147*t*
- D-cycloserine, 149
- Death, leading causes of, 44*t*
- Debrancher enzyme deficiency, 176*t*
- Decanoate, 836*t*
- Declomycin (demeclocycline), 580
- Deferoxamine, 486*t*, 726
- Degenerative joint disease, 658–661
- Dehydration, 915*t*
- Dehydroepiandrosterone, 746*t*
- Delavirdine, 834*t*
- Delayed gastric emptying (DGE), 558
- Deli, 492*t*
- Delphinidin, 500*t*
- Deltasone, 296*t*
- Deltasone (prednisone), 657
- Delusional disorder, 222*t*
- Demeclocycline (Declomycin), 580
- Dementia, 56*t*, 227–231
- Demerol (meperidine), 844
- Dental abscess, 98*t*
- Dental caries, 56*t*, 99–100, 739*t*
- Dental problems, 96–101
 nutrients for, 97*t*
 symptoms, 98–99*t*
 treatment of, 98–99*t*
- Depacon, 241*t*
- Depakene, 241*t*, 616*t*
- Depakote, 241*t*, 616*t*
- Depen (D-penicillamine), 217, 486*t*
- Depersonalization disorder, 223*t*
- Deplin (L-methylfolate), 168, 277, 704
- Depo-Provera, 616*t*
- Depression, 277–280
- Depressive disorders, 223*t*
- Dermatitis herpetiformis, 111, 112, 415
- Desamino-8-arginine vasopressin (DDAVP), 722
- Desferal (deferrioxamine), 486*t*
- Desipramine, 149, 284*t*, 289
- Desoxyn (methamphetamine), 147*t*
- Desserts, 303*t*
- DETERMINE checklist, 60*t*
- Devil's claw, 73*t*
- Dexamethasone, 154
- Dexedrine, 31
- Dexedrine (dextroamphetamine), 147*t*
- Dexferrum, 695
- Dexmethylphenidate, 147*t*
- Dextroamphetamine, 31, 147*t*
- Dextrose, 532*t*
- Diabeta (glyburide), 547*t*
- Diabetes insipidus, 577–578
- Diabetes mellitus, 44*t*, 520–526. *See also*
 Endocrine disorders
 assessment factors, 519–520
 assessment in, 519–520
 as cause of death, 338*t*
 complications of, 522–525*t*
 etiologic classification of, 521*t*
 evaluation for, 522*t*
 exercise guidelines for, 536*t*
 gestational, 523*t*, 552–555
 herbs and supplements, 534*t*
 management of, 526*t*
 prediabetes, 542–544
 pregnancy and, 523*t*
 type 1, 414, 520, 528–536
 in children, 521*t*, 523*t*
 clinical indicators, 529
 drugs and side effects, 531
 medical nutrition therapy for, 529–531
 patient education, 531–536
 warning signs, 519
 type 2, 520
 in adults, 544–549
 in children, 521*t*, 523*t*
 in children and teens, 549–551
 clinical indicators, 545*t*, 550*t*
 drugs and side effects, 547–548, 551
 medical nutrition therapy for, 545*t*, 546–547, 550–551
 medications for, 547*t*
 patient education, 548–549, 551
 risk factors, 519
 supplements, 548, 551
 type 3, 227
- Diabetic gastroparesis, 558–559
- Diabetic ketoacidosis (DKA), 522*t*, 560–562
- Diabetic retinopathy, 106

- Diallyl sulfide, 433, 644
- Dialysis, 874–878
- Diamond-Blackfan anemia, 692–693
- Diarrhea, 421–424. *See also* Gastrointestinal disorders
- bacterial, 421
 - Bristol stool scale, 422*t*
 - in cancer patients, 740*t*
 - Clostridium difficile* infection, 422
 - drugs and side effects, 423–424
 - early childhood, 421–422
 - fecal incontinence and, 463*t*
 - in infants, 21*t*
 - nutritional guidelines for, 423
 - nutritional objectives for, 423
 - traveler's diarrhea, 422
 - types of, 421*t*
- Diazepam (Valium), 284*t*
- Diazoside, 568
- Didanosine, 834*t*
- Diet
- African/African American, 85
 - Asian, 85
 - Hispanic/Latino, 85
 - Hmong, 85
 - Indian/Pakistani, 86
 - Mediterranean diet, 86
 - Middle Eastern, 86
 - religious food practices, 86
 - Eastern, 91–92
 - Middle Eastern, 95–96
 - Western, 93–95
 - vegetarian, 88–90
- Dietary fats, 55*t*
- in breast milk, 13*t*
 - in diet, 302*t*
 - dietary guideline for, 3*t*
 - health claims, 55*t*
 - in post-transplant nutrition, 495*t*
 - recommended intakes for children, 29*t*
- Dietary fiber
- bone health and, 665*t*
 - breast cancer and, 784
 - cardiovascular disease, 349
 - in common foods, 465*t*
 - constipation and, 235
 - health claims, 55*t*, 56*t*
 - heart disease and, 337*t*, 338*t*
 - insoluble, 736*t*
 - myocardial infarction and, 374
 - recommended intakes, 49
 - recommended intakes for children, 29*t*
 - soluble, 736*t*
 - in vegetarian diet, 89*t*
- Dietary guidelines, 3–5*t*
- American, 3–4*t*
 - for athletes, 41*t*
 - Canadian, 4*t*
 - Chinese, 4*t*
 - MyPyramid, 35
 - South African, 5*t*
- Diethylpropion (Tenuate), 617*t*
- Digestion, 384
- Digitalis, 350, 361*t*, 586
- Digoxin, 350, 356, 366
- Dihydrochalcones, 734*t*
- Dilantin (phenytoin), 235, 239, 241*t*, 376
- Dilated congestive cardiomyopathy, 354–355
- Diltiazem, 345
- Dimenhydrinate (Dramamine), 559
- Diovan (valsartan), 886
- Diphenhydramine, 616*t*
- Dipsogenic diabetes insipidus, 577
- Dipyridamole, 181
- Direct renin inhibitors, 371*t*
- Disability Rating Scale, 238
- Discolored teeth, 98*t*
- Disease-modifying antirheumatic drugs (DMARDs), 680*t*
- Disopyramide (Norpace), 345
- Disruptive behavior, 223*t*
- Dissociative disorders, 223*t*
- Dissociative identity disorder, 223*t*
- Distal colitis, 434
- Distal muscular dystrophy, 653*t*
- Disulfiram (Antabuse), 476
- Diuretic-antihypertensives, 371*t*
- Diuretics, 152, 154, 329*t*, 356, 361*t*, 364*t*, 366, 371*t*, 376, 478, 486*t*, 496*t*, 498*t*, 510*t*, 538*t*, 596, 886
- Diuril (chlorothiazide), 486*t*
- Divalproex sodium, 241*t*
- Diverticular diseases, 425–426
- Diverticulitis, 425–426
- Diverticulosis, 426
- Docosahexaenoic acid (DHA), 362, 378
- Docusate, 695
- Docusate sodium, 417, 420*t*
- Domperidone, 404, 559, 744*t*
- Donepezil (Aricept), 230*t*
- Dong quai, 73*t*
- Dopamine, 224*t*, 287, 587*t*
- Dopamine agonists, 255*t*
- Dopamine antagonists, 404
- Dopamine receptor antagonists, 263
- Down syndrome, 166–167
- Doxazosin (Cardura), 616*t*
- Doxepin (sinequan), 284*t*, 616*t*
- Doxercalciferol (Hectorol), 598, 872*t*
- Doxil, 512
- Doxorubicin, 512, 774, 784, 798, 835*t*
- Doxycycline, 467
- D-penicillamine, 217
- DPP-4 inhibitors, 547*t*
- Dramamine (dimenhydrinate), 559
- Dronabinol (Marinol), 631, 836*t*
- Droxia (hydroxyurea), 719
- DSM-IV, 222*t*
- Duchenne muscular dystrophy, 653*t*
- Duchenne/Becker muscular syndrome, 45*t*
- Dulcolax (bisacodyl), 417
- Duloxetine (Cymbalta), 284*t*, 657
- Duphalac (lactulose), 491*t*
- Dyrenium (triamterene), 486*t*
- Dysentery, 421*t*, 422
- Dysgeusia, 740*t*
- Dyslipidemia, 347–351, 525*t*, 540, 875
- Dyspepsia, 397–399
- Dysphagia, 386–390. *See also* Gastrointestinal disorders
- cancer and, 740*t*
 - causes of, 387*t*
 - clinical indicators, 387*t*
 - drugs and side effects, 390
 - evaluation of, 387*t*
 - nutritional guidelines for, 388
 - nutritional objectives for, 388
 - patient education, 390
 - supplements, 390
- Dysthymia, 277
- Dysthymic disorder, 223*t*
- Earache, 128
- Early childhood caries (ECC), 99–100
- Early childhood diarrhea, 421–422
- Eastern Orthodox Christian, dietary practices of, 94
- Eating disorder, 223*t*
- anorexia athletica, 274*t*
 - anorexia nervosa, 266–268
 - bigorexia, 274*t*
 - binge, 269–270
 - body dysmorphic disorder, 274*t*
 - bulimia nervosa, 270–273
 - compulsive exercising, 274*t*
 - cyclic vomiting syndrome, 274*t*
 - eating disorders not otherwise specified (ED-NOS), 274*t*
 - muscle dysmorphic disorder, 274*t*
 - night eating syndrome, 274*t*
 - nocturnal sleep-related eating disorder, 274*t*
 - orthorexia nervosa, 274*t*
 - pica, 274*t*
 - rumination syndrome, 274*t*
- Eating disorders not otherwise specified (ED-NOS), 274*t*
- Echinacea, 74*t*, 661*t*, 736*t*, 746*t*, 808*t*
- Ecstasy, 288*t*
- Eczema, 110–111
- Edema, 740*t*, 880
- Edentulism, 99, 101
- Efavirenz, 834*t*
- Effexor (venlafaxine), 284*t*
- Eggs
- allergy to, 125*t*, 127*t*
 - heart disease and, 338*t*
- Eicosapentaenoic acid (EPA), 362
- Elavil (amitriptyline), 284*t*, 616*t*, 657
- Eldepryl (selegiline), 230*t*, 255*t*
- Elderly, 58–66
- clinical indicators, 59*t*
 - diabetes in, 523*t*
 - drug effects in, 63, 64*t*
 - drugs and side effects, 58
 - food safety tips, 66
 - immunocompetence of, 822*t*
 - medical nutrition therapy for, 58–59
 - nutrition assessment for, 60*t*
 - nutritional education for, 64–66
 - nutritional guidelines for, 61
 - nutritional objectives for, 59–61
 - patient education for, 66
 - physiological characteristics of, 58
 - recommended intakes for, 62–63*t*
 - stature for, 66*t*
 - supplements, 63–64
 - weight table for, 65*t*
- Elderly Dietary Index (EDI), 336
- Electrolytes, 63*t*, 806–807*t*, 915*t*
- Eleuthero, 746*t*
- Ellagic acid, 433, 500*t*, 644
- Ellagitannins, 500*t*
- Emery-Dreyfus muscular dystrophy, 653*t*

- Emitasol, 559
Emollient laxatives, 420*t*
Emphysema, 300
Emtricitabine, 834*t*
Emtriva, 834*t*
Enalapril (Vasotec), 886
Enbrel (etanercept), 332*t*, 681*t*
Encephalomalacia, 705–706
Encopresis, 418–419
Endemic goiter, 592
Endocannabinoids, 225*t*
Endocrine disorders, 519–527
 acromegaly, 573–574
 Addison's disease, 582–584
 adrenocortical insufficiency, 582–584
 assessment factors, 519–520
 Cushing's syndrome, 575–576
 diabetes. *see* Diabetes mellitus
 diabetes insipidus, 577–578
 diabetic gastroparesis, 558–559
 diabetic ketoacidosis, 560–563
 hyperaldosteronism, 585–586
 hypercalcemia, 596–598
 hyperinsulinism, 567–569
 hyperosmolar hyperglycemic state, 563–564
 hyperparathyroidism, 596–598
 hyperthyroidism, 589–591
 hypocalcemia, 595–596
 hypoglycemia, 565–566
 hypoparathyroidism, 595–596
 hypopituitarism, 571–573
 hypothyroidism, 591–594
 metabolic syndrome, 539–541
 pheochromocytoma, 586–588
 polycystic ovarian syndrome, 580–582
 prediabetes, 542–544
 pre-eclampsia, 556–557
 spontaneous hypoglycemia, 567–569
 syndrome of inappropriate antidiuretic hormone, 579–580
Endocrine system cancers, 732*t*
End-of-life care, 900–901*t*
End-stage renal disease, 524*t*
Enemas, 466
Energy, 3*t*
Energy requirements, 608*t*
 in athletes, 38
 in children, 29*t*, 142*t*
 in infants, 142*t*
 protein-energy malnutrition, 626–631
Enfuvirtide, 835*t*
Entacapone (Comtan), 255*t*
Entamoeba histolytica, 845*t*
Entecavir (baraclude), 486*t*
Enteral nutrition, 902–911. *See also* Parenteral nutrition
 assessment factors, 897
 checklist, 910*t*
 clinical indicators, 904–905*t*
 clinical practice guidelines, 905*t*
 for coma patients, 900–901*t*
 complications, 908*t*
 consequences of not feeding in, 904*t*
 contraindications, 908*t*
 delivery methods, 908*t*
 for dialysis patients, 877*t*
 disadvantages of, 903
 drugs and side effects, 907
 feeding site selection, 908*t*
 fluid needs in, 908*t*
 formula selection, 908*t*
 formulas, 906*t*
 indications and contraindications, 738*t*, 850
 issues in, 908*t*
 overview, 898–901
 patient education, 910–911
 terminology, 899*t*
Enteric fever, 828*t*
Enteric nervous system stem cells (ENSSCs), 448
Enterobius vermicularis, 845*t*
Enteropathy-associated T-cell lymphoma (EATL), 795
Entocort (budesonide), 432
Entry inhibitors, 835*t*
Eosinophilic esophagitis, 122, 395
Eosinophilic gastroenteritis, 122
Ephedra, 42*t*, 80*t*, 272, 283, 295, 302, 356, 615, 808*t*
Ephedrine, 42*t*
Epicatechin, 499*t*
Epidermolysis bullosa, 111, 112
Epidural hemorrhages, 237
Epigallocatechin, 499*t*
Epigallocatechin gallate (ECGC), 735*t*
Epilepsy, 240–242
Epinephrine, 126, 224*t*, 296*t*, 570*t*, 587*t*
Epithelioma, 732*t*
Epivir (lamivudine), 486*t*, 834*t*
Eplerenone, 586
Epoetin, 872*t*
Epzicom, 834*t*
Equal (aspartame), 533*t*
Equilactin, 420*t*
Erectile dysfunction, 52*t*
Ergocalciferol, 595–596
Eriodictyol, 499*t*, 736*t*
Erlotinib (Tarceva), 779
Erucic acid, 185
Erythremia, 726–728
Erythroblastosis fetalis, 692
Erythrocyte sedimentation rate, 338*t*
Erythromycin, 404, 559
Erythropoietin, 688, 860*t*
Erythropoietin stimulating agents (ESAs), 695
Escherichia coli, 851
Esidrix, 486*t*
Eskalith, 616*t*
Esomeprazole (Nexium), 397, 398, 402, 406, 409*t*, 512
Esophageal cancer, 763–766
Esophageal spasm, 390–391
Esophageal stricture, 390–391
Esophageal trauma, 392–393
Esophageal varices, 393–394
Esophagitis, 395–397, 740*t*
Essential fatty acids (EFAs), 9, 110–111, 225*t*
Essential oils, 534*t*
Essiac, 746*t*
Estimated energy requirement (EER), 605*t*
Estrogen, 5, 338*t*, 370, 517, 570*t*, 572, 784
Etanercept (Enbrel), 332*t*, 681*t*
Ethambutol, 332*t*, 376
Ethionamide, 332*t*
Ethopropazine, 255*t*
Ethosuximide (Zarontin), 241*t*
Etoposide, 787
Eucalyptus, 74*t*
Eugenol, 433, 500*t*, 644
Eurixor, 81*t*
Eustachian tube, 202
Evening primrose oil, 74*t*, 534*t*, 661*t*, 746*t*
Evista (raloxifene), 670*t*
Exanta (ximelagatran), 381
Exelon (rivastigmine), 230*t*
Exenatide (Byetta), 547*t*
Exercise
 breastfeeding and, 17
 carbohydrate ingestion and, 38
 for diabetic patients, 536*t*
 heart disease and, 338*t*
Expectorants, 296*t*, 298
Facial nerve, 221*t*
Factitious disorder, 223*t*
Failure to thrive (FTT), 169–171, 280
Falcarninol, 746*t*
Familial adenomatous polyposis (FAP), 46*t*
Familial hemolytic jaundice, 705*t*
Family meals, 49
Famotidine (Pepcid), 409*t*
Fanconi anemia, 45*t*
Fanconi-Bickel syndrome, 176*t*
Fanconi's anemia, 696–698
Fanconi's syndrome, 165–166
Fascioscapulohumeral muscular dystrophy, 653*t*
Fasting, 95–96
Fat malabsorption syndrome, 427–430
Fatigue, 740*t*
Fats
 in breast milk, 13*t*
 in diet, 302*t*
 dietary guideline for, 3*t*
 health claims, 55*t*
 in post-transplant nutrition, 495*t*
 recommended intakes for children, 29*t*
Fatty acid oxidation disorders, 172–173
Fatty acid synthase, 786
Fatty acids, 638–639
Febrile conditions, 825–829
Febuxostat (Uloric), 646
Fecal incontinence, 463–465
Felbamate, 241*t*
Felbatol, 241*t*
Feldene (piroxicam), 660*t*
Felt's syndrome, 677*t*
Female athlete triad, 38
Fenfluramine-phentermine, 366
Fenofibrate, 350*t*
Fenugreek, 74*t*, 340*t*, 534*t*
Fermented foods, 247*t*, 492*t*
Ferritin, 689*t*, 707
Ferulic acid, 734*t*
Fetal alcohol syndrome, 173–175
Feverfew, 74*t*, 113, 247
Fiber
 bone health and, 665*t*
 breast cancer and, 784
 cardiovascular disease, 349
 in common foods, 465*t*
 constipation and, 235
 health claims, 55*t*, 56*t*
 heart disease and, 337*t*, 338*t*

- insoluble, 736*t*
 myocardial infarction and, 374
 recommended intakes, 49
 recommended intakes for children, 29*t*
 soluble, 736*t*
 in vegetarian diet, 89*t*
- Fiberall, 420*t*
 FiberCon (calcium polycarbophil), 420*t*
 Fiber-Lax, 420*t*
 Fibrin acids, 350*t*
 Fibromyalgia, 656–657
 Filgrastim (Neupogen), 755*t*
 Finasteride (Proscar), 52*t*
 Fish, 492*t*
 allergy to, 125*t*, 127*t*
 sodium content, 359*t*
- FK506 (tacrolimus), 364*t*, 442, 510*t*
 FK5-6 (tacrolimus), 496*t*, 538*t*, 893*t*
 Flagyl (metronidazole), 283
 Flavanones, 499*t*, 734*t*, 736*t*
 Flavoglycosides, 500*t*
 Flavones, 294*t*, 499*t*, 734*t*
 Flavonoids, 294*t*, 338*t*, 349, 737*t*, 771
 Flavonolignans, 500*t*
 Flavonols, 499*t*, 734*t*, 735*t*
 Flaxseed, 74*t*, 746*t*
 Fleet Mineral Oil, 420*t*
 Fleet Phospho-Soda, 420*t*
 Flexeril (cyclobenzaprine), 657
 Florinef (fludrocortisone), 583
 Flovent (fluticasone), 296*t*
 Floxin (ofloxacin), 895
 Flu, 826*t*
 Flucytosine, 744*t*, 835*t*
 Fludarabine, 755*t*
 Fludrocortisone (Florinef), 583
 Fluid overload, 915*t*
 Flunisolide, 296*t*
 Fluoride, 97*t*
 Fluoroquinolone, 895
 Fluorouracil, 46*t*, 512, 744*t*, 762, 768, 784
 Fluoxetine, 149, 272, 279, 284*t*, 616*t*
 Flurazepam (Dalmane), 284*t*
 Fluticasone (Flovent), 296*t*
 Fluvastatin, 350*t*, 886
 Fluvoxamine (Luvox), 283*t*, 616*t*
 Focal segmental glomerulosclerosis, 880
 Focalin (dexamethylphenidate), 147*t*
 Folate
 deficiency of, 712*t*
 dementia and, 229
 drug interactions, 195
 health claims, 55*t*
 for healthy vision, 108*t*
 for oral tissue and dental care, 97*t*
 recommended intakes, 341*t*
 recommended intakes for children, 29*t*
 schizophrenia and, 281
 Folate antagonists, 744*t*
 Folic acid, 56*t*, 119*t*, 121, 181, 226*t*, 229, 338*t*, 661*t*, 665*t*, 701–704, 735*t*, 760
 Folic acid deficiency anemia, 701–704
 Folinic acid, 149
 Folk remedy oils, 74*t*
 Follicle-stimulating hormone (FSH), 571
 Food additives, allergy to, 125*t*
 Food Allergen Labeling and Consumer Protection Act (FALCPA), 123
 Food allergies/intolerances, 122–127
 allergens, 125*t*
 clinical indicators, 124
 education, 131
 food processing concerns, 126*t*
 food safety tips, 131*t*
 gastrointestinal, 122–123
 nutritional guidelines for, 124–125
 nutritional objectives for, 124
 patient education, 126–127
 prevalence of, 122
 supplements, 126
 symptoms, 122
 Food labeling terms, 55*t*
 Food protein-induced enterocolitis syndrome (FPIES), 122–123
 Food scale, 612*t*
 Foodborne illnesses, 130–136
 clinical indicators, 130*t*
 drugs and side effects, 134–135
 food handling/safety guidelines, 134*t*, 135
 nutritional objectives for, 131
 outbreaks, 130
 pathogens, 132–133*t*
 refrigerator food storage, 135*t*
 symptoms, 132–133*t*
 Food-dependent exercise-induced anaphylaxis (FDEIA), 123
 Food-induced anaphylaxis, 123
 Foods
 fruits, 54*t*
 functional, 50–51*t*
 labeling terms, 55*t*
 oxygen radical absorbance capacity (ORAC), 503–505*t*
 vegetables, 54*t*
 Foradil, 296*t*
 Forbes disease, 176*t*
 Forebrain, 220*t*
 Formiminoglutamic acid, 701
 Formula-fed infants, 20
 Formulation, 899*t*
 Forskolin, 73*t*, 74*t*
 Forteo, 670*t*
 Fosamax (alendronate), 52*t*, 670*t*
 Fosamprenavir, 834*t*
 Fosarnet, 835*t*
 Foscavir, 835*t*
 Fosfree, 669*t*
 Fosphenytoin (Cerebyx), 241*t*
 Fosrenol (lanthanum carbonate), 872*t*
 Fractures, 842–844
 Fragile X syndrome, 45*t*, 148
 Frankincense, 660*t*
 Frondanol A5, 762
 Frontal lobe, 220*t*, 234
 Frontotemporal dementia, 45*t*
 Frozen foods, 492*t*
 Fructose, 532*t*
 Fructose intolerance, 155
 Fructose-1,6-disphosphatase deficiency, 45*t*
 Fructosemia, 157
 Fruits
 eating tips, 53*t*
 fiber content, 465*t*
 headaches and, 247*t*
 health claims, 55*t*
 nutrients in, 54–55
 Fumarylacetoacetate hydrolase (FAH), 212
 Functional foods, 49, 734–737*t*
 Furadantin (nitrofurantoin), 895
 Furosemide (Lasix), 478, 486*t*, 886
 Fusion inhibitors, 835*t*
 Fuzeon, 835*t*
 Gabapentin (Neurontin), 241*t*, 616*t*
 Gabitril (tiagabine), 241*t*
 Galactosemia, 155, 156
 Galantamine, 230*t*
 Gallate esters, 499*t*
 Gallbladder cancer, 516
 Gallbladder disorders, 473, 516–518, 915*t*
 Gallic acid, 500*t*, 735*t*
 Gallocatechin, 499*t*
 Gallotannins, 500*t*
 Gallstones, 516
 Gamma aminobutyric acid, 224*t*
 Gamma linolenic acid, 74*t*, 295, 534*t*, 661*t*, 746*t*
 Ganciclovir, 835*t*
 Gantrisin (sulfisoxazole), 895
 Garcinia, 615
 Garlic, 74*t*, 340*t*, 534*t*, 661*t*, 747*t*, 808*t*
 Gastrectomy, 399–401
 Gastric bypass surgery, 812–815
 Gastric cancer, 767–769
 Gastric mucosa, 569*t*
 Gastric residual volume, 907
 Gastric retention, 403–405
 Gastrin, 569*t*
 Gastrinoma, 511–512
 Gastritis, 401–403
 Gastroduodenostomy, 399
 Gastroenteritis, 401–403
 Gastroesophageal reflux disease (GERD), 395–397
 Gastrointestinal agents, 409*t*
 Gastrointestinal cancers, 732*t*
 Gastrointestinal disorders, 383–385
 achalasia, 390–391
 assessment factors, 383
 carcinoid syndrome, 412–413
 celiac disease, 414–417
 conditions that may cause fear of eating, 384*t*
 constipation, 418–420
 Crohn's disease, 430–433
 diarrhea, 421–424
 diverticular diseases, 425–427
 dysentery, 421–424
 dysphagia, 386–390
 esophageal stricture/spasm, 390–391
 esophageal trauma, 392–393
 esophageal varices, 393–394
 esophagitis, 395–397
 fat malabsorption syndrome, 427–430
 fecal incontinence, 463–465
 gastric retention, 403–405
 gastritis, 401–403
 gastroenteritis, 401–403
 gastroesophageal reflux disease, 395–397
 gastroparesis, 403–405
 giant hypertrophic gastritis, 405–406
 hemorrhoids, 466–467
 hiatal hernia, 395–397
 intestinal fuels for, 385*t*
 intestinal lymphangiectasia, 439–440

- Gastrointestinal disorders (*continued*)
- irritable bowel syndrome, 443–445
 - lactose maldigestion, 445–447
 - malabsorption, 384*t*
 - malnutrition and, 384*t*
 - mechanical function, 384*t*
 - megacolon, 447–449
 - Ménétrier's disease, 405–406
 - peptic ulcer disease, 407–410
 - peritonitis, 454–455
 - proctitis, 467–468
 - short bowel syndrome, 456–459
 - traveler's diarrhea, 421–424
 - tropical sprue, 460–461
 - ulcerative colitis, 434–436
 - vomiting, pernicious, 410–412
 - Whipple's disease, 461–462
 - Zenker's diverticulum, 390–391
- Gastrointestinal neuropathy, 524*t*
- Gastrointestinal stromal tumor (GIST), 767
- Gastrojejunostomy, 399
- Gastroparesis, 403–405
- Gaviscon, 409*t*
- GBL, 288*t*
- Gelusil, 409*t*
- Gemcitabine (Gemzar), 784
- Gemfibrozil, 350, 350*t*
- Gemzar (gemcitabine), 784
- Generalized anxiety disorder, 223*t*
- Genetic disorders
- abetalipoproteinemia, 144–145
 - assessment factors, 137–142*t*
 - attention-deficit disorders, 145–147
 - autism spectrum disorder, 148–150
 - biliary atresia, 150–152
 - bronchopulmonary dysplasia, 152–154
 - carbohydrate metabolic disorders, 155–157
 - cerebral palsy, 158–160
 - congenital heart disease, 163–164
 - congenital megacolon, 175–177
 - cystinosis, 165–166
 - Down syndrome, 167–168
 - Fanconi's syndrome, 165–166
 - fatty acid oxidation disorders, 172–173
 - fetal alcohol syndrome, 173–175
 - Hirschsprung's disease, 175–177
 - HIV infection, pediatric, 177–179
 - homocystinuria, 180–182
 - infant macrosomia, 182–183
 - intrauterine growth restriction, 210–211
 - leukodystrophies, 184–185
 - maple syrup urine disease, 189–191
 - myelomeningocele, 194–196
 - necrotizing enterocolitis, 192–193
 - neural-tube defects, 194–196
 - orofacial clefts, 161–162
 - phenylketonuria, 203–204
 - Prader-Willi syndrome, 206–207
 - small for gestational age, 210–211
 - spina bifida, 194–196
 - tyrosinemia, 212–213
 - urea cycle disorders, 214–216
 - Wilson's disease, 216–218
- Genetically modified foods, 123
- Gengraf (cyclosporine), 893*t*
- Genistein, 499*t*, 736*t*
- Genitourinary tract disturbances, 524*t*
- Gentamicin, 895
- Geodon (ziprasidone), 283*t*
- Germander, 80*t*
- Germinomas, 757*t*
- Gestational diabetes, 523*t*, 552–555
- Gestational diabetes insipidus, 577
- GHB, 288*t*
- Ghrelin, 206–207
- Giant cell arteritis, 346
- Giant hypertrophic gastritis, 405–406
- Giardia*, 845*t*
- Giardia intestinalis*, 460
- Gigantism, 573
- Ginger, 10*t*, 74*t*, 398, 410, 411, 644, 661*t*, 747*t*
- Gingerol, 433, 644, 747*t*
- Gingivitis, 103–104
- Ginkgo biloba, 74*t*, 229, 272, 283, 534*t*, 661*t*
- Ginkgo, 808*t*
- Ginkgo biloba, 747*t*
- Ginkgolides, 735*t*
- Ginseng, 42*t*, 75*t*, 229, 230*t*, 283, 661*t*, 808*t*
- Ginseng, American, 534*t*, 747*t*
- Ginseng, Asian, 747*t*
- Glandular extracts, 81*t*
- Glargine (Lantus), 533*t*
- Glasgow Coma Scale, 238, 855*t*
- Glasgow Outcome Scale, 238
- Glaucoma, 106
- Gleevec, 755*t*, 768, 794*t*
- Glehnia, 75*t*
- Gliadins, 417
- Glimepiride (Amaryl), 547*t*
- Glioblastoma multiforme, 757
- Gliomas, 757*t*
- Glipizide (Glucotrol), 547*t*
- Glomerular diseases, 879–881
- Glomerular filtration rate (GFR), 865*t*, 867*t*
- Glomerulonephritis, 879
- Glomerulosclerosis, 879–880
- Glossopharyngeal nerve, 221*t*
- Glucagon, 566, 569*t*
- Glucarate, 747*t*
- Glucocorticoids, 570*t*, 583–584
- Gluconeogenesis, 565–566
- Glucosamine sulfate, 75*t*, 660*t*, 661
- Glucose, 532*t*, 860*t*
- Glucose transporter type 1 (Glut1) deficiency syndrome, 155, 157
- Glucose-6-phosphate dehydrogenase deficiency anemia, 705*t*
- Glucosinolates, 735*t*
- Glucotrol (glipizide), 547*t*
- Glutamate, 224*t*
- Glutamine, 153, 458, 903
- Glutathione, 310*t*, 734*t*
- Gluten, 247*t*
- Glyburide, 547*t*
- Glycemic index, 535*t*
- Glycemic load, 338*t*, 535*t*
- Glycine, 224*t*
- Glycitein, 499*t*
- Glycogen, 38, 622
- Glycogen storage disorders (GSDs), 155, 157, 176*t*
- Glycogen synthase kinase-3 (GSK-3), 227
- Glycogenolysis, 565–566
- Glycolax, 420*t*
- Glycomacropeptide, 204
- Glycyrrhizin, 735*t*
- Glyset (miglitol), 547*t*
- Goiter, 592
- Gold sodium thiomalate (Ridaura), 680*t*
- Goldenseal, 80*t*
- Gonadocorticoids, 570*t*
- Gonadotropin-releasing hormone (GnRH), 569*t*
- Gonadotropins, 569*t*
- Gonads, 570*t*
- Gotu kola, 75*t*
- Gout, 645–647
- Graft-versus-host disease, 740*t*
- Graft-versus-host disease prophylaxis, 755*t*
- Grains, 359*t*, 416*t*, 491*t*, 535*t*
- Granisetron, 744*t*
- Grapefruit, 340*t*
- Graves' disease, 589
- Green coffee bean extract, 370
- Green tea, 75*t*, 370, 615, 655, 747*t*, 760
- Growth factors, 13*t*
- Growth hormone, 58, 152, 310, 459*t*, 571, 841*t*, 872*t*
- Growth hormone deficiency, 45*t*
- Guar gum, 534*t*
- Guggul, 75*t*, 340*t*
- Gugulipid, 340*t*
- Guillain-Barré syndrome, 242–243
- Gum disease, 98*t*
- Gut immunity, 821*t*
- Gut-associated lymphoid tissue (GALT), 123
- Gymnema sylvestre*, 534*t*
- Gynecological cancer, 732*t*
- H₂-receptor antagonists, 409*t*, 498*t*
- Haemophilus influenzae*, 315
- Halal, 95
- Halcion (triazolam), 284*t*
- Haldol, 283*t*, 616*t*
- Haloperidol, 149, 616*t*
- Hang time, 899*t*
- Haram, 95
- Harris-Benedict equation, 606*t*, 824*t*, 838
- Hartnup disorder, 887–888
- Hashimoto's thyroiditis, 591–592
- Hawthorn, 75*t*, 340*t*
- Head and neck cancer, 763–766
- Health claims, 55–56*t*
- Healthcare-associated pneumonia, 314*t*
- Hearing loss, 107, 109
- Heart disease, 44*t*
- dietary recommendations for, 337*t*
 - factors in, 338–339*t*
 - herbs and botanical products for, 340*t*
- Heart failure, 357–362
- Heart transplantation, 363–365
- Heart valve diseases, 365–367
- Heart valve replacement, 809*t*
- Heart-lung transplantation, 363–365
- Hectorol (doxercalciferol), 598, 872*t*
- Hedagenin, 734*t*
- Helicobacter pylori*, 11, 18, 406, 407–410, 767
- Helper T cells, 821*t*
- Hematochromatosis, 724–726
- Hematologic disorders
- anemia. *see* Anemia
 - assessment factors, 687
 - hemochromatosis, 724–726

- hemophilia, 722–724
- hemorrhage, 722–724
- iron overload, 724–726
- leukemia, 791–794
- myeloma, 797–798
- thalassemias, 720–721
- thrombocytopenia, 728–729
- Hematopoietic stem-cell transplantation, 753–756
- Hemianopia, 106
- Hemochromatosis, 45*t*
- Hemoglobin, 688, 689*t*, 707
- Hemolytic anemia, 705–706
- Hemolytic disease of the newborn, 692
- Hemophilia, 722–724
- Hemorrhage, 722–724
- Hemorrhagic gastritis, 401
- Hemorrhoidectomy, 816
- Hemorrhoids, 466–467
- Heparin, 318
- Hepatic cirrhosis, 483–486
- Hepatic coma, 488
- Hepatic encephalopathy, 487–492
- Hepatic failure, 487–490
- Hepatitis, 479–482
- Hepatitis A virus, 479, 480*t*
- Hepatitis B virus, 479, 480*t*
- Hepatitis C virus, 480, 480*t*
- Hepatitis D virus, 480, 480*t*
- Hepatitis E virus, 480, 480*t*
- Hepatobiliary disorders, 471–473
 - alcoholic liver disease, 474–477
 - ascites, 477–479
 - biliary cirrhosis, 512–514
 - cholestasis, 514–516
 - chylous ascites, 477–479
 - cirrhosis, 483–486
 - gallbladder disorders, 516–518
 - hepatic coma, 487–492
 - hepatic encephalopathy, 487–492
 - hepatic failure, 487–492
 - hepatitis, 479–482
 - pancreatic cancer, 777–779
 - pancreatic insufficiency, 507–508
 - pancreatitis, acute, 497–501
 - pancreatitis, chronic, 501–506
 - Zollinger-Ellison syndrome, 511–512
- Hepatocellular carcinoma, 769–771
- Hepatolenticular degeneration, 216–218
- Hepcidin, 688
- Hepsera (adefovir), 834*t*
- Herbs and supplements. *See* Complementary nutrition
- Herceptin (trastuzumab), 784
- Hereditary hematochromatosis, 724
- Hereditary nonspherocytic hemolytic anemia, 705*t*
- Heroin, 288*t*
- Herpes simplex, 826*t*
- Herpes zoster, 826*t*
- Hers disease, 176*t*
- Hesperetin, 499*t*, 736*t*
- Hiatal hernia, 395–397
- High-calorie diet, 302
- High-density lipoprotein cholesterol (HDL-C), 338*t*
- Highly active antiretroviral therapy (HAART), 177, 179
- High-protein diet, 302
- Hindbrain, 220*t*
- Hinduism, dietary practices of, 91
- Hip replacement, 810*t*
- Hirschsprung's disease, 175–177
- Hirschsprung's-associated enterocolitis, 171*t*
- Hispanic diet, 85
- Histamine, 123, 224*t*, 247*t*
- Histidine, 701
- HIV infection, pediatric, 177–179
- Hivid (zalcitabine), 834*t*
- HLA-DR* gene expression, 151
- HMG-CoA reductase, 348
- Hmong food, 85
- Hodgkin's lymphoma, 795–796
- Homocysteine, 338*t*, 513
- Homocystinuria, 45*t*, 180–182
- Honey, 532*t*
- Hookworms, 845*t*
- Hormonal therapy, 732*t*
- Hormones, 13*t*
- Horse chestnut, 75*t*, 80*t*
- Horseradish, 75*t*
- Huang lian, 75*t*
- Humalog (lispro), 533*t*, 559
- Human chorionic gonadotropin (hCG), 569*t*
- Human growth hormone, 569*t*
- Human immunodeficiency virus (HIV)
 - infection, 829–837
 - clinical staging, 830*t*
- Humira (adalimumab), 332*t*, 681*t*
- Humulin R, 533*t*
- Huntington's disease, 45*t*, 244–245
- Huperzine A, 229
- Hydergine, 230*t*
- Hydralazine, 376
- Hydrea (hydroxyurea), 719
- Hydrochlorothiazide, 486*t*, 591, 645
- Hydrocortisone, 329*t*, 364*t*, 572
- HydroDIURIL, 486*t*
- Hydroxychloroquine, 651, 680*t*
- Hydroxycinnamic acids, 734*t*
- Hydroxycitric acid, 74*t*
- 4-Hydroxyphenylpyruvate dioxygenase (HPD), 212
- Hydroxyurea, 719
- Hyperaldosteronism, 585–586
- Hyperammonemia, 214*t*
- Hyperargininemia, 214*t*
- Hypercalcemia, 596–598, 806*t*, 807*t*, 915*t*
- Hypercholesterolemia, 45*t*
- Hyperchromia, 689*t*
- Hyperemesis, 10*t*
- Hyperglycemia, 183, 193, 522*t*, 796, 803, 915*t*
- Hyperinsulinism, 567–569
- Hyperkalemia, 806*t*, 807*t*, 915*t*
- Hyperkinesis, 145
- Hypermagnesemia, 806*t*, 807*t*, 915*t*
- Hypernatremia, 806*t*, 915*t*
- Hyperosmolar hyperglycemic state, 563–564
- Hyperosmolar laxatives, 420*t*
- Hyperoxaluria, 429
- Hyperparathyroidism, 596–598
- Hyperphagia, 206–207
- Hyperphosphatemia, 807*t*, 915*t*
- Hypertension, 55*t*, 337*t*, 367–371, 525*t*, 556–557
- Hyperthyroidism, 589–591
- Hyperuricemia, 645
- Hypervitaminosis, 9
- Hypocalcemia, 595–596, 806*t*, 807*t*, 915*t*
- Hypochromia, 689*t*
- Hypoglossal nerve, 221*t*
- Hypoglycemia, 183, 522*t*, 565–566, 915*t*
- Hypokalemia, 806*t*, 915*t*
- Hypomagnesemia, 806*t*, 807*t*, 915*t*
- Hyponatremia, 580, 806*t*, 915*t*
- Hypoparathyroidism, 595–596
- Hypopharynx, 764*t*
- Hypophosphatemia, 807*t*, 915*t*
- Hypophosphatemic rickets, 887–888
- Hypopituitarism, 571–572
- Hypostatic pneumonia, 314*t*
- Hypothalamic lesions, 234
- Hypothalamus, 220*t*, 569*t*
- Hypothermia, 65
- Hypothyroidism, 591–594
- Hysterectomy, abdominal, 810*t*
- Hytrin (terazosin), 616*t*
- Ibandronate (Boniva), 670*t*, 844
- Ibuprofen, 230*t*, 255*t*, 408, 657, 660*t*, 679*t*, 719
- Ice cream, 247*t*
- Idarubicin, 798
- Ideal body weight, 606*t*
- Ileal pouch rectal anastomosis (IPRA), 467
- Ileoanal anastomosis, 452–454
- Ileostomy, 452–454
- Ileum, loss of, 456*t*
- Imatinib, 768, 794*t*
- Imdur (isosorbide), 345
- Imidazoquinazoline, 729
- Imipramine (Tofranil), 31, 284*t*, 289, 616*t*
- Immobilization, 647–648
- Immune system, 820
 - assessment factors, 819
 - cells of, 820–821*t*
 - gut immunity, 821*t*
 - innate and acquired immunity, 820*t*
 - nutrition and, 820
- Immunity, nutritional and host factors in, 823–824*t*
- Immunocompromised persons, 822*t*
- Immunosuppressants, 329*t*, 364*t*, 442*t*, 496*t*, 510*t*, 538*t*, 755*t*
- Imodium (loperamide), 447
- Impulse control disorders, 223*t*
- Imuran (azathioprine), 250, 312, 329*t*, 364*t*, 486*t*, 496*t*, 510*t*, 651
- Incomplete fracture, 842
- Incretin mimetics, 547*t*
- Inderal (propranolol), 486*t*, 616*t*
- Indeterminate colitis, 434
- Indian diet, 86
- Indian snakeroot, 283
- Indigestion, 397–399
- Indinavir, 835*t*
- Indirect calorimetry, 824*t*
- Indirubin, 76*t*
- Indocin (indomethacin), 660*t*
- Indoles, 735*t*, 790*t*
- Indomethacin (Indocin), 660*t*
- Induction therapy, 442*t*
- Infant macrosomia, 182–183
- Infantile nephropathic cystinosis, 165–166

Infants

- ages 0-6 months, 19-21
 - breastfeeding, 19-20
 - food and nutrition, 20
 - food safety tips, 21
 - nutrition education, 21
 - nutritional objectives for, 19-20
 - recommended intakes, 20
 - solid foods, 20
 - supplements, 21
- ages 6-12 months, 22-26
 - breastfeeding, 22
 - clinical indicators, 23
 - complementary nutrition for, 22
 - drugs and side effects, 25
 - feeding, 24*t*
 - food and nutrition, 23-24
 - food safety tips, 26
 - nutritional guidelines for, 25-26
 - supplements, 25-26
- anemia in, 692-694
 - clinical indicators, 19
 - energy requirements/expenditures, 142*t*
 - failure to thrive, 169-171
 - feeding problems, 21
 - formula-fed, 20
 - growth monitoring, 19
 - HIV infection, 177-179
 - HIV infection in, 177-179
 - immunocompetence of, 821*t*
 - large for gestational age, 182-183
 - low birth weight, 186-189
 - normal growth rates, 164*t*
 - pediatric disorders, 137-143
 - anthropometric, 138*t*
 - behavioral, 138-139*t*
 - clinical, 139-140*t*
 - developmental disabilities, 140*t*
 - eating/feeding skills, 140*t*
 - genetic/metabolic, 140*t*
 - nutritional risks, 143*t*
 - premature, 186-189
 - small for gestational age, 210-211
- Infections, 825-829
- Infectious arthritis, 638
- Infective endocarditis, 164
- Infertility, 48*t*, 52*t*
- Inflammation, 638-639
- Inflammatory bowel diseases
 - Crohn's disease, 430-433
 - ulcerative colitis, 434-436
- Infliximab (Remicade), 332*t*, 436, 674, 681*t*
- Influenza, 44*t*, 826*t*
- Innate immunity, 820*t*
- Inositol, 153, 734*t*
- Insomnia, 285
- Insulin, 9, 183, 193, 230*t*, 235, 356, 476, 486*t*, 496*t*, 498*t*, 510*t*, 531, 533*t*, 538*t*, 562, 569*t*, 616*t*, 779, 804, 841*t*, 872*t*
- Insulin-like growth factor 1 (IGF-1), 573
- Intal (cromolyn), 296*t*
- Integrase inhibitors, 835*t*
- Integrative nutrition. *See* Complementary nutrition
- Interferon, 250, 312, 481, 744*t*, 773
- Interferon-alpha, 486*t*, 798, 841*t*
- Interferon-gamma, 841*t*
- Interleukin-1, 838
- Interleukin-1 inhibitor, 681*t*
- Interleukin-2, 744*t*, 773
- Interstitial cystitis, 894
- Interstitial lung disease, 311-313
- Intestinal fistula, 437-438
- Intestinal flora modifiers, 429, 461
- Intestinal lipodystrophy, 461-462
- Intestinal lymphangiectasia, 439-440
- Intestinal parasite infections, 845*t*
- Intestinal transplantation, 440-442
- Intracerebral hemorrhage, 237
- Intracranial hemorrhage, 237
- Intrauterine growth restriction (IUGR), 210-211
- Intravenous fat emulsion, 899*t*
- Intron A, 486*t*
- Inulin, 771
- Invirase, 835*t*
- Iodine, 8
- Ionamin (phentermine), 617*t*
- Ireton-Jones formula, 824*t*, 838
- Irinotecan (Camptosar), 744*t*
- Iron, 706-709
 - bone health and, 665*t*
 - for brain health, 225*t*
 - deficiency of, 712*t*
 - for dialysis patients, 872*t*
 - heart disease and, 339*t*
 - infection and, 829*t*
 - for oral tissue and dental care, 97*t*
 - overload, 724
 - for pregnant women, 9
 - recommended intakes for children, 29*t*
- Iron deficiency, 19, 36*t*
- Iron deficiency anemia, 89*t*
- Iron dextran, 695
- Iron sucrose (Venofer), 695
- Iron-deficiency anemia, 706-709
- Irritable bowel syndrome, 443-445
- Isatis root, 747*t*
- Isador, 748*t*
- Ischemia, 347-348
- Isentress, 835*t*
- Islet cell transplantation, 537-539
- Isocarboxazid (Marplan), 284*t*, 616*t*
- Isoflavone phytoestrogens, 499*t*
- Isoflavones, 736*t*
- Isoniazid, 332*t*, 376
- Isordil (isosorbide), 345
- Isorhamnetin, 499*t*, 734*t*
- Isosorbide dinitrate, 391
- Isosorbide, 345
- Isothiocyanates, 790*t*
- Isotretinoin, 9
- Isotretinoin (Accutane), 112
- Isoxsuprine (Vasodilan), 379
- Jainism, dietary practices of, 91
- Januvia (sitagliptin), 547*t*
- Jasmonates, 735*t*
- Jejunostomy, 559
- Jejunum, loss of, 456*t*
- Judaism, dietary practices of, 93-94
- Juniper, 76*t*
- Juvenile rheumatic arthritis, 677*t*
- Kaempferol, 499*t*, 734*t*
- Kaletra, 835*t*
- Kaolin, 413, 423-424
- Kaopectate, 401, 413, 423-424
- Karela, 76*t*
- Kasai procedure, 151
- Kashrut*, 93
- Kava, 76*t*, 80*t*, 283, 661*t*, 808*t*
- Kelp, 80*t*
- Keppra (levetiracetam), 241*t*
- Ketamine, 288*t*
- Ketek (telithromycin), 315
- Ketoconazole, 835*t*
- Ketones, 561
- Ketoprofen, 679*t*
- Kidney, 860*t*
- Kidney cancer, 772-773
- Kidney diseases, 44*t*
- Kidney Early Evaluation Program (KEEP), 866
- Kidney stones, 882-884
- Kineret (anakinra), 681*t*
- Klonopin (clonazepam), 160, 241*t*, 284*t*
- Kock pouch, 453
- Kombucha tea, 80*t*
- Konsyl, 420*t*
- Kosher, 93
- Kristalose, 420*t*, 486*t*
- Kudzu, 76*t*
- Kuvan, 205
- Kwashiorkor, 626
- Kyushin, 76*t*
- Lactation, 12-18, 523*t*. *See also* Breastfeeding
- Lactobacillus*, 96
- Lactobacillus acidophilus*, 193
- Lactose intolerance, 155
- Lactose maldigestion, 445-447
- Lactulose, 420*t*, 491*t*
- Lamictal (lamotrigine), 241*t*
- Lamivudine, 486*t*, 834*t*
- Lamotrigine, 276
- Lamotrigine (Lamictal), 241*t*
- Lanoxin, 350
- Lansoprazole (Prevacid), 397, 398, 402, 406, 409*t*, 512
- Lanthanum carbonate (Fosrenol), 872*t*
- Lantus (glargine), 533*t*
- Laparoscopic Roux-en-Y gastric bypass (LRYGB), 813
- Lap-band adjustable gastric banding, 813
- Large for gestational age (LGA), 182-183
- Large intestine, 384
- L-arginine, 310*t*, 340*t*
- Larynx, 764*t*
- Lasix (furosemide), 478, 486*t*, 886
- Latino diet, 85
- Laxatives, 217, 230*t*, 235, 258, 417, 420*t*, 466, 486*t*, 491*t*, 804
- Lead poisoning, 23, 32*t*
- Learning disorders, 223*t*
- Leflunomide, 644, 680*t*
- Lenalidomide, 798
- Lente, 533*t*
- Leucovorin, 762
- Leukemia, 46*t*, 791-794
- Leukeran (chlorambucil), 794*t*
- Leukocytes, 820-821*t*
- Leukodystrophies, 184-185
- Leukotriene modifiers, 296*t*
- Levalbuterol, 296*t*

- Levetiracetam (Keppra), 241*t*
 Levodopa, 255*t*
 Levothyroxine, 572
 Lexiva, 834*t*
 Librium (chlordiazepoxide), 284*t*, 616*t*
 Licorice, 76*t*, 410, 476, 747*t*
 Life expectancy, 44, 58
 Life stage-specific assessments, 2
 Lignan, 500*t*, 735*t*
 Limb-girdle muscular dystrophy, 653*t*
 Limonene, 736*t*
 Limonoids, 736*t*
 Linoleic acid, 734*t*
 Lioresal, 250
 Liotrix, 592
 Lipid-lowering drugs, 872*t*
 Lipids
 in breast milk, 13*t*
 cardiovascular disorders and, 336
 Lipitor (atorvastatin), 886
 Lipoic acid, 500*t*, 748*t*
 Lisdexamphetamine dimesylate, 147*t*
 Lispro (Humalog), 533*t*, 559
Listeria, 18
 Lithane, 276
 Lithium, 230*t*, 276, 594, 616*t*
 Lithobid, 276, 616*t*
 Lithotabs, 276
 Live glycogen phosphorylase deficiency, 176*t*
 Liver cancer, 769–771
 Liver disease, 44*t*
 alcoholic, 474–477
 ascites, 477–479
 biliary cirrhosis, 512–514
 cholestasis, 514–516
 chylous ascites, 477–479
 cirrhosis, 483–486
 hepatic coma, 487–492
 hepatic encephalopathy, 487–492
 hepatic failure, 487–492
 hepatitis, 479–482
 liver cancer, 769–771
 Liver phosphorylase deficiency, 176*t*
 Liver transplantation, 493–496
 L-methylfolate, 229, 279
 Lobelia, 81*t*
 Lomotil, 424, 451, 454
 Long-bone structure, 842
 Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, 172
 Loop diuretics, 361*t*, 486*t*
 Loose teeth, 99*t*
 Loperamide, 401, 447
 Lipid (gemfibrozil), 350
 Lopinavir, 835*t*
 Lopressor (metoprolol), 486*t*, 616*t*
 Lorazepam (Ativan), 284*t*
 Lorelco (probuco), 350
 Lorenzo's oil, 185
 Losartan (Cozaar), 886
 Lotensin (benazepril), 886
 Lou Gehrig's disease, 232–234
 Lovastatin, 185, 350*t*
 Low birth weight (LBW), 6, 36*t*, 186–189, 202
 Low vision, 106–108
 Low-density lipoprotein cholesterol (LDL-C), 30, 337*t*, 338*t*
 Low-sodium diet, 359*t*
 Lubiprostone (Amitiza), 420*t*
 Lubricant laxatives, 420*t*
 Lumbarradiculopathy, 683
 Luminal (phenobarbital), 241*t*
 Lung cancer, 774–776
 Lung transplantation, 327–329
 Lupus, 649–651
 Lutein, 108*t*, 109, 499*t*, 735*t*, 790*t*
 Luteinizing hormone (LH), 571
 Luteolin, 499*t*, 734*t*
 Luvox (fluvoxamine), 283*t*, 616*t*
 Lycium, 76*t*
 Lycopene, 232, 499*t*, 736*t*, 790*t*
 Lymphocytes, 821*t*
 Lymphogranuloma venereum, 467
 Lymphomas, 795–796
 Lynch syndrome, 46*t*
 Lyrica (pregabalin), 657
 Lysergic acid diethylamide (LSD), 288*t*
 Ma huang, 42*t*, 272, 283, 295, 302, 615, 808*t*
 Maalox (aluminum hydroxide), 396–397
 Macrobiotic diet, 748*t*
 Macrocytic anemia, 689*t*
 Macrodantin (nitrofurantoin), 895
 Macroglossia, 405–406
 Macronutrients, 63*t*, 142*t*, 823*t*
 Macrosomia, 182–183
 Madopar, 255*t*
 Magaldrate (Riopan), 409*t*
 Magnesium, 97*t*, 232, 294*t*, 342*t*, 495*t*, 534*t*, 661*t*, 665*t*, 806*t*
 Magnesium carbonate, 872*t*
 Magnesium hydroxide, 409*t*
 Malabsorption, 740*t*
 Malaria, 710–712
 Malignant of fulminant multiple sclerosis, 249*t*
 Malnutrition, 601–608
 assessment factors, 601
 biochemical changes in, 631*t*
 in children, 27–28
 consequences of not feeding in, 632*t*
 drugs and side effects, 631
 effects on body systems, 627*t*
 gastrointestinal disorders, 384*t*
 indicators of, 628*t*
 nutritional guidelines for, 630–631
 protein-energy, 626–631
 in pulmonary disorders, 291–292
 refeeding syndrome, 633–635
 types of, 601
 universal screening tool, 629–630*t*
 Malnutrition-inflammation complex syndrome, 865
 Maltose, 532*t*
 Maltose intolerance, 157
 Malvidin, 500*t*
 Manganese, 665*t*
 Maple syrup urine disease, 189–191
 Marasmic kwashiorkor, 626
 Marasmus, 626
 Maraviroc, 835*t*
 Marfan syndrome, 45*t*
 Marijuana, 288*t*
 Marinol (dronabinol), 631, 744*t*
 Marjoram, 748*t*
 Marplan (isocarboxazid), 284*t*, 616*t*
Mashbooh, 95
 Matairesinol, 735*t*
 Matrix extracellular phosphoglycoprotein (MEPE), 664
 Maturity-onset diabetes of the young (MODY), 521*t*
 Maxamaid XPHEN, 212
 Maxaquin (fluoroquinolone), 895
 McArdle disease, 176*t*
 Meadowsweet, 76*t*
 Measles, 32*t*
 Meat, 303*t*, 359*t*, 492*t*
 Meat substitutes, 303*t*
 Mecizine, 411
 Mediterranean anemia, 720
 Mediterranean diet, 49, 86, 339*t*, 374, 640*t*, 784, 877*t*
 Medium-chain triglycerides, 145
 Medium-chain acyl-CoA dehydrogenase deficiency (MCAD), 172–173
 Medium-chain triglycerides (MCTs), 429*t*
 Medrol, 296*t*
 Medroxyprogesterone acetate, 616*t*
 Medulla, 586–588
 Medullary oblongata, 220*t*
 Medullary thyroid carcinoma, 46*t*
 Medulloblastomas, 757*t*
 Megace, 52*t*, 631, 836*t*
 Megacolon, 448–449
 Megaloblastic anemia, 689*t*, 713–714
 Megestrol acetate, 52*t*, 631, 784, 836*t*
 Meglitinides, 547*t*
 Melatonin, 76*t*, 371*t*, 500*t*, 570*t*, 615, 748*t*
 Mellaril (thioridazine HCl), 616*t*
 Melphalan (Alkeran), 798
 Memantine (Namenda), 230*t*
 Ménétrier's disease, 405–406
 Ménière's syndrome, 128–129
 Meningiomas, 757, 757*t*
 Meningitis, 827*t*
 Meningoceles, 194
 Menopause, 48*t*, 52*t*
 Mental disorder, 223*t*
 Mental health disorders, 222–224*t*
 Meperidine, 844
 Mephyton (phytonadione), 486*t*
 6-Mercaptoguanine, 436
 Meridia (sibutramine), 617*t*
 Mesalamine, 436
 Metabolic bone disease, 915*t*
 Metabolic disorders, 45*t*
 Metabolic syndrome, 339*t*, 344*t*, 539–541.
 See also Obesity
 clinical indicators, 539–540*t*
 diagnostic criteria for, 539
 drugs and side effects, 541
 elevated glucose, 540
 nutritional objectives for, 540
 patient education, 541
 proinflammatory state, 540
 prothrombic state, 540
 supplements, 541
 Metadate (methylphenidate), 147*t*
 Metafolin, 703–704
 Metal chelating agents, 486*t*
 Metamucil (laxative), 235, 340*t*, 417, 436, 444, 451, 454, 466
 Metaprel (metaproterenol), 296*t*

- Metaproterenol, 296*t*
 Metformin, 195, 543
 Methadone, 793
 Methamphetamines, 147*t*, 288*t*
 Methicillin-resistant *Staphylococcus aureus* (MRSA) infection, 828*t*
 Methimazole (Tapazole), 590
 Methionine, 339*t*
 Methotrexate, 195, 323, 644, 651, 681*t*, 744*t*, 755*t*, 762, 764*t*, 784, 787, 796
 Methylcellulose, 420*t*, 444
 Methylcobalamin, 149
 5-10-Methylene-tetrahydrofolate reductase (MTHFR), 180–181, 281–282
 Methylphenidate, 31, 147*t*
 Methylprednisolone, 296*t*, 436, 476, 680*t*
 Methylprednisone, 154, 312
 Methylselenol, 760
 Methyltetrahydrofolate, 229, 703
 5-10-Methyltetrahydrofolate-homocysteine methyltransferase (MTR), 181
 5-10-Methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), 181
 Metoclopramide, 404, 559, 744*t*, 804, 841*t*
 Metoprolol (Lopressor), 486*t*, 616*t*
 Metronidazole, 283, 436
 Mexiletine (Mexitil), 374
 Mexitil, 374
 Miacalcin (calcitonin), 670*t*
 Microalbuminuria, 524*t*
 Microcytic anemia, 689*t*
 Micronase (glyburide), 547*t*
 Micronutrients, 823*t*
 dietary guideline for, 3*t*
 Micropreemies, 186
 Midamor (amiloride), 486*t*
 Midazolam (Versed), 284*t*
 Midbrain, 220*t*
 Middle Eastern food, 86
 Mifflin-St. Jeor equation, 838
 Miglitol (Glyset), 547*t*
 Migraine, 245–247
 Milk, 536*t*
 allergy to, 125*t*, 127*t*
 Milk of magnesia, 409*t*, 420*t*
 Milk powder, 303*t*
 Milk thistle, 76*t*, 476, 748*t*
 Mineralocorticoids, 570*t*
 Minerals, 459*t*, 823*t*
 in breast milk, 13*t*
 for dialysis patients, 877*t*
 Mini Nutrition Assessment (MNA), 60*t*
 Minimal enteral feeding, 20
 Minipress (prazosin), 616*t*
 Minocycline, 245
 Minoxidil (Rogaine), 52*t*
 Mint, 76*t*
 Miralax, 420*t*
 Mirapex (pramipexole), 255*t*
 Mirtazapine (Remeron), 616*t*
 Misoprostol (Cytotec), 660*t*
 Mistletoe, 81*t*, 748*t*
 Mitochondrial disorders, 46*t*
 Mitomycin C, 768
 Mitral stenosis, 365
 Mitral valve prolapse, 365
 Mixed connective tissue disease, 638
 Moban, 616*t*
 Modular enteral feeding, 899*t*
 Molasses, 532*t*
 Monoamine oxidase inhibitors (MAOIs), 283, 284*t*, 616*t*
 Monoclonal antibodies, 744*t*, 893*t*
 Mononucleosis, 827*t*
 Monosodium glutamate (MSG), 85
 allergy to, 125*t*
 Monounsaturated fats, 338*t*, 736*t*
 Mood stabilizers, 230*t*, 276, 616*t*
 Mormons, dietary practices of, 94
 Morphine, 374, 844
 Motherwort, 76*t*
 Motilium (domperidone), 559
 Motrin (ibuprofen), 408, 657, 660*t*
 Mouth ulcers, 99, 101
 Mucolytics, 310*t*
 Mucositis, 740*t*
 Mulberry, 748*t*
 Multichamber bag, 899*t*
 Multiple organ dysfunction syndrome (MODS), 847–850
 Multiple pregnancy, 6
 Multiple sclerosis, 248–250
 Muromonab (Orthoclone OKT3), 496*t*
 Muscle dysmorphic disorder, 274*t*
 Muscle glucagon phosphorylase deficiency, 176*t*
 Muscle glycogen, 38
 Muscle relaxants, 683
 Muscle wasting, 741*t*
 Muscular disorders, 45*t*
 Muscular dystrophy, 652–655
 Musculoskeletal disorders
 ankylosing spondylitis, 643–644
 assessment factors, 633–635
 bone disorders, 641–642
 degenerative joint disease, 658–661
 fibromyalgia, 656–657
 gout, 645–647
 immobilization, 647–649
 lupus, 651
 muscular dystrophy, 652–655
 myofascial pain syndromes, 656–657
 osteoarthritis, 656–657
 osteomalacia, 664–666
 osteomyelitis, 662–663
 osteopenia, 666–671
 osteoporosis, 666–671
 Paget's disease, 672–673
 polyarteritis nodosa, 673–674
 polymyalgia rheumatica, 656–657
 rhabdomyolysis, 675–676
 rheumatic disorders, 638–640
 rheumatoid arthritis, 677–682
 ruptured disc, 683–684
 scleroderma, 684–686
 Mushrooms, 76*t*
 Muslims, dietary practices of, 95
 Mustard, allergy to, 125*t*
 Mustard seed, 748*t*
 Myambutol, 332*t*
 Myasthenia gravis, 251–252
 Mycelex (clotrimazole), 755*t*
Mycobacterium tuberculosis, 330
 Mycophenolate mofetil, 496*t*
 Myeloma, 797–798
 Myelomeningocele, 194
 Myelosuppressive agents, 727, 729
 Mylanta, 409*t*
 Myocardial infarction (MI), 372–375
 Myofascial pain syndromes, 656–657
 Myotonic dystrophy, 653*t*
 MyPyramid Food Guidance System, 35, 61
 Myricetin, 499*t*, 734*t*, 736*t*
 Mysoline (primidone), 241*t*
 Myxedema, 592
 Nabumetone (Relafen), 660*t*
 N-acetylcysteine, 229, 500*t*
 N-acetylglutamate synthetase deficiency, 214*t*
 N-acetyl-L-cysteine, 76*t*
 Nadolol, 345, 476
 Nadolol (Corgard), 486*t*
 Naloxone, 289
 Naltrexone, 149, 289, 476
 Namenda (memantine), 230*t*
 Nandrolone, 836*t*
 Naprosyn (naproxen), 657, 660*t*
 Naproxen (Naprosyn), 657, 660*t*, 679*t*
 Nardil (phenelzine), 284*t*, 616*t*
 Naringenin, 499*t*, 736*t*
 Nasal cavity, 764*t*
 Nasopharynx, 764*t*
 Native American diet, 86
 Naturacil, 417
 Nausea, 741*t*
 Navane (thiothixene), 283*t*, 616*t*
Necator americanus, 845*t*
 Necrotizing enterocolitis, 186, 192–193
 Nedocromil (Tilade), 296*t*
 Neevo, 9
 Nefazodone (Serzone), 616*t*
 Nelfinavir, 835*t*
 Neomycin, 491*t*
 Neonatal hepatitis, 150–152
 Neoplastic disorders, 46*t*
 Neoral (cyclosporine), 893*t*
 Neotame, 533*t*
 Nephrogenic diabetes insipidus, 577
 Nephrolithiasis, 884*t*
 Nephropathy, 524*t*
 Nephrotic syndrome, 885–886
 Nesiritide, 164
 Neupogen (filgrastim), 755*t*
 Neural-tube defects, 55*t*, 194–196
 Neuroblastoma, 757*t*
 Neurogenic diabetes insipidus, 577
 Neurological disorders, 45*t*
 Alzheimer's disease, 227–231
 amyotrophic lateral sclerosis, 232–234
 assessment factors, 219*t*
 brain trauma, 234–236
 cerebral aneurysm, 236–238
 cerebrovascular accident, 259–263
 coma, 238–239
 dementia, 227–231
 epilepsy, 240–242
 Guillain-Barré syndrome, 242–243
 Huntington's disease, 244–245
 migraine, 245–247
 multiple sclerosis, 248–250
 myasthenia gravis, 251–252
 neuromuscular junction disorders, 251–252
 Parkinson's disease, 253–255

- persistent vegetative state, 238–239
 seizure disorders, 240–242
 spinal cord injury, 256–259
 stroke, 259–263
 tardive dyskinesia, 263–264
 trigeminal neuralgia, 265–266
 Neuromuscular junction disorders, 251–252
 Neurontin (gabapentin), 241*t*, 616*t*
 Neuro-psychiatric disorders, 219–226
 Neurotransmitter, 587*t*
 Neutropenia, 740*t*
 Neutrophils, 821*t*
 Nevirapine, 834*t*
 Nexium (esomeprazole), 397, 398, 402, 406, 409*t*, 512
 Niacin
 for brain health, 226*t*
 deficiency of, 119*t*, 121
 drug interactions, 262
 for healthy vision, 108*t*
 for heart disease, 340*t*
 heart disease and, 339*t*
 lipoprotein metabolism and, 350*t*
 recommended intakes for children, 29*t*
 sources of, 121
 toxicity of, 121
 Nicardipine, 345
 Nickel dermatitis, 111, 112
 Nicotinamide adenine dinucleotide (NAD), 249, 566
 Nicotine, 280, 288*t*
 Nicotinic acid. *See* Niacin
 Nifedipine, 345, 391
 Night eating syndrome, 274*t*, 611*t*
 Nilotinib (Tasigna), 794*t*
 Nimodipine, 237
 Nitisone (Orfadin), 212
 Nitoman (tetrabenazine), 263
 Nitrofurantoin, 895
 Nitroglycerin, 391
 Nizatidine (Axid), 409*t*
 Nocturnal sleep-related eating disorder, 274*t*
 Non-Hodgkin's lymphoma, 795–796
 Noni juice, 748*t*
 Non-small cell lung cancer (NSCLC), 46*t*, 774
 Non-steroidal anti-inflammatory drugs (NSAIDs), 247, 323, 376, 638, 657, 660*t*, 679*t*
 Nonnucleoside reverse transcriptase inhibitors (NNRTIs), 834*t*
 Noradrenalin, 570*t*
 Noradrenaline, 224*t*
 Noraldex (tamoxifen), 784
 Norepinephrine, 570*t*, 587*t*
 Norfloxacin (Noroxin), 895
 Normochromia, 689*t*
 Normocytic anemia, 689*t*
 Noroxin (norfloxacin), 895
 Norpace (disopyramide), 345
 Norpramin, 284*t*
 Nortriptyline, 284*t*, 616*t*
 Norvir, 835*t*
 Novolin R, 533*t*
 Novolog (aspart), 533*t*
 NPH, 533*t*
 Nucleoside reverse transcriptase inhibitors (NRTIs), 834*t*
 Nummular eczematous dermatitis, 111
 Nutramigen, 20
 NutraSweet (aspartame), 533*t*
 Nutrition screening and assessment factors, 1–2
 Nutrition support process, 899*t*
 Nutrition support service, 899*t*
 Nutrition support teams, 904
 Nutritional guidelines
 for acquired immunodeficiency syndrome (AIDS), 831*t*, 833
 for adolescents, 36–38
 for adults, 49–53
 for allergies, 124–125
 athletes, 40, 42*t*
 for cancer, 742–743
 for childhood obesity, 200–201
 for children, 29–30, 31
 for chronic kidney disease (CKD), 869
 for congenital heart disease (CHD), 164
 for diarrhea, 423
 for dysphagia, 388
 for elderly, 61
 for food allergies/intolerances, 124–125
 for infants, 25–26
 for malnutrition, 630–631
 for obesity, 614–615
 for osteoporosis, 668–669
 for overweight, 614–615
 for pregnancy, 9–11
 for rheumatoid arthritis, 679
 sports nutrition, 40, 42*t*
 for stroke, 261–262
 Nuts, 337*t*, 339*t*
 allergy to, 125*t*, 127*t*
 headaches and, 247*t*
 seeds, 491*t*
 Nydrazid (isoniazid), 376
 Nytol (diphenhydramine), 616*t*
 Obesity, 609–620. *See also* Metabolic syndrome
 body mass index and, 198
 colorectal cancer and, 760
 diet program comparisons, 620*t*
 drugs and side effects, 615
 heart disease and, 339*t*
 medications that cause weight gain, 616*t*
 nutritional guidelines for, 614–615
 nutritional objectives for, 612–614
 patient education, 615–619
 supplements, 615
 weight management counseling, 610
 Obesity, childhood, 197–201
 clinical indicators, 198*t*
 complications, 198*t*
 drugs and side effects, 200
 food safety tips, 201*t*
 genetic markers, 198*t*
 nutritional guidelines for, 200–201
 nutritional objectives for, 199–200
 patient education, 200–201
 weight loss diets for, 199*t*
 weight loss program for, 201*t*
 Obsessive-compulsive disorder, 223*t*
 Obstructive jaundice, 512–514
 Obstructive sleep apnea, 324–325
 Occipital lobe, 220*t*
 Octreotide (Sandostatin), 134, 304, 437–438, 498*t*, 574
 Oculomotor nerve, 221*t*
 Oculopharyngeal muscular dystrophy, 653*t*
 Odoricide, 748*t*
 Ofloxacin, 895
 Oils, 491*t*
 Olanzapine (Zyprexa), 149, 264, 283*t*, 616*t*
 Oleandrin, 748*t*
 Oleanic acid, 734*t*
 Oleic acid, 185
 Olfactory nerve, 221*t*
 Oligosaccharides, 737*t*, 771
 Oliguria, 880
 Olive leaf extract, 370
 Olive oil, 246
 Olsalazine, 436
 Omega-3 fatty acids, 56*t*, 89*t*, 108*t*, 126, 185, 186, 225*t*, 229, 230*t*, 246, 294*t*, 295, 296*t*, 337*t*, 339*t*, 340*t*, 356, 413, 643, 660*t*, 736*t*, 760, 794, 803, 877*t*
 Omega-6 fatty acids, 108*t*, 225*t*, 229, 294*t*, 736*t*
 Omeprazole (Prilosec), 397, 398, 402, 406, 409*t*, 459*t*, 512
 Oncaspar (pegaspargase), 794*t*
 Oncovin, 787, 796, 798
 Ondansetron, 744*t*
 Oolong tea, 370
 Open fracture, 842
 Opiates, 498*t*
 Opioids, 657
 Oppositional defiant disorder, 223*t*
 Optic nerve, 221*t*
 Oral allergy syndrome, 123
 Oral cavity, 764*t*
 Oral contraceptives, 370, 517
 Oral disorders, 96–101
 dental problems, 96–101
 gingivitis, 103–104
 periodontal disease, 103–104
 temporomandibular joint dysfunction, 104–105
 Oral health, 339*t*
 Orapred, 296*t*
 Orasone (prednisone), 657
 Oregano, 76*t*
 Oregon grape root, 76*t*
 Orfadin (nitisinone), 212
 Organ extracts, 81*t*
 Orlistat, 429–430
 Orlistat (Xenical), 617*t*
 Ornithine transcarbamylase (OTC), 214*t*
 Orofacial clefts, 161–162
 Oropharynx, 764*t*
 Orthoclone OKT3 (muromonab), 496*t*
 Orthorexia nervosa, 274*t*
 Os-Cal 500, 669*t*
 Osler-Vasquez disease, 726–728
 Osmolality, 899*t*
 Osmotic laxatives, 420*t*
 Osteitis deformans, 672–673
 Osteoarthritis, 658–661
 Osteoblasts, 641
 Osteocalcin, 641
 Osteomalacia, 664–666
 Osteomyelitis, 662–663
 Osteopenia, 666
 Osteoporosis, 666–671. *See also* Musculoskeletal disorders
 calcium and, 55*t*

- Osteoporosis (*continued*)
 calcium supplements for, 669*t*
 clinical indicators, 668*t*
 drugs and side effects, 669
 medications for, 670*t*
 nutritional guidelines for, 668–669
 nutritional objectives for, 668
 pathogenesis of, 103
 patient education, 670–671
 prevention of, 642*t*
 related genes, 45*t*
 risk factors, 667*t*
- Osteoprotegerin, 673
- Osteosarcoma, 751–752
- Ostomy
 colostomy, 450–452
 ileostomy, 452–454
- Otitis media, 202–203
- Ovarian cancer, 46*t*
- Ovaries, 570*t*
- Overnutrition, 602, 603*t*, 822*t*
- Overweight, 198, 609–620. *See also* Malnutrition;
 Metabolic syndrome; Underweight
 diet program comparisons, 620*t*
 drugs and side effects, 615
 medications that cause weight gain, 616*t*
 nutritional guidelines for, 614–615
 nutritional objectives for, 612–614
 patient education, 615–619
 prevalence of, 609
 supplements, 615
 weight management counseling, 610*t*
- Oxalic acid, 500*t*
- Oxaliplatin, 762
- Oxandrin, 631, 836*t*
- Oxandrolone, 258, 631, 836*t*
- Oxazepam (Serax), 284*t*
- Oxcarbazepine (Trileptal), 241*t*
- Oxygen radical absorbance capacity (ORAC),
 503–505*t*
- Oxymetholone, 616*t*
- Oxytocin, 569*t*
- Paget's disease, 672–673
- Pain, 741*t*
- Pain disorder, 223*t*
- Painkillers, 498*t*
- Pakistani diet, 86
- Pamelor, 284*t*, 616*t*
- Pamidronate (Aredia), 673, 798
- Panax ginseng, 747*t*
- Pancreas, 569*t*
- Pancreatic cancer, 777–779
- Pancreatic disorders, 471–473
- Pancreatic enzyme, 459*t*, 498*t*, 508, 510*t*, 538*t*,
 779, 836*t*
- Pancreatic insufficiency, 507–508
- Pancreatic surgery, 810*t*
- Pancreatic transplantation, 509–510
- Pancreatin, 779
- Pancreatitis, acute, 497–501
- Pancreatitis, chronic, 501–506
- Pancrelipase, 310*t*, 779
- Panic disorder, 223*t*
- Pantoprazole (Protonix), 409*t*, 512
- Pantothenic acid, 121
 deficiency of, 119*t*
 toxicity of, 121
- Papaverine, 237
- Para-amino benzoic acid (PABA), 701
- Paracalcitol (Zemplar), 872*t*
- Paranasal sinuses, 764*t*
- Paraplegia, 257*t*
- Parasitic anemia, 710–712
- Parathyroid glands, 570*t*, 594
- Parathyroid hormone (PTH), 357, 570*t*, 594
- Parathyroidectomy, 811*t*
- Parenteral nutrition, 911–916. *See also* Enteral
 nutrition
 assessment factors, 897
 in brain trauma, 234
 central, 899*t*, 911–912
 in chylothorax patients, 304
 clinical indicators, 912*t*
 clinical practice guidelines, 905*t*
 for coma patients, 900–901*t*
 complications, 915*t*
 for dialysis patients, 875
 drugs and side effects, 915–916
 guidelines, 913–914
 infusion safety, 916
 overview, 898–901
 patient education, 916
 peripheral, 899*t*, 911
 of preterm infants, 188*t*
 standardized, 899*t*
 supplements, 915–916
 terminology, 899*t*
- Paricalcitol (Zemplar), 598
- Pariet (rabeprazole), 409*t*
- Parietal lobe, 220*t*
- Parkinson's disease, 45*t*, 253–255
- Parlodel (bromocriptine), 255*t*, 289, 574
- Parnate (tranlycypromine), 284*t*, 616*t*
- Parotid gland, 764*t*
- Paroxetine (Paxil), 284*t*, 616*t*
- Parsley, 76*t*
- Passion flower, 81*t*
- Paxil (paroxetine), 284*t*, 616*t*
- Peanuts
 allergy to, 125*t*, 127*t*
 headaches and, 247*t*
- Peas, 491*t*
- Pediatric constipation, 418–419
- Pediatric disorders, 137–143
 abetalipoproteinemia, 144–145
 anthropometric, 138*t*
 assessment factors, 137–142*t*
 attention-deficit disorders, 145–147
 autism spectrum disorder, 148–150
 behavioral, 138–139*t*
 biliary atresia, 150–152
 bronchopulmonary dysplasia, 152–154
 carbohydrate metabolic disorders, 155–157
 cerebral palsy, 158–160
 clinical, 139–140*t*
 congenital heart disease, 163–164
 congenital megacolon, 175–177
 cystinosis, 165–166
 developmental disabilities, 140*t*
 Down syndrome, 167–168
 eating/feeding skills, 140*t*
 Fanconi's syndrome, 165–166
 fatty acid oxidation disorders, 172–173
 fetal alcohol syndrome, 173–175
 genetic/metabolic, 140*t*
- Hirschsprung's disease, 175–177
- HIV infection, pediatric, 177–179
- homocystinuria, 180–182
- infant macrosomia, 182–183
- intrauterine growth restriction, 210–211
- leukodystrophies, 184–185
- maple syrup urine disease, 189–191
- myelomeningocele, 194–196
- necrotizing enterocolitis, 192–193
- neural-tube defects, 194–196
- nutritional risks, 143*t*
- obesity, 197–201
- orofacial clefts, 161–162
- otitis media, 202–203
- phenylketonuria, 203–204
- Prader-Willi syndrome, 206–207
- rickets, 208–209
- small for gestational age, 210–211
- spina bifida, 194–196
- tyrosinemia, 212–213
- urea cycle disorders, 214–216
- Wilson's disease, 216–218
- Pegaspargase (Oncaspar), 794*t*
- Pegasys, 481
- Peginterferon-alpha, 836*t*
- Pegvisomant, 574
- Pelargonidin, 500*t*
- Pelvic exenteration, 811*t*
- Pelvic floor dysfunction, 463*t*
- Pelvic inflammatory disease, 827*t*
- Penicillamine, 486*t*
- Penicillin, 895
- Pennyroyal oil, 81*t*
- Pentoxifylline (Trental), 379, 685
- Peonidin, 500*t*
- Pepcid (famotidine), 409*t*
- Peppermint, 77*t*
- Peppermint oil, 444
- Peptic ulcer disease, 407–410
- Peptides, 459*t*
- Pepto-Bismol, 408
- Percutaneous automated discectomy, 683
- Periactin, 631
- Periarthritis nodosa, 346
- Pericarditis, 375–377
- Peridex, 103
- Perimenopause, 48*t*
- Perimolysis, 273*t*
- Periodontal disease, 103–104
- Periodontoclasia, 103
- Peripheral artery disease (PAD), 377–379
- Peripheral vascular disease (PVD), 377–379
- Peritoneal dialysis, 875
- Peritonitis, 454–455
- Pernicious anemia, 713–714
- Peroxisome biogenesis disorders, 184–185
- Perphenazine (Trilafon), 616*t*
- Persistent vegetative state, 238–239, 900–901*t*
- Personality disorders, 223*t*
- Pervasive developmental disorders (PDDs),
 148, 223*t*
- Petunidin, 500*t*
- Phenelzine, 284*t*, 616*t*
- Phenobarbital, 152, 241*t*
- Phenolic acids, 500*t*, 734*t*, 735*t*, 736*t*
- Phenoptin, 205
- Phentermine, 617*t*
- Phenylalanine, 204, 225*t*

- Phenylalanine hydroxylase, 204
 Phenylketonuria, 126, 203–205
 Phenylpropanolamine, 615
 Phenytoin, 195, 235, 239, 241*t*
 Phenytoin (Dilantin), 376
 Pheochromocytoma, 586–588
 Phosphate binders, 872*t*
 Phosphatidylserine, 56*t*
 Phosphorus, 598*t*
 for bone health, 665*t*
 for dialysis patients, 877*t*
 in diet, 869
 for oral tissue and dental care, 97*t*
 in post-transplant nutrition, 495*t*
 Phytates, 736*t*
 Phytic acid, 500*t*
 Phytochemicals, 433, 639, 640*t*, 734–737*t*
 Phytoestrogen, 734*t*, 786, 790
 Phytonadione, 486*t*
 Phytosterols, 49, 339*t*, 736*t*
 Pica, 10*t*, 148, 274*t*, 707
 Pickled foods, 492*t*
 Pickwickian syndrome, 619*t*
 Pilocarpine, 764*t*
 Pilocarpine hydroxide (Salagen), 681*t*
 Pine bark extract, 748*t*
 Pineal gland, 570*t*
 Pineal gland tumors, 757*t*
 Pinworm, 845*t*
 Pioglitazone (Actos), 547*t*
 Piroxicam (Feldene), 660*t*
 Pituitary gland, 569*t*. *See also* Endocrine disorders
 acromegaly, 573–574
 anterior, 573–574, 575–576
 Cushing's syndrome, 575–576
 diabetes insipidus, 577–578
 hypopituitarism, 571–572
 posterior, 577–578
 syndrome of inappropriate antidiuretic hormone, 579–580
 Pituitary hormone deficiency, 45*t*
 Placenta, 569*t*
 Plant stanols, 735*t*
 Plant sterols, 49, 56*t*
 Plaquenil (hydroxychloroquine), 651
 Plasma lipoprotein, 339*t*
 Plasma volume and osmolality, 860*t*
Pneumocystis carinii pneumonia, 314*t*
 Pneumonia, 44*t*, 313–315
 Poke root, 81*t*
 Pokeweed, 748*t*
 Policosanols, 77*t*
 Poliomyelitis, 827*t*
 Polyarteritis nodosa, 673–674
 Polycillin (ampicillin), 486*t*
 Polycystic kidney disease (PKD), 46*t*, 889–890
 Polycystic ovarian syndrome (PCOS), 34, 580–582
 Polycythemia vera, 726–728
 Polyendocrine deficiency syndrome, 583
 Polyethylene glycol 3350, 420*t*
 Polymyalgia rheumatica, 346, 656–657
 Polyphenols, 49, 734*t*, 735*t*, 771
 Polyunsaturated fatty acids (PUFA), 349, 640*t*
 Pompe disease, 176*t*
 Pons, 220*t*
 Poplar, 77*t*
 Porphyria cutanea tarda (PCT), 725
 Porphyrias, 724–725
 Portal hypertension, 483
 Postmenopause, 48*t*
 Postpartum depression, 277, 280
 Posture (calcium supplement), 669*t*
 Posture-Vitamin D, 669*t*
 Potassium, 63*t*
 for dialysis patients, 877*t*
 in diet, 869
 dietary guideline for, 4*t*
 imbalance, 806*t*
 for oral tissue and dental care, 97*t*
 in post-transplant nutrition, 495*t*
 recommended intakes, 340
 in salt, salt substitutes and herbal seasonings, 370*t*
 sources of, 341*t*
 Potassium-sparing diuretics, 486*t*
 Poultry, 492*t*
 Prader-Willi syndrome, 206–207, 305
 Pramipexole (Mirapex), 255*t*
 Prandin (repaglinide), 547*t*
 Pravachol (fluvastatin), 886
 Pravastatin, 350*t*
 Prazosin (Minipress), 616*t*
 Prealbumin, 867*t*
 Prebiotics, 385*t*, 420*t*, 425, 442*t*, 451, 454, 459*t*, 491–492*t*, 736*t*, 771
 Preconception, 523*t*
 Precose (Acrobose), 547*t*
 Prediabetes, 542–544
 Prednisone, 258, 312, 323, 329*t*, 364*t*, 376, 436, 442*t*, 451, 486*t*, 496*t*, 510*t*, 657, 680*t*, 729, 744*t*, 835*t*, 893*t*
 Preeclampsia, 10*t*
 Pre-eclampsia, 556–557
 Pregabalin (Lyrica), 657
 Pregestimil, 20
 Pregnancy, 5–11
 adolescent, 36*t*
 body mass index and, 604*t*
 clinical indicators, 7*t*
 deficiency of micronutrients in, 6
 diabetes and, 523*t*
 drugs in, 9
 early, 6
 food and nutrition in, 8–9
 food safety in, 11
 hypertension in, 525*t*
 intervention, 7–8
 multiple, 6, 10*t*
 nutrition care process steps, 7*t*
 nutritional guidelines for, 9–11
 prenatal risk assessments, 6*t*
 preterm births, 11*t*
 recommendations for pregnant women, 8*t*
 spacing of, 6
 supplements, 9
 tissue growth in, 5
 weight gain in, 5, 17
 Pregnancy-induced hypertension, 556–557
 Prehypertension, 44
 Prelief (calcium glycerophosphate), 397
 Prelone, 296*t*
 Prematurity, 186–189
 Premenstrual dysphoric disorder (PMDD), 48*t*, 223*t*
 Premenstrual syndrome (PMS), 48*t*
 Prescription medications, addiction to, 288*t*
 Pressure ulcers, 114–118
 clinical indicators, 115*t*
 drugs and side effects, 116
 Medicare costs, 114
 nutritional objectives for, 116
 patient education, 116–118
 skin changes with aging, 115*t*
 stages, 115*t*
 supplements, 116
 Preterm infants, nutrient needs of, 188*t*
 Prevacid (lansoprazole), 397, 398, 402, 406, 409*t*, 512
 Preveon (adefovir), 834*t*
 Prezista (darunavir), 834*t*
 Prilosec (omeprazole), 397, 398, 402, 406, 409*t*, 512
 Primary adrenal insufficiency, 583
 Primary biliary cirrhosis, 513
 Primary hyperparathyroidism, 596
 Primary-progressive multiple sclerosis (PPMS), 249*t*
 Primidone (Mysoline), 241*t*
 Proanthocyanidins, 499*t*, 734*t*
 Probenecid (Benemid), 646
 Probiotics, 77*t*, 126, 193, 385*t*, 420*t*, 425, 433, 442*t*, 451, 454, 455, 459*t*, 461, 491–492*t*, 737*t*, 748*t*
 Probutol (Lorelco), 350
 Procainamide, 374, 376
 Procanbid, 376
 Procardia (nifedipine), 345
 Processed meats, 247*t*
 Proctitis, 122, 467–468
 Proctocolitis, 122
 Procyanidins, 734*t*, 735*t*
 Product recalls, 126*t*
 Progesterational agents, 616*t*
 Progesterone, 5, 570*t*, 572
 Prograf (tacrolimus), 364*t*, 442*t*, 496*t*, 510*t*, 538*t*, 893*t*
 Progressive-relapsing multiple sclerosis (PRMS), 249*t*
 Prolactin, 569*t*
 Promethazine (Phenergan), 744*t*
 Promotility agents, 841*t*
 Pronestyl, 376
 Propafenone (Rythmol), 374
 Propoxyphene (Darvon), 283
 Propranolol, 394, 476
 Propranolol (Inderal), 486*t*, 616*t*
 Propylthiouracil, 590
 Proscar (finasteride), 52*t*
 Prostaglandin, 442*t*, 860*t*
 Prostate, 52*t*
 Prostate cancer, 788–790
 Protease inhibitors, 737*t*, 834–835*t*
 Proteasome inhibitors, 893*t*
 Protein-energy malnutrition, 626–631. *See also* Malnutrition
 Proteins
 adding to diet, 303*t*
 for athletes, 40*t*
 body storage of, 622
 bone health and, 665*t*
 for dialysis patients, 877*t*
 dietary guideline for, 3*t*

- Proteins (*continued*)
 for healthy vision, 108*t*
 in post-transplant nutrition, 495*t*
 recommended intakes for children, 29*t*
 requirements in infants, 20
 vegetarian diet and, 89*t*
- Protestants, dietary practices of, 94
- Proton pump inhibitors (PPIs), 396, 397, 402, 409*t*, 455, 478, 512
- Protonix (pantoprazole), 409*t*, 512
- Proventil (albuterol), 296*t*
- Provera, 616*t*
- Prozac (fluoxetine), 279, 283*t*, 284*t*, 616*t*
- Psoriasis, 111, 112, 113
- Psychiatric disorders
 addiction, 287–289
 anorexia nervosa, 266–269
 assessment factors, 219*t*
 binge eating disorder, 269–270
 bipolar disorders, 273–276
 bulimia nervosa, 270–273
 circadian rhythm disorder, 285–286
 depression, 277–280
 DSM-IV classification of, 222–224*t*
 schizophrenia, 281–284
 sleep disorders, 285–286
 substance use disorders, 287–289
- Psyllium, 77*t*, 283, 340*t*, 420*t*, 424, 436, 451, 454, 466
- Pterostilbene, 500*t*
- Public health
 achievements, 2
 essential services, 2
- Pulmicort (budesonide), 296*t*
- Pulmonary disorders, 291–292
 assessment factors, 291
 asthma, 293–296
 bronchiectasis, 297–298
 bronchitis, acute, 298–299
 chronic obstructive pulmonary disease, 300–303
 chylothorax, 304–305
 cor pulmonale, 305–306
 cystic fibrosis, 307–310
 interstitial lung disease, 311–313
 malnutrition in, 291–292
 pneumonia, 313–315
 pulmonary embolism, 315–317
 respiratory distress syndrome, 317–319
 respiratory failure, 319–321
 sarcoidosis, 322–324
 sleep apnea, 324–326
 thoracic empyema, 324–326
 tuberculosis, 330–333
- Pulmonary embolism (PE), 315–317
- Pulmozyme, 310*t*
- Punicalagin, 736*t*
- Pycnogenol, 748*t*
- Pyelonephritis, 894–896
- Pygeum, 790
- Pyorrhea alveolaris, 103
- Pyrazinamide, 332*t*, 376
- Quadruplegia, 257*t*
- Quercetin, 49, 295, 339*t*, 499*t*, 734*t*, 748*t*
- Questran (cholestyramine), 424
- Quetiapine (Seroquel), 264, 283*t*
- Quinolones, 895
- Qvar (beclomethasone HFA), 296*t*
- Rabeprazole, 409*t*, 512
- Radiation enteritis, 741*t*
- Radiation therapy, 741*t*
- Rajasic foods, 86
- Raloxifene (Evista), 670*t*
- Raltegravir, 835*t*
- Ranitidine (Zantac), 409*t*
- Rapamycin, 773
- Rasagiline (Azilect), 255*t*
- Raynaud's syndrome, 378
- Razadyne (galantamine), 230*t*
- Reader disorder, 223*t*
- Rebetol (ribavirin), 481
- Rebif, 250
- Rebound hyperglycemia, 522*t*
- Recombinant human erythropoietin, 872*t*
- Rectal cancer, 760
- Rectum, 384
- Red blood cells (RBCs), 688, 715–716
- Red clover, 77*t*
- Red yeast rice, 80*t*
- Reed-Sternberg's cells, 795
- Refeeding syndrome, 633–635
- Reflux, 21*t*
- Refsum's disease, 184
- Reglan, 235, 559, 744*t*, 804
- Regurgitation, 21*t*
- Reishe mushroom, 748*t*
- Relafen (nabumetone), 660*t*
- Relapsing-remitting multiple sclerosis (RRMS), 249*t*
- Religious dietary practices, 86
 Eastern, 91–92
 Middle Eastern, 95–96
 Western, 93–95
- Remeron (mirtazapine), 616*t*
- Remicade (infliximab), 332*t*, 436, 681*t*
- Remifemin, 746*t*
- Reminyl (galantamine), 230*t*
- Renagel (sevelamer), 872*t*
- Renal cell cancer (RCC), 772
- Renal disorders, 859–861
 Alport syndrome, 862–864
 anemia of, 694–696
 assessment factors, 859
 autoimmune kidney diseases, 879–881
 chronic kidney disease, 864–873
 collagen-IV nephropathies, 862–864
 glomerulonephritis, 875–878, 879–881
 Hartnup disorder, 887–888
 hypophosphatemic rickets, 887–888
 kidney stones, 882–884
 nephrotic syndrome, 885–886
 nutritional interventions for, 860–861
 polycystic kidney disease, 889–890
 renal failure, 864–873
 symptoms, 859
 thin glomerular basement membrane nephropathy, 862–864
 urinary tract infection, 894–896
- Renal metabolic disorders, 887–888
- Renal transplantation, 891–893
- Renin, 860*t*
- Repaglinide (Prandin), 547*t*
- Repertaxin, 784
- Reproductive disorders, 46*t*
- Requip (ropinirole), 255*t*
- Rescriptor (delavirdine), 834*t*
- Reserpine, 263
- Respiratory distress syndrome (RDS), 292, 317–319
- Respiratory failure, 319–321
- Respiratory quotient, 292*t*
- Resting metabolic rates (RMR), 606*t*
- Restoril (temazepam), 284*t*
- Restrictive cardiomyopathy, 354
- Resveratrol, 500*t*, 737*t*, 771, 790*t*
- Retacrit (epoetin zeta), 872*t*
- Retin A (retinoic acid), 112
- Retinitis pigmentosa, 144
- Retinoblastoma, 46*t*
- Retinoic acid, 112, 433
- Retinoids, 736*t*
- Retinopathy, 524*t*
- Retrovir, 834*t*
- Rett syndrome, 45*t*, 148
- Reyataz (atazanavir), 834*t*
- Rhabdomyolysis, 675–676, 813
- Rheumatic arthritis, 671*t*
- Rheumatic disorders, 638–640
- Rheumatic fever, 828*t*
- Rheumatoid arthritis, 677–682. *See also*
 Musculoskeletal disorders
 clinical indicators, 678*t*
 drugs and side effects, 679
 juvenile, 677*t*
 medications for, 679–681*t*
 nutritional guidelines for, 679
 nutritional objectives for, 679
 patient education, 682
 supplements, 682
 variant forms of, 677*t*
- Rheumatoid vasculitis, 677*t*
- Rheumatrex (methotrexate), 651, 681*t*, 762
- Rhodiola, 77*t*
- Rhubarb, 77*t*
- Ribavirin, 481, 486*t*
- Riboflavin
 deficiency of, 119*t*, 712*t*
 for healthy vision, 108*t*
 for migraine headache, 247
 recommended intakes for children, 29*t*
 sources of, 121
 toxicity of, 121
- Rice, 85
 allergy to, 125*t*
- Rice bran oil, 77*t*
- Rickets, 89*t*, 208–209
- Ridaura (gold sodium thiomalate), 680*t*
- Rifadin, 332*t*
- Rifampin, 332*t*, 376
- Rifaximin, 424, 491*t*
- Riluzole, 233, 245
- Rimactane, 332*t*
- Riopan (magaldrate), 409*t*
- Risedronate, 669, 670*t*, 673, 844
- Risperdal (risperidone), 264, 283*t*, 616*t*
- Risperidone (Risperdal), 149, 264, 283*t*, 616*t*
- Ritalin (methylphenidate), 31, 147*t*
- Ritonavir, 835*t*
- Rituxan, 744*t*
- Rituximab, 681*t*, 719, 729, 744*t*, 893*t*
- Rivaroxaban, 317
- Rivastigmine (Exelon), 230*t*
- Rocaltrol (calcitriol), 872*t*
- Rofecoxib, 719
- Roferon-A, 486*t*
- Rogaine (minoxidil), 52*t*

- Rohypnol, 288*t*
 Roman Catholics, dietary practices of, 94
 Ropinirole (Requip), 255*t*
 Rosacea, 111, 112
 Rosemary, 77*t*, 748*t*
 Rosiglitazone (Avandia), 547*t*
 Rosmarinic acid, 500*t*
 Rosuvastatin, 676, 886
 Roundworms, 845*t*
 Roux-en-Y gastric bypass (RYGB), 813
 Royal jelly, 77*t*
 Rumination disorder, 223*t*
 Rumination syndrome, 274*t*
 Ruptured disc, 683–684
 Rutin, 499*t*
 Rythmol (propafenone), 374
- S-5-adenosyl-methionine, 284*t*
 Sabril (vigabatrin), 241*t*
 Saccharin, 533*t*
 S-adenosylmethionine (S-AdoMet), 661*t*, 702
 Salagen (pilocarpine hydroxide), 681*t*
 Salbumol, 296*t*
 Salicylates, 338*t*
 Salicylic acid, 113, 500*t*
 Salivary gland, 764*t*
 S-allylcysteine, 736*t*
Salmonella, 135
 Salt substitutes, 361*t*, 370*t*
 Sandimmune (cyclosporine), 755*t*, 893*t*
 Sandostatin (octreotide), 134, 304, 574
 Saponins, 78*t*, 734*t*
 Saquinavir, 835*t*
 Sarcoidosis, 322–323
 Sarcopenia, 602*t*
 Sassafras, 81*t*
 Sattvic foods, 86
 Saturated fatty acids (SFA), 338*t*, 349
 Saw palmetto, 77*t*, 749*t*, 790
 Scabies, 113
 Schisandra, 77*t*
 Schizoaffective disorder, 224*t*
 Schizophrenia, 281–284
 Schmidt's syndrome, 583
 Schwannoma, 757*t*
 Scleroderma, 684–686
 Scleroderma renal crisis, 684
 Sclerotherapy, 466
 Sea cucumber extract, 762
 Seasonal affective disorder, 224*t*
 Secoisolariciresinol, 735*t*
 Secondary hyperparathyroidism, 596
 Secondary-progressive multiple sclerosis (SPMS), 249*t*
 Secretin, 569*t*
 Seeds, 339*t*
 Seizure disorders, 240–242
 Selective costimulation modulator, 681*t*
 Selective serotonin 5-hydroxytryptamine-3 (5-HT₃), 411
 Selective serotonin reuptake inhibitors (SSRIs), 279, 283*t*, 284*t*, 616*t*, 669
 Selegiline (Eldepryl), 230*t*, 255*t*
 Selenium, 56*t*, 108*t*, 225*t*, 294*t*, 712*t*, 734*t*, 735*t*, 760
 Self-feeding problems, 106–109
 Selzentry, 835*t*
 Senaglinide (Starlix), 547*t*
 Senna, 77*t*
- Sensipar (cinacalcet), 598, 872*t*
 Separation anxiety disorder, 224*t*
 Sepsis, 850–854
 Septra, 486*t*, 836*t*, 895
 Serax (oxazepam), 284*t*
 Serevent (salmeterol xinafoate), 296*t*
 Serlect, 616*t*
 Seronegative arthritis, 638
 Seroquel (quetiapine), 264, 283*t*
 Serotonin, 224*t*
 Serpalan (reserpine), 263
 Serpasil (reserpine), 263
 Sertraline, 272
 Sertraline (Zoloft), 284*t*, 616*t*
 Serum ferritin, 689*t*
 Serum iron, 689*t*
 Serutan, 420*t*
 Serzone (nefazodone), 616*t*
 Sevelamer (Renagel), 872*t*
 Seventh-Day Adventists, dietary practices of, 94
- Sexual maturation, 34
 Sfforon, 749*t*
 Shared psychotic disorder, 224*t*
 Shark cartilage, 749*t*
 Shark oil, 749*t*
 Sheep sorrel, 77*t*
 Shell fish, allergy to, 125*t*, 127*t*
 Shepherd's purse, 78*t*
 Shiitake mushroom, 749*t*
 Shingles, 826*t*
 Short bowel syndrome, 456–459, 816
 Siberian ginseng, 746*t*
 Sibutramine, 270, 617*t*
 Sickle cell anemia, 719
 Sideroblastic anemia, 715–716
 Sikhism, dietary practices of, 91
 Sildenafil, 306
 Sildenafil citrate (Viagra), 52*t*
 Silicon, 665*t*
 Silymarin, 500*t*, 736*t*, 748*t*
 Simple fractures, 842
 Simvastatin, 886
 Sinemet, 245, 250, 255*t*
 Sinequan (Doxepin), 284*t*, 616*t*
 Single-nucleotide polymorphisms (SNPs), 44, 415*t*
- Singular, 296*t*
 Sirolimus, 755*t*, 893*t*
 Sitagliptin (Januvia), 547*t*
 Sjögren's syndrome, 677*t*
 Skeletal disorders, 45*t*
 Skin disorders, 110–113
 Skullcap, 81*t*, 749*t*
 Sleep apnea, 324–325, 619*t*
 Sleep disorders, 224*t*, 285–286
 Slippery elm, 78*t*
 Slow Food movement, 52
 Small bowel surgery, 816–818
 Small for gestational age (SGA), 210–211
 Small intestinal mucosa, 569*t*
 Small intestine, 384
 Small-cell lung cancer (SCLC), 774
 Smilax, 42*t*
 Smoking, 36*t*, 52*t*, 339*t*
 Smoking cessation, 619*t*
 Snacks, 302*t*, 492*t*, 536*t*
 Snakeroot, 283
 SNAP, 60*t*
- Sodium
 for asthma, 294*t*
 bone health and, 665*t*
 for dialysis patients, 877*t*
 dietary guideline for, 4*t*
 dietary recommendations for, 63*t*
 health claims, 55*t*
 for healthy vision, 108*t*
 imbalance, 806*t*
 low-sodium diet, 359*t*
 in post-transplant nutrition, 495*t*
 recommended intakes, 340
 reduction, 368
 restriction, 354, 356
 in salt, salt substitutes and herbal seasonings, 370*t*
 in typical food items, 359*t*
 Sodium bicarbonate, 103, 166
 Sodium fluoride, 670*t*
 Sodium levothyroxine, 592
 Sodium phenylbutyrate, 215
 Solu-Cortef, 442*t*, 496*t*, 510*t*, 893*t*
 Somatostatin analogs, 478
 Somatotropin, 572, 573
 Somatuline Depot, 574
 Somogyi effect, 522*t*
 Sorbitol, 423
 Sour orange, 760
 Soy
 allergy to, 125*t*, 127*t*
 formulas, 20
 isoflavones, 749*t*
 protein, 49, 56*t*, 337*t*, 339*t*
 Spastic constipation, 418–419
 Speech disorder, 224*t*
 Spherocytic anemia, 705*t*
 Sphingomyelin, 735*t*
 Spices, 492*t*, 640*t*
 allergy to, 125*t*
 Spina bifida, 194
 Spina bifida cystica, 194
 Spina bifida occulta, 194
 Spinach, 73*t*
 Spinal accessory nerve, 221*t*
 Spinal arthritis, 643–644
 Spinal cord, 220*t*
 Spinal cord injury, 256–259
 Spinal surgery, 811*t*
 Spirulina, 78*t*, 749*t*
 Splenda (sucralose), 533*t*
 Splenorenal shunting, 484–485
 Spondyloarthropathies, 643
 Spondylosis, 638
 Spontaneous hypoglycemia, 567–569
 Sports nutrition, 38–43
 children and adolescent athletes, 38
 drugs and side effects, 40–42
 female athletes, 38
 food safety tips, 43
 meal planning, 41*t*
 nutritional guidelines, 40, 42*t*
 objectives, 39–40
 protein, 40*t*
 supplements, 42, 42*t*
 Sprycel (dasatinib), 794*t*
 Squalene, 736*t*
 St. John's wort, 78*t*, 250, 272, 295, 661*t*, 749*t*, 794, 808*t*
 Stains, 109

- Stanols, 337*t*, 339*t*, 615, 735*t*
Staphylococcus aureus, 662, 828*t*
 Starch, 85, 416*t*
 Starlix (senaglinide), 547*t*
 Starvation, 602*t*
 Statins, 230*t*, 337*t*, 350, 350*t*, 361*t*, 364*t*, 366, 379, 670*t*, 676, 886
 Stature, calculation of, 66*t*
 Stavudine, 834*t*
 Steroids, 40, 288*t*, 616*t*, 660*t*
 Sterol esters, 56*t*
 Sterols, 337*t*, 339*t*, 615, 736*t*
 Stigmasterol, 736*t*
 Stilbenes, 737*t*
 Stilbenoids, 500*t*
 Stillingia, 78*t*
 Stimulant laxatives, 420*t*
 Stomach acid protector, 409*t*
 Stomatitis, 740*t*
 Stool softeners, 420*t*
 Strattera (atomoxetine), 31, 147*t*
Streptococcus, 851
Streptococcus mutans, 96
 Streptomycin, 332*t*
 Streptozotocin (Zanosar), 512
 Stress fractures, 842
 Stroke, 259–263
 as cause of death, 44*t*
 clinical indicators, 260*t*
 diabetes and, 525*t*
 drugs and side effects, 262
 nutritional guidelines for, 261–262
 nutritional objectives for, 261
 prevention of, 261–262
 supplements, 262
 symptoms, 260*t*
 Struvite stones, 882, 884*t*
 Subarachnoid hemorrhages, 237
 Subclinical hypothyroidism, 592
 Subdural hemorrhages, 237
 Subjective Global Assessment (SGA), 60*t*
 Suboxone, 289
 Substance use disorders, 287–289
 Substance-related disorders, 224*t*
 Subutex, 289
 Sucralfate, 402, 409*t*
 Sucralose, 533*t*
 Sucrose, 532*t*
 Sucrose intolerance, 155, 157
 Sudden infant death syndrome (SIDS), 172
 Sugar, 532*t*
 Sugar alcohols, 56*t*, 532*t*
 Suicide, 44*t*
 Sulfasalazine, 195, 436, 644, 681*t*
 Sulfapyrazone (Anturane), 646
 Sulfisoxazole (Gantrisin), 895
 Sulfites, 247*t*
 allergy to, 125*t*
 Sulfonyleureas, 547*t*, 616*t*
 Sulforaphane, 407, 640*t*, 734*t*, 760, 790*t*
 Sulphadoxine-pyrimethamine, 712*t*
 Sunburn, 113
 Sunette (acesulfame potassium), 533*t*
 Sunitinib (Sutent), 769, 773
 Supertasters, 44
 Surfak (docusate sodium), 417
 Surgery, 800–811
 amputations, 808*t*
 assessment factors, 799
 bariatric, 812–815
 bowel, 816–818
 clinical indicators, 801*t*
 colostomy, 450–452
 drugs and side effects, 804
 electrolyte imbalances in, 806–807*t*
 gastrectomy, 399–401
 gastric bypass, 812–815
 herbal medications, 808*t*
 ileostomy, 452–454
 immunity concerns in, 822*t*
 nutritional objectives, 809–811*t*
 nutritional support in, 802–804
 patient education, 805
 postoperative concerns in, 802, 803–804
 postsurgical status, 799
 preoperative concerns in, 801–803
 presurgical status, 799
 small intestine after, 803*t*
 types of, 809–811*t*
 vagotomy, 399–401
 Surmontil (trimipramine), 616*t*
 Sutent (sunitinib), 773
 Sweet 'N Low (saccharin), 533*t*
 Sweeteners, 126, 532–533*t*
 Sweets, 302*t*, 532*t*, 536*t*
 Symlin (amylin), 547*t*
 Symmetrel (amantadine), 255*t*
 Synbiotics, 385*t*, 459*t*
 Syndrome of inappropriate antidiuretic hormone (SIADH), 579–580
 Synthroid, 593
 Syprine (trientine), 486*t*
 Systemic inflammation response syndrome (SIRS), 848, 850–854, 903
 Systemic sclerosis, 684–686

 T cells, 821*t*
 Tachycardia, 373
 Tacrine (Cognex), 230*t*
 Tacrolimus, 329*t*, 364*t*, 442*t*, 496*t*, 510*t*, 538*t*, 646, 755*t*, 893*t*
 Tadalafil (Cialis), 52*t*
 Tagamet (cimetidine), 283, 409*t*
 Takayasu's arteritis, 346
 Tamasic foods, 86
 Tamoxifen (Norallex), 784
 Tangeritin, 499*t*
 Tanner stages, 33–34
 Tannins, 78*t*, 735*t*, 771
 Tansy, 113
 Tapazole (methimazole), 590
 Tarceva, 774, 779
 Tardive dyskinesia (TD), 263–264
 Tartrazine, allergy to, 125*t*
 Tarui disease, 176*t*
 Tarvil, 263
 Tasigna (nilotinib), 794*t*
 Tasmar (tolcapone), 255*t*
 Taste, 44
 Tay-Sachs disease, 45*t*
 T-cell prolymphocytic leukemia, 793*t*
 Tea tree oil, 78*t*
 Tegaserod (Zelnorm), 420*t*
 Tegretol (carbamazepine), 241*t*, 265, 616*t*
 Telithromycin (Ketek), 315
 Temazepam (Restoril), 284*t*

 Temporal lobe, 220*t*
 Temporomandibular joint (TMJ) disorder, 104–105
 Tenofovir DF, 834*t*
 Tenormin (atenolol), 486*t*, 616*t*
 Tenuate (diethylpropion), 617*t*
 Terazosin (Hytrin), 616*t*
 Teriparatide, 670*t*
 Terminally ill patients, 238*t*
 Terpenes, 734*t*, 735*t*, 736*t*
 Terpenoids, 499*t*
 Testes, 570*t*
 Testoderm, 616*t*
 Testosterone, 570*t*, 572, 616*t*
 Tetrabenazine, 245, 263
 Tetracycline, 112, 461, 486*t*
 Tetrahydrobiopterin, 204, 205
 Tetranectin, 538*t*
 Tetrathiomolybdate, 217
 TF constipation, 418–419
 Thalamus, 220*t*
 Thalassemias, 720–721
 Thalidomide, 798
 Theaflavin, 499*t*
 Thearubigins, 499*t*
 Theo-Dur, 302
 Theophylline, 296*t*, 299
 Thermal injury, 838–841
 Thiamin
 deficiency of, 119*t*
 for healthy vision, 108*t*
 recommended intakes for children, 29*t*
 toxicity of, 121
 Thiazide, 306, 350
 Thiazide diuretics, 361*t*, 370, 486*t*, 886
 Thiazolidinediones, 547*t*, 616*t*
 Thin glomerular basement membrane nephropathy (TBMN), 862–863
 6-Thioguanine, 436
 Thiols, 734*t*, 735*t*
 Thionamides, 590–591
 Thiopurine toxicity, 46*t*
 Thioridazine HCl (Mellaril), 616*t*
 Thiothixene (Navane), 283*t*, 616*t*
 Thitoic acid, 534*t*
 Thoracic empyema, 326–327
 Thorazine (chlorpromazine), 283*t*
 Thrombocytopenia, 45*t*, 192
 Thrombocytopenia purpura, 728–729
 Thrombolytics, 381
 Thrombophilia, 45*t*
 Thrombophlebitis, 379–381
 Thymoglobulin, 538
 Thymosin, 570*t*
 Thymus, 570*t*
 Thyrocalcitonin, 673
 Thyroid cancer, 763–766
 Thyroid crisis, 589
 Thyroid gland, 570*t*
 hypercalcemia, 596–598
 hyperparathyroidism, 596–598
 hyperthyroidism, 589–591
 hypocalcemia, 595–596
 hypoparathyroidism, 595–596
 hypothyroidism, 591–594
 Thyroid hormones, 593–594
 Thyroid storm, 589
 Thyroid-stimulating hormone, 569*t*

- Thyrototoxicosis, 589
 Tiagabine (Gabitril), 241*t*
 Tilade (nedocromil), 296*t*
 Timolol (Blocadren), 486*t*
 Tinnitus, 128
 Tipranavir, 834*t*, 835*t*
 Tissue transglutaminase (TTG), 415
 Tobramycin, 310*t*
 Tocolytics, 9
 Tofranil (imipramine), 31, 284*t*, 616*t*
 Tolcapone (Tasmar), 255*t*
 Tongue disorders, 99, 101
 Tonsillectomy, 811*t*
 Toothache, 99*t*
 Topamax (topiramate), 241*t*, 270
 Topical pain relievers, 660*t*
 Topiramate, 276
 Topiramate (Topamax), 241*t*, 270
 Total nutrient admixture, 899*t*
 Total-body irradiation, 755*t*
 Toxic shock syndrome, 828*t*
 Tramadol (Ultram), 660*t*
 Tranquilizers, 283*t*
 Trans fatty acids, 339*t*
 Transferrin, 689*t*
 Transplantation
 bone marrow, 753–756
 heart-lung, 363–365
 hematopoietic stem-cell, 753–756
 intestinal, 440–442
 islet cell, 537–539
 liver, 493–496
 lung, 327–329
 pancreatic, 509–510
 renal, 891–893
 Transtheoretical Model for Stages of Change, 52
 Transthyretin, 867*t*
 Tranxene (clorazepate), 284*t*
 Tranylcypromine (Parnate), 284*t*, 616*t*
 Trastuzumab (Herceptin), 784
 Trauma, 822*t*, 854–856
 Traumatic brain injury (TBI), 234–236
 Traveler's diarrhea, 421*t*, 422
 Trecator-SC, 332*t*
 Trental (pentoxifylline), 379, 685
 Triamcinolone (Azmecort), 296*t*
 Triamterene, 195
 Triamterene (Dyrenium)₂, 486*t*
 Triazolam (Halcion), 284*t*
 Tribulus, 42*t*
Tribulus terrestris, 78*t*
Trichinella spiralis, 845*t*
 Tricyclic antidepressants, 284*t*, 616*t*, 657
 Trientine (Syprine), 486*t*
 Trigeminal nerve, 221*t*
 Trigeminal neuralgia, 265–266
 Triglycerides, 339*t*
 Trihexyphenidyl (Artane), 255*t*
 Trilafon (perphenazine), 616*t*
 Tripleptal (oxcarbazepine), 241*t*
 Trimethoprim (Trimpex), 895
 Trimethoprim-sulfamethoxazole, 486*t*, 836*t*, 895
 Trimipramine (Surmontil), 616*t*
 Trimox (amoxicillin), 895
 Trimpex (trimethoprim), 895
 Trinsicon, 714
 Trisenox (arsenic trioxide), 798
 Triterpene glycoside, 735*t*
 Trizivir, 834*t*
 Trochlear nerve, 221*t*
Tropheryma whippelii, 461
 Tropical sprue, 460–461
 Trovafloxin, 895
 Troxerutin, 466
 Truvada, 834*t*
 Tryptophan, 42*t*, 78*t*, 225*t*, 283
 Tube feeding, 100, 101
 Tuberculosis, 330–333
 Tumor necrosis factor alpha (TNF α), 638, 643
 Tumor necrosis factor (TNF), 838
 Tumor necrosis factor (TNF) inhibitors, 681*t*
 Tums (calcium supplement), 669*t*
 Turkey tail mushroom, 749*t*
 Turmeric, 78*t*, 476, 534*t*, 644, 749*t*
 Twinrix, 481
 Typhoid fever, 828*t*
 Tyramine, 247*t*
 TYREX, 212
 TYROMEX-1, 212
 TYROS, 212
 Tyrosine, 204, 212–213, 225*t*
 Tyrosine aminotransferase (TAT), 212
 Tyrosinemia, 212–213
 Ubiquinone, 340*t*, 736*t*
 Ukraine, 78*t*
 ulcerative colitis, 434–436
 Ulcerative colitis, 760
 Uloric (febuxostat), 646
 Ultralente, 533*t*
 Ultram (tramadol), 660*t*
 Undernutrition, 602–603*t*, 626–631, 822*t*.
 See also Malnutrition
 Underweight, 622–626. *See also* Malnutrition;
 Overweight
 body mass index and, 622
 clinical indicators, 623*t*
 drugs and side effects, 624
 nutritional guidelines for, 624
 patient education, 624–625
 strengthening tips, 623*t*
 Upper respiratory infections, 822*t*
 Urea cycle disorders, 213–216
 Uremia, 880
 Uric acid, 500*t*, 645–646
 Uric acid stones, 882
 Uricosuric drugs, 646
 Uridine, 226*t*
 Urinary incontinence, 894
 Urinary tract cancer, 772–773
 Urinary tract infection, 894–896
 Urolithiasis, 884*t*
 Urso, 517
 Ursodeoxycholic acid, 310*t*, 491*t*, 514, 515, 517, 755*t*
 Ursodiol, 152, 517
 Ursolic acid, 433, 644, 748*t*
 Vaccines, 522*t*
 Vagotomy, 399–401
 Vagus nerve, 221*t*
 Valcyte, 836*t*
 Valdecocixib, 679*t*
 Valerian, 78*t*, 283, 661*t*, 749*t*, 808*t*
 Valganciclovir, 836*t*
 Valium (diazepam), 284*t*
 Valproate, 241*t*, 268
 Valproic acid, 241*t*, 616*t*
 Valsartan (Diovan), 886
 Vanadium, 79*t*, 534*t*
 Vanatrip (amitriptyline), 616*t*
 Vancomycin, 424
 Vascular access device, 899*t*
 Vasodilan (isoxsuprine), 379
 Vasopressin, 569*t*
 Vasotec (enalapril), 886
 Vegan vegetarians, 10*t*
 Vegetables
 eating tips, 53*t*
 fiber content, 465*t*
 glycemic index, 535*t*
 headaches and, 247*t*
 health claims, 55*t*
 nutrients in, 54–55
 Vegetarian diet, 88–90
 Velcade (bortezomib), 798
 Venlafaxine (Effexor), 284*t*
 Venofer, 695
 Ventilator, 319–321
 Ventolin (albuterol), 296*t*
 Verapamil, 345
 Versed (midazolam), 284*t*
 Very long-chain fatty acid (VLCFA), 184–185
 Very low birth weight (VLBW), 153
 Vestibulocochlear nerve, 221*t*
 Viagra (sildenafil citrate), 52*t*
 Video-assisted thoracoscopy (VATS), 326
 Videx (didanosine), 834*t*
 Vigabatrin (Sabril), 241*t*
 Vinblastine, 744*t*
 Vinca alkaloids, 744*t*
 Vincent's disease, 103
 Vincristine, 744*t*, 796, 835*t*
 Viracept, 835*t*
 Viral pneumonia, 314*t*
 Viramune (nevirapine), 834*t*
 Virazole (ribavirin), 486*t*
 Virchow triad, 315
 Viread, 834*t*
 Vistide, 835*t*
 Vitamin A
 for asthma, 294*t*
 bone health and, 665*t*
 deficiency of, 119*t*, 120, 712*t*
 in functional foods, 735*t*
 for healthy vision, 108*t*
 for heart disease, 337*t*
 for oral tissue and dental care, 97*t*
 for pregnant women, 9
 recommended intakes for children, 29*t*
 sources of, 499*t*
 toxicity of, 121
 Vitamin B complex, 97*t*
 Vitamin B₁₂
 Alzheimer's disease and, 227
 for bone health, 665*t*
 for brain health, 226*t*
 deficiency anemia, 713–714
 deficiency of, 89*t*, 119*t*, 121
 for healthy vision, 108*t*
 for homocystinuria, 181–182
 for pancreatic cancer, 779

- Vitamin B₁₂ (*continued*)
 schizophrenia and, 281
 sources of, 121
- Vitamin B₆
 Alzheimer's disease and, 227
 for bone health, 665*t*
 for brain health, 226*t*
 deficiency of, 119*t*, 121
 for diabetic patients, 534*t*
 in functional foods, 735*t*
 for healthy vision, 108*t*
 metabolic disorder, 180
 for sideroblastic anemia, 716
 sources of, 121
 toxicity of, 121
- Vitamin C
 for asthma, 294*t*
 bone health and, 665*t*
 in cancer prevention, 736*t*
 deficiency of, 120*t*, 121, 712*t*
 in functional foods, 736*t*
 for healthy vision, 108*t*
 for heart disease, 337*t*, 339*t*, 340*t*
 recommended intakes for children, 29*t*
 role in brain, 226*t*
 side effects of, 423
 sources of, 499*t*
 toxicity of, 121
- Vitamin D
 bone health and, 665*t*
 for Crohn's disease, 433
 deficiency of, 89*t*, 119*t*, 121, 208–209
 in diabetes management, 534*t*
 for dialysis patients, 872*t*
 for healthy vision, 108*t*
 for infants, 19
 for oral tissue and dental care, 97*t*
 rheumatic disorders and, 640*t*
 role in brain, 226*t*
 supplementation
 for asthma, 294*t*
 for chronic obstructive pulmonary disease, 302
 for dialysis patients, 876
 toxicity of, 121
- Vitamin D₃, 208, 278, 669, 735*t*, 771, 850, 878*t*
- Vitamin E
 Alzheimer's disease and, 229, 230*t*
 arthritis and, 661*t*
 for asthma, 294*t*
 for colorectal cancer, 760
 deficiency of, 120*t*, 712*t*
 in functional foods, 735*t*, 736*t*
 for healthy vision, 108*t*
 for heart disease, 337*t*, 339*t*, 340*t*
 side effects of, 356
 sources of, 499*t*
 for stroke patients, 262
 toxicity of, 121
- Vitamin E-sensitive hemolytic anemia, 705*t*
- Vitamin K, 722–724
 blood clotting and, 394, 804
 bone health and, 665*t*
 for cirrhosis, 486*t*
 deficiency of, 120*t*, 121
 food sources, 723*t*
 heart disease and, 339*t*
 for oral tissue and dental care, 97*t*
 toxicity of, 121
 warfarin and, 350
- Vitamins, 118–121
 in breast milk, 13*t*
 deficiency of, 118–121
 for dialysis patients, 877*t*
 immunonutrition and, 823*t*
- Vitex, 79*t*
- Vomiting, 741*t*
- Vomiting, pernicious, 410–412
- Von Gierke disease, 176*t*
- Von Willebrand disease, 722
- Vyvanse (lisdexamfetamine dimesylate), 147*t*
- Warfarin, 317, 318, 356, 374, 381, 886
- Waste excretion, 860*t*
- Water, 340
- Weight, calculation of, 604*t*
- Weight gain. *See also* Body mass index (BMI)
 activity level or illness, 608*t*
 medications that cause, 616*t*
 in pregnancy, 7, 17
 smoking cessation and, 619*t*
- Weight loss
 activity level or illness, 608*t*
 in cancer patients, 741*t*
 in malnutrition, 602*t*
 medications for, 617*t*
 unintentional, 622–626
- Wellbutrin, 284*t*, 835*t*
- Wheat, allergy to, 125*t*, 127*t*
- Wheat grass, 81*t*, 749*t*
- Whipple's disease, 461–462
- White birch, 749*t*
- White willow, 79*t*
- Wild yams, 42*t*, 79*t*
- Willow bark, 79*t*
- Willow yam, 79*t*
- Wilm's tumor, 46*t*, 772–773
- Wilson's disease, 216–218
- Wired jaw, 99–100
- Witch hazel, 79*t*
- Women
 medications, 52*t*
 nutrition-related concerns for, 48*t*
- Wymox (amoxicillin), 895
- Xanax (alprazolam), 284*t*, 616*t*
- Xanthene oxidase inhibitors, 646
- Xanthones, 500*t*
- Xenazine (tetraabenazine), 245
- Xenical (orlistat), 617*t*
- Xerostomia, 101, 178, 273*t*, 740*t*
- Xifaxan (rifaximin), 424
- Ximelagatran (Exanta), 381
- X-linked adrenoleukodystrophy, 184
- X-linked hypophosphatemic rickets (XLH), 887–888
- X-linked sideroblastic anemia, 715–716
- Yersinia enterocolitis*, 851
- Yew, 79*t*
- Yogurt, 536*t*
- Yohimbe, 42*t*, 81*t*, 283
- Zalcitabine, 834*t*
- Zanosar (streptozotocin), 512
- Zantac (ranitidine), 409*t*
- Zarontin (ethosuximide), 241*t*
- Zeaxanthin, 108*t*, 109, 499*t*, 735*t*, 790*t*
- Zeldox, 616*t*
- Zellweger's syndrome, 184
- Zelnorm (tegaserod), 420*t*
- Zemlar (paricalcitol), 598, 872*t*
- Zenker's diverticulum, 390–391
- Zerit, 834*t*
- Ziagen (abacavir), 834*t*
- Zidovudine, 834*t*
- Zinc, 19, 42*t*, 79*t*, 89*t*, 97*t*, 108*t*, 225*t*, 294*t*, 534*t*, 661*t*, 665*t*, 698, 712*t*, 736*t*
- Zinc acetate, 217
- Ziprasidone (Geodon), 283*t*
- Zocor (simvastatin), 886
- Zofrab, 559
- Zoledronic acid, 773
- Zoledronic acid (Zometa), 673, 798
- Zollinger-Ellison syndrome, 511–512
- Zoloft, 283*t*
- Zoloft (sertraline), 284*t*, 616*t*, 835*t*
- Zometa (zoledronic acid), 673, 798
- Zonegran, 241*t*
- Zonisamide, 241*t*
- Zovirax, 835*t*
- Zyflo, 296*t*
- Zymenol, 420*t*
- Zyprexa (olanzapine), 149, 264, 283*t*, 616*t*